






# 65th ASH<sup>®</sup> Annual Meeting and Exposition

December 9-12, 2023  
San Diego, CA



## PROGRAM-AT-A-GLANCE

 **DARZALEX**<sup>®</sup>  
(daratumumab)  
injection for intravenous infusion  
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro**<sup>®</sup>  
(daratumumab and hyaluronidase-fihj)  
Injection for subcutaneous use | 1,800mg/30,000units

Review the data at the  
2023 ASH Annual Meeting  
& Exposition.



**THERE'S  
SO MUCH TO  
DISCOVER**



Come visit us  
December 9-12 at booth #1033  
or visit [DARZALEXHCP.com](https://www.darzalexhcp.com)

 **Janssen**  PHARMACEUTICAL COMPANY OF  
**Johnson & Johnson**

© Janssen Biotech, Inc. 2023  
10/23 cp-414476v1

**PROGRAM OF THE 65TH ANNUAL MEETING OF**

**AMERICAN SOCIETY OF HEMATOLOGY**



---

*December 9 - 12, 2023*

---

Printed in the USA  
Copyright © 2023 by the American Society of Hematology, Washington, DC  
All rights reserved.



# American Society of Hematology

Helping hematologists conquer blood diseases worldwide

## Call for Editor Nominations

### ASH Seeks Inaugural Editor-in-Chief for a New Journal

ASH has begun the process of selecting an inaugural editor to lead a new open access journal focused on global hematology, recently approved for addition to the Society's peer-reviewed *Blood* journals portfolio beginning in 2024.

---

***Blood Global Hematology*** is a new open access, peer-reviewed journal which aims to publish high-quality research, local adaptations of clinical guidelines, and opinion articles that improve the lives of patients in low- and middle-income countries. It will offer an online, rapid publishing venue for research focused on hematology-specific healthcare delivery in local or regional settings conducted in or focused on low- and middle-income countries and/or with a global reach and applicability. As part of the *Blood* journals portfolio, *Blood Global Hematology* will connect to the ASH mission of educating hematologists worldwide to improve patient care.

---

The inaugural editor-in-chief will begin work in the Spring of 2024 and will help establish the initial editorial team and peer review procedures. Candidates must have significant editorial experience, preferably as an editor of a peer-reviewed journal; a distinguished research record; broad and comprehensive knowledge of basic, translational, and clinical research; and a record of leadership in the community. Successful candidates should have an interest in developing innovative new content, knowledge of ASH programs and initiatives, experience coordinating international collaborations, and familiarity with international experts in the field to solicit relevant, high-quality articles.

Candidates must be ASH members in good standing with an MD, MD/PhD, or equivalent degree. The term is five years with the potential for one five-year extension. An honorarium will be provided.

ASH members may self-nominate for this position by submitting a cover letter, a CV, a brief description of previous editorial experience, and a vision statement for the journal. Nominations from international members are encouraged. Members are also welcome to nominate a colleague by submitting a brief informal endorsement. ASH will confirm the nominee's membership status and request submission of additional materials to complete the nomination. ASH prohibits members employed by a pharmaceutical or biomedical company from serving in an editorial position.

► All submissions should be sent to [EditorSearch@hematology.org](mailto:EditorSearch@hematology.org) by the deadline of 11:59 P.M. EST on December 20, 2023.

# Table of Contents



## About ASH

ASH Executive and Program Committees	5
Reviewers of Abstracts and <i>Hematology 2023</i>	8
Corporate Acknowledgements	11
Recipients of Awards	15

## Guide to Navigating the Meeting

General Information	23
Diversity, Equity, and Inclusion at ASH	35
Non-CME Sessions	37

## Meeting Schedule

Day-At-A-Glance	41
-----------------	----

## Invited Speaker Sessions

General Sessions	65
Special Interest Sessions	67
Trainee Activities (Open to Trainees Only)	75

*continued on next page*

# Table of Contents

*continued*

## Education Program

Education Sessions	83
Education Spotlight Sessions	93
How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions)	95

## Scientific Program

Scientific Sessions	101
Scientific Symposia	107
Scientific Spotlight Sessions	109
Scientific Workshops	113
ASH Poster Walks	117
Meet the Scientist (Ticketed Sessions)	119

## Abstract Sessions

Scientific Categories	121
Oral Abstract Sessions	125
Poster Presentations	133

## Exhibitors

Satellite Symposia	139
Product Theaters	151
Industry Theaters	157
Company Showcases	159
Exhibitor Directory	161

# AMERICAN SOCIETY OF HEMATOLOGY EXECUTIVE COMMITTEE

## STAFF LIAISONS:

Martha Liggett, Esq., [mliggett@hematology.org](mailto:mliggett@hematology.org)  
Matthew Gertzog, MBA, CAE, [mgertzog@hematology.org](mailto:mgertzog@hematology.org)  
LaFaundra Neville Ingram, CAP, [Ineville@hematology.org](mailto:Ineville@hematology.org)

## OFFICERS:

**President:** Robert A. Brodsky, MD  
**President-Elect:** Mohandas Narla, DSc  
**Vice President:** Belinda Avalos, MD  
**Secretary:** Cynthia E. Dunbar, MD  
**Treasurer:** Joseph Mikhael, MD, FRCPC, MEd

## COUNCILLORS:

Christopher R. Flowers, MD, MSc ('26)  
Alison Loren, MD ('23)  
Bob Löwenberg, MD, PhD ('23)  
Charlotte Marie Niemeyer, MD ('26)  
Sarah H. O'Brien, MD ('25)  
Betty Pace, MD ('24)  
Jamile M. Shammo, MD ('24)  
Wendy Stock, MD ('25)

# PROGRAM COMMITTEE

## STAFF LIAISON:

Ana Velarde

E-mail: [avelarde@hematology.org](mailto:avelarde@hematology.org)

### **Robert A. Brodsky, MD ('23) - Chairperson, President**

Mohandas Narla, DSc ('23) - Ex-Officio: President-Elect

Joseph Mikhael, MD, FRCPC, MEd ('23) - Ex-Officio: Treasurer

Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary

Belinda Avalos ('25) - Ex-Officio: Vice President

Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, *Blood*

Catherine M. Bollard, MD ('26) - Liaison, *Blood Advances* Editor-in-Chief

Jennifer R. Brown, MD, PhD ('23) - Liaison, Chair, Committee on Educational Affairs

Hetty Carraway, MD ('24) - Liaison, Chair, Committee on Training

Adam Cuker, MD ('23) - Liaison, Chair, Committee on Quality

Chancellor E. Donald, MD ('23) - Liaison, Chair, Committee on Practice

Aaron T. Gerds, MD, MS ('23) - Liaison, Editor-in-Chief, *ASH Clinical News*

Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee

Shaji Kunnathu Kumar, MD ('25) - Liaison, Editor-in-Chief, *The Hematologist*

Eduardo Magalhães Rego, MD, PhD ('23) - Liaison, Chair, International Members Committee

Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, *Blood*

Mikhael A. Sekeres, MD ('22) - Liaison, Chair, Committee on Communications

Andrew S. Weyrich, PhD ('26) - Liaison, *Blood Advances* Deputy Editor

Allison Walker, MD, MPH, MBA – Liaison, Chair, Committee on Diversity, Equity and Inclusion

Alisa Wolberg, PhD ('24) - Liaison, Chair, Committee on Scientific Affairs

# ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

## STAFF LIAISON:

Ana Velarde

E-mail: [avelarde@hematology.org](mailto:avelarde@hematology.org)

**Jean M. Connors, MD ('23) - 2023 Education Program Co-Chair**  
**Amy E. DeZern, MD ('23) - 2023 Education Program Co-Chair**  
**Kojo Elenitoba-Johnson, MD ('23) - 2023 Scientific Program Co-Chair**  
**Elizabeta Nemeth, PhD ('23) - 2023 Scientific Program Co-Chair**

John Koreth, MD, PhD ('24) - 2024 Education Program Co-Chair  
Rakhi Naik, MD, MHS ('24) - 2024 Education Program Co-Chair  
Sant Rayn Pasricha, MBBS, MPH, PhD ('24) – 2024 Scientific Program Co-Chair  
Jennifer Trowbridge, PhD ('24) – 2024 Scientific Program Co-Chair  
Hanny Al-Samkari, MD ('24) - Editor, Hematology  
Suneet Agarwal, MD, PhD ('23) - Appointed Member  
Alice Bertaina, MD, PhD ('24) – Appointed Member  
Steven Fein, MD ('23) – Appointed Member  
Francesca Gay, MD, PhD ('23) – Appointed Member  
Andreas Greinacher, MD ('23) – Appointed Member  
Betty Hamilton, MD ('23) – Appointed Member  
Manali Kamdar, MD ('23) – Appointed Member  
Richard M. Kaufman, MD ('23) - Appointed Member  
Judith Kleinerman, MD ('23) - Liaison, Chair, CME Accreditation Committee  
Dipti Patel Donnelly, MD ('23) – Appointed Member  
Kristen Pettit, MD ('23) - Appointed Member  
David Sallman, MD ('23) - Appointed Member  
Sharon Savage, MD ('23) – Appointed Member  
Clifford Takemoto, MD ('23) - Appointed Member  
Justin Taylor, MD ('23) - Appointed Member

# 2023 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of *Hematology 2023*, the ASH Education Program.

## ASH ABSTRACTS COORDINATING REVIEWERS

Maureen Okam Achebe	Delfim Duarte	Sangmoo Jeong	Bethan Psaila
Diego Adrianzen Herrera	Barbara Eichhorst	Courtney Jones	Muna Qayed
Josefin Ahnstrom	Tarec Christoffer El-Galaly	Swetha Kambhampati	Patrick Reagan
Juan Alderuccio	Carmen Fava	Shaji Kumar	Andreas Reiter
Immacolata Andolfo	Jonathan Flanagan	Catherine Lai	Kerry Rogers
Anthony Audino	Lucy Fox	Catherine Lee	Jacob Rowe
Karen Ballen	Miguel Ganuza Fernandez	Jessica Leonard	Elna Saah
Joao Barata	Ulrich Germing	Sheng Li	Bethany Samuelson Bannow
Roger Belizaire	Mark Geyer	Richard Little	Jordan Schaefer
Adam Binder	Arnab Ghosh	Rui Lu	David Scott
Robert Bowman	James Godfrey	Nadim Mahmud	Urvi Shah
Hetty Carraway	Kandace Gollomp	Enrica Marchi	Kenneth Shain
Namrata Chandhok	Damian Green	Kathy McGraw	Kristin Shimano
Shanmuganathan Chandrakasan	Emma Groarke	Maximilian Merz	Melody Smith
Shruti Chaturvedi	Boglarka Gyurkocza	Lekha Mikkilineni	Anna Maria Sureda Balari
David Coffey	Tanja Hartmann	Ghulam Rehman Mohyuddin	Natasha Szuber
Rachel Cook	Rong He	Florence Nguyen-Khac	Ali Taher
Raul Cordoba	Alex Herrera	Grzegorz Nowakowski	Douglas Tremblay
Emily Curran	Michael Heuser	Olubusola Oluwole	Cindy Varga
Susan DeWolf	Kyle Hewitt	Sung-Yun Pai	
Meghan Drayton Jackson	Matthew Hsieh	Freda Passam	
Martin Dreyling	Andrew Intlekofer	Fabiana Perna	

## ASH ABSTRACTS REVIEWERS

Yasmin Abaza	Nabanita Bhunia	Hua-Jay Cherng	Firas El Chaer
Oussama Abla	Giada Bianchi	Matthew Cheung	Najla El Jurdi
Jeremy Abramson	James Bieker	Annalisa Chiappella	Shannon Elf
Melissa Acquazzino	Melinda Ann Biernacki	Nora Chokr	Patrick Ellsworth
Lionel Ades	Andrea Biondi	Joseph Clara	Miriam Erlacher
Catherine Aftandilian	Lionel Blanc	Audrey Cleuren	Jason Farrar
Imo Akpan	Judith Boer	Edward R. Scheffer Cliff	Jonathan Feld
Ibrahim Aldoss	Kelly Bolton	Graham Collins	Francisca Ferrer Marin
Alvaro Alencar	Claire Booth	Raffaella Colombatti	Simone Ferrero
Lapo Alinari	Mercedes Borge	Laura Connelly-Smith	Lynda Foltz
Jessica Altman	Prithviraj Bose	Nicola Conran	Lisa Forbes Satter
Ran An	Marita Bosticardo	Joselle Cook	Henrik Frederiksen
Larry Anderson	Alexander Boucher	Mhairi Copland	Sylvie Freeman
Jacob Appelbaum	Jeanne Boudreaux	Luciano Costa	Matthew Frigault
Jane Apperley	Andrew Branagan	Francesca Cottini	Hideaki Fujiwara
Caroline Arber	Thorsten Braun	Angelo D'Alessandro	David Gailani
Alberto Arribas	Marc Braunstein	Alexey Danilov	Radhika Gangaraju
Kenneth Ataga	Annamaria Brioli	Faith Davies	Sylvain Garciaz
Ehab Atallah	Jennifer Brudno	Blachy Davila Saldana	Moshe Gatt
Andishe Attarbaschi	Andrew Brunner	Kara Davis	Valter Gattei
Yesim Aydinok	Emily Bryer	Lucia De Franceschi	Aaron Gerds
Melissa Azul	Barbara Buldini	Maria Eugenia de la Morena-Barrío	Irene Ghobrial
Ashish Bajel	Lambert Busque	Laurence de Leval	David Gibb
Pere Barba	Craig Byersdorfer	Erich De Paula	Eva Gine
Paul Barr	Anna Candoni	Thomas Deloughery	Domenico Girelli
Jose Maria Bastida	Antonino Carbone	Karl Desch	Nicola Giuliani
Taha Bat	Jennifer Carew	Ani Deshpande	Benjamin Goldenson
Kiran Batta	Shannon Carpenter	Roberta Di Blasi	Andres Gomez-De Leon
Anna Beaudin	Luciano Cascione	Anita D'Souza	Michael Green
Wendy Béguelin	Fausto Castagnetti	Sarah Ducamp	Philipp Greif
Meral Beksac	Carla Casulo	Jarrod Dudakov	Hildegard Greinix
Pavan Bendapudi	Francesco Ceppi	Amy Duffield	Nicole Grieselhuber
N. Nora Bennani	Leandro Cerchiatti	Carlo Dufour	Kira Gritsman
Maria Ester Bernader	James Cerhan	Remy Dulery	Tanja Gruber
Ofrat Beyar Katz	Lynette C.Y. Chee	Amy Dunn	Sonia Guedan
Neha Bhasin	Chun-Wei David Chen	Walter Dzik	Fabio Guolo
Rukhmi Bhat	Evan Chen	Karen Effinger	Carmelo Gurnari

## 2023 REVIEWERS

Alejandro Gutierrez  
 Fernanda Gutierrez-Rodriguez  
 Monica Guzman  
 Claudia Haferlach  
 Roman Hajek  
 Stephanie Halene  
 Mehdi Hamadani  
 Betty Hamilton  
 Doris Hansen  
 Eliza Hawkes  
 Caroline Heckman  
 Ute Hegenbart  
 Florian Heidel  
 Olaf Heidenreich  
 Jens Hillengass  
 Devendra Hiwase  
 Gabriela Hobbs  
 Toril Holien  
 Junshik Hong  
 Alessandro Isidori  
 Raphael Itzykson  
 Shai Izraeli  
 Elias Jabbour  
 Salvia Jain  
 Sakshi Jasra  
 Reena Jayani  
 Mats Jerkeman  
 Patrick Connor Johnson  
 Wojciech Jurczak  
 Jonas Jutzi  
 Martin Kaiser  
 Matko Kalac  
 Maggie Kalev-Zylinska  
 Christopher Kanakry  
 Reem Karmali  
 Adetola Kassim  
 Malgorzata Kasztan  
 Arnon Kater  
 Motohiro Kato  
 Colm Keane  
 Amar Kelkar  
 Vanessa Kennedy  
 Jennifer Kesselheim  
 Nigel Key  
 Nandita Khara  
 Arushi Khurana  
 Jean-Jacques Kiladjian  
 Katherine King  
 Frederikus Klok  
 Vidyasagar Koduri  
 Christian Koenecke  
 Steffen Koschmieder  
 Stavroula Kousteni  
 Amrita Krishnan  
 Andrea Kuhn  
 Kevin H.M. Kuo  
 David Kuter  
 Marco Ladetto  
 Rahul Lakhota  
 Nicole Lamanna  
 Daniel Landsburg  
 Hans Lee  
 Eva Leinoe  
 Georg Lenz  
 Huihui Li  
 John Ligon  
 Ming Y Yeong Lim  
 Emily Limerick  
 Luca Lo Nigro  
 Cheryl Lobo  
 Camille Lobry  
 Richard Lock  
 Alison Loren  
 Izidore Lossos  
 Daniel Lucas-Alcaraz  
 Stefano Luminari  
 Maria Teresa Lupo Stanghellini  
 Meng Lv  
 Joseph Maakaron  
 Kylee Maclachlan  
 Yazan Madanat  
 Kami Maddocks  
 Kris Michael Mahadeo  
 Johnny Mahlangu  
 Francois Mahon  
 Ajay Major  
 Florent Malard  
 Luca Malcovati  
 Ariela Marshall  
 Sven Maschek  
 Matthew Maurer  
 Hind Medyouf  
 Reid Merryman  
 Laura Michaelis  
 Kenichi Miharada  
 Courtney Nicole Miller-Chism  
 Coraline Mlynarczyk  
 Mohamad Mohty  
 John Molina  
 Francesca Montanari  
 Jerome Moreaux  
 Kerry Morrone  
 Moaath Mustafa Ali  
 Satu Mustjoki  
 Niroshan Nadarajah  
 Bertrand Nadel  
 Swati Naik  
 Ranjit Nair  
 Cindy Neunert  
 Peter Newburger  
 Laura Newell  
 Diu T.T. Nguyen  
 Ruben Niesvizky  
 Robin Norris  
 Sarah O'Brien  
 Alexander Oeser  
 Yishai Ofran  
 Hiroto Ohguchi  
 Bilal Omer  
 Oluwatoyosi Onwuemene  
 Jad Othman  
 Neil Palmisiano  
 Helen Papadaki  
 Erin Parry  
 Anand Ashwin Patel  
 Mrinal Patnaik  
 Robert Paulson  
 Katerina Pavenski  
 Miguel Arturo Pavlovsky  
 Tea Pemovska  
 Guilherme Fleury Perini  
 Caroline Philpott  
 Georgios Pongas  
 Maurilio Ponzoni  
 Jerlym Porter  
 Nicola Pozzi  
 Pedro Prata  
 Anca Prica  
 Barbara Pro  
 John Anto Pulikkan  
 Hang Quach  
 Anne Quinquenel  
 Brittany Knick Ragon  
 Ramy Rahmé  
 Ron Ram  
 Muthalagu Ramanathan  
 Pavan Reddy  
 Christopher Reilly  
 Linda Resar  
 Rebecca Richards  
 Ingo Ringshausen  
 Antonio Risitano  
 Jason Romancik  
 Rizwan Romee  
 Marlies Rossmann  
 Harvey Roweth  
 Sergio Rutella  
 Russell Ryan  
 Zohar Sachs  
 Neeraj Saini  
 R. Leo Sakemura  
 Ben Samelson-Jones  
 Jose Sandoval-Sus  
 Kristen Sanfilippo  
 Jolanda Sarno  
 Prakash Satwani  
 Tim Sauer  
 Caner Saygin  
 Alexandra Schifferli  
 Fredrik Schjesvold  
 Sol Schulman  
 Liora Michal Schultz  
 Eduard Schulz  
 Jan Jacob Schuringa  
 Juliana Schwaab  
 Juerg Schwaller  
 Marie Scully  
 Mikkael Sekeres  
 Valentina Serafin  
 Brian Shaffer  
 Nishi Shah  
 Jamile Shammo  
 Naranie Shanmuganathan  
 Noha Sharafeldin  
 Joseph Shaw  
 Geoffrey Shouse  
 Elizabeth Shpall  
 Tanya Siddiqi  
 David Siegel  
 Robert Signer  
 Wellington Silva  
 Laura Silvestri  
 Sharon Singh  
 Pratibha Singh  
 Ankur Singh  
 Shireen Sirhan  
 Julia Skokowa  
 Luke Smart  
 Andrew Snow  
 Simona Soverini  
 Adam Sperling  
 Maximilian Stahl  
 Joseph Stanek  
 Kimberly Stegmaier  
 Laurie Steiner  
 Paolo Strati  
 Jonathan Strefford  
 Christopher Su  
 Senthil Sukumar  
 Prithu Sundd  
 Agoston Gyula Szabo  
 Owen Tamplin  
 Yvette Tanheco  
 Benoit Tessoulin  
 Suzanne Thibodeaux  
 Meghan Thompson  
 Courtney Thornburg  
 Sigrun Thorsteinsdottir  
 Swapna Thota  
 Brian Till  
 Zuzana Tothova  
 Jan Trka  
 Steven Tsai  
 Mazie Tsang  
 Venee Tubman  
 Lucie Turcotte  
 Dimitrios Tzachanis  
 Masumi Ueda Oshima  
 Bert Van der Reijden  
 Antiopi Varelias  
 Anant Vatsayan  
 Leandro Venturutti  
 Sangeetha Venugopal  
 Amit Verma  
 Vip Viprakesit  
 Linus Voelker  
 Bastian von Tresckow  
 Ajay Vora  
 Radovan Vrhovac  
 Vladan Vucinic  
 Franziska Wachter  
 Aman Wadhwa  
 Nina Wagner-Johnston  
 Johannes Waldschmidt  
 Alison Walker  
 Roland Walter  
 Anthony Washington  
 Jonathan Webster  
 Lachelle Weeks  
 Andrew Wei  
 Jeffrey Weitz  
 Jason Westin  
 Joseph Wiemels  
 Adrian Wiestner  
 Lindsay Wilde  
 Jennifer Wilkes  
 Eric Winer  
 Eric Wong  
 Chuanfeng Wu  
 Ana Xavier  
 Stephanie Xie  
 Victor Yazbeck  
 Andrew Yee  
 Jonathan Yen  
 Guy Young  
 Neil Zakai  
 Emanuele Zucca  
 Jeffrey Zwicker

## HEMATOLOGY 2023 REVIEWERS

Jeremy S. Abramson  
 Catherine Aftandilian  
 Suneet Agarwal  
 Haris Ali  
 Pamela Blair Allen  
 Andrew S. Artz  
 Michael Auerbach  
 Nizar J. Bahlis  
 Brian J. Ball  
 Kenneth A. Bauer  
 Pavan K. Bendapudi  
 Alice Bertaina  
 Bhavana Bhatnagar  
 Neel S. Bhatt  
 Javier Bolaños-Meade  
 Prithviraj Bose  
 Robert A. Brodsky  
 Jennifer N. Brudno  
 Patricia A.R. Brunker  
 Andrew M. Brunner  
 John M. Burke  
 James B. Bussel  
 Scott Canna  
 Maria Dominica Cappellini  
 Hetty E. Carraway  
 Marc Carrier  
 Shruti Chaturvedi  
 Luke Y.C. Chen  
 Yi-Bin Chen  
 Jacques Chiaroni  
 Satheesh Chonat  
 Douglas B. Cines  
 Nathan T. Connell  
 Mhairi Copland  
 Jorge Cortes  
 Luciano J. Costa  
 Anita D'Souza  
 Alexey V. Danilov  
 Thomas G. DeLoughery  
 Amy E. DeZern  
 Yvonne A. Efebera  
 Hesham Eissa  
 Andrew M. Evens  
 Lorenzo Falchi  
 Steven Fein  
 Courtney Fitzhugh  
 Courtney D. Fitzhugh  
 Radhika Gangaraju  
 David A. Garcia  
 Valentin Garcia-Gutierrez  
 Francesca Gay  
 Nilanjan Ghosh  
 Andreas Glenthøj  
 Ajay K. Gopal  
 Jed B. Gorlin  
 Rachael F. Grace  
 Tara Graff  
 Elizabeth A. Griffiths  
 Emma M. Groarke  
 Monique Hartley-Brown  
 David Henry  
 Gabriela Hobbs  
 Christopher S. Hourigan  
 Amanda Jacobson-Kelly  
 Nitin Jain  
 Siddhartha Jaiswal  
 Murali Janakiram  
 Martin F. Kaiser  
 Theodosia A. Kalfa  
 Manali Kamdar  
 Julie Kanter  
 Richard M Kaufman  
 Sioban B. Keel  
 Steve Kitchen  
 Adam S. Kittai  
 Jan-Henning Klusmann  
 Paul Knoebl  
 Peter Kouides  
 Taxiarchis V. Kourelis  
 Nicolaus Kröger  
 Amrita Y. Krishnan  
 Rebecca Kruse-Jarres  
 Nicole Kucine  
 Stephan Ladisch  
 Michele P. Lambert  
 Rebecca Karp Leaf  
 Jerrold H. Levy  
 Howard Allen Liebman  
 Tara L. Lin  
 Ton Lisman  
 Frederick L. Locke  
 Sagar Lonial  
 Tiffany L. Lucas  
 Marlise R. Luskin  
 Leo Luznik  
 Ryan C. Lynch  
 Stephen MacDonald  
 Katerina Machova Polakova  
 John P. Manis  
 Deepa Manwani  
 Camila Masias  
 Jennifer McNeer  
 Robert T. Means  
 Matthew G. Mei  
 Reid W. Merryman  
 Saskia Middeldorp  
 Tamara P. Miller  
 Alice S. Mims  
 Alison J. Moskowitz  
 Fionnuala B. Ní Áinle  
 Swati Naik  
 Eneida R. Nemecek  
 Cindy E. Neunert  
 Marena Rebekka Niewisch  
 Sven R. Olson  
 Timothy S. Olson  
 Giovanni Palladini  
 Jeanne M. Palmer  
 Anand A. Patel  
 Dipti Patel-Donnelly  
 Steven Z. Pavletic  
 Françoise Pirenne  
 Allyson Pishko  
 Daniel A. Pollyea  
 Keith W. Pratz  
 Muna Qayed  
 Christian Récher  
 Jean-Antoine Ribeil  
 Lara N. Roberts  
 David A. Sallman  
 Bethany T. Samuelson Bannow  
 Sharon A. Savage  
 Bipin N. Savani  
 Jordan K. Schaefer  
 Zbigniew Macdonald  
 Szczepiorkowski  
 Gary J. Schiller  
 Jecko Thachil  
 Alvin H. Schmaier  
 Alexis A. Thompson  
 Kirk R. Schultz  
 Andreas Tiede  
 Roger E.G. Schutgens  
 Chaitra Ujjani  
 Mikkael A. Sekeres  
 Rolf T. Urbanus  
 Nirali N. Shah  
 Celalettin Ustun  
 Urvi A. Shah  
 Jurjen Versluis  
 Naranie Shanmuganathan  
 Jeff P. Sharman  
 Joseph J. Shatzel  
 Akiko Shimamura  
 Michelle Sholzberg  
 Roni Shouval  
 Deborah M. Siegal  
 Leslie Skeith  
 Heather J. Symons  
 Zbigniew Macdonald  
 Szczepiorkowski  
 Jecko Thachil  
 Alexis A. Thompson  
 Andreas Tiede  
 Chaitra Ujjani  
 Rolf T. Urbanus  
 Celalettin Ustun  
 Jurjen Versluis  
 Adrianna Vlachos  
 Alison R. Walker  
 Alan S. Wayne  
 Jason R. Westin  
 Joshua F. Zeidner  
 Jeffrey A. Zonder

# 2023 CORPORATE ACKNOWLEDGMENTS

*These acknowledgments reflect contributions made prior to October 13, 2023.*

## 2023 ASH Annual Meeting Foundation Run/Walk Supporters

### PREMIER

Acrotech Biopharma, Inc.  
AstraZeneca  
Biomea Fusion, Inc.  
Editas Medicine  
Gilead and Kite Oncology  
GSK  
Regeneron  
Syndax Pharmaceuticals

### LEAD

AbbVie  
Blueprint Medicines  
Seagen Inc.

### SUPPORTING

Freeman  
Novartis  
Ono Pharmaceuticals

## 2023 ASH Annual Meeting Education Supporters

*ASH would like to acknowledge the following companies for the educational grants provided in support of the 2023 ASH Annual Meeting:*

### **Hematology 2023: The Education Program**

AstraZeneca  
GlaxoSmithKline  
Incyte Corporation  
Jazz Pharmaceuticals  
Merck Sharp & Dohme Corp.  
Novartis Pharmaceuticals Corporation

### **General Education Grant**

AbbVie  
AstraZeneca  
GlaxoSmithKline  
Incyte Corporation  
Lilly USA, LLC  
Merck Sharp & Dohme Corp.  
Novartis Pharmaceuticals Corporation  
Pfizer Inc.  
Seagen  
Syndax Pharmaceuticals Inc.

# 2023 CORPORATE ACKNOWLEDGMENTS

*These acknowledgments reflect contributions made prior to October 13, 2023.*

## 2023 ASH Independent Medical Education Supporters

*ASH would like to acknowledge the following companies for their support:*

Agios Pharmaceuticals Inc.  
Astellas Pharma US, Inc.  
Bristol Myers Squibb  
CRISPR Therapeutics, Inc.  
Daiichi Sankyo, Inc.  
GlaxoSmithKline  
Johnson & Johnson Innovative Medicine  
Kite Pharma Inc.  
Novartis Pharmaceuticals  
Pfizer Inc.  
Syneos Health  
Vertex Pharmaceuticals Incorporated

## 2023 ASH Award Supporters

*ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Minority Recruitment Initiative and Scholar Award programs:*

AstraZeneca  
Novartis Pharmaceuticals

## 2023 Annual Meeting Corporate Supporters

*ASH would like to acknowledge the following companies for their support of the 2022 Annual Meeting:*

### AbbVie

ASH Red

### AstraZeneca

Exhibit Hall Aisle Signs

### Daiichi Sankyo, Inc.

PosterCast

### Gilead and Kite Oncology

Internet Stations and Wi-Fi

### GSK

ASH Hotel Door Drop Bag  
Mobile Device Charging Stations

### Incyte

Hydration Stations

### Johnson & Johnson

Hand Sanitizing Stations  
Headshot Alley  
Mobile Device Charging Stations

### Loxo@Lilly

Photo Zone and Social Media Wall

### NMDP

ASH-a-Palooza – Gold Level Supporter

### Sanofi

ASH Park @ the Plaza  
Hand Sanitizing Stations  
Mobile Device Charging Stations  
(Marriott Marquis San Diego Marina)

### Spark Therapeutics

ASH-a-Palooza – Silver Level Supporter  
ASH-a-Palooza – Photo Zone

### Syndax Pharmaceuticals

Mobile App

# 2023 CORPORATE ACKNOWLEDGMENTS

*These acknowledgments reflect contributions made prior to October 13, 2023.*

## 2023 ASH Global Initiatives

*ASH would like to acknowledge and thank the following companies and foundation for supporting ASH's international consortia:*

### Consortium on Newborn Screening in Africa

Bristol-Myers Squibb

Novartis

Revvity

### International Consortium on Acute Leukemia

Torsten Haferlach Leukemia Diagnostics Foundation

Illumina

## 2023 ASH Corporate Friends

*ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:*

Premier Circle	Partner Circle	Advocate Circle	Insider Circle
GSK	AstraZeneca	Agios	Bluebird Bio
Pfizer	BristolMyersSquibb	Amgen	Kura Oncology
Regeneron	Kite	Astellas	Orca Bio
	Lilly	Beigene	Rigel
	Novartis	Genentech	Syndax
	Vertex	Genmab	
		Johnson & Johnson Innovative Medicine	
		Merck	
		Novo Nordisk	
		Sanofi	

## 2023 ASH Health Equity Collective

*The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH's work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:*

BristolMyersSquibb	Merck
Genentech	Novartis
GSK	Pfizer
Johnson & Johnson Innovative Medicine	Sanofi
Lilly	Vertex




# American Society of Hematology


Helping hematologists conquer blood diseases worldwide



## 8th Edition ASH-SAP Self-Assessment Program



- ▶ **25 New & Updated Chapters** – covering malignant and classical (non-malignant) disorders
- ▶ **17 New & Updated Multi-Media** features for key topics
- ▶ **260 NEW Questions** in the Question and Answer Book
- ▶ **75 - CME/MOC Credits**



PRINT VERSION ONLY

### The Question and Answer Book allows for preparation for the CME/MOC Test featuring:

- Laboratory Hematology & Cellular Therapy
- Consultative Hematology
- Anemia, Iron Physiology, and Iron Disorders
- Thrombosis & Hemostasis
- Myeloid Diseases
- Lymphoid Disorders

**ORDER TODAY AT:**  
ASH Store on-site | [hematology.org/store](http://hematology.org/store)



# RECIPIENTS OF AWARDS

## WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

2023	Blanche P. Alter	2017	Marshall A. Lichtman	2011	David G. Nathan
2022	Irving Weissman	2016	Thalia Papayannopoulou	2010	Volker Diehl
2021	Harvey Lodish	2015	Aaron Marcus	2009	H. Franklin Bunn
2020	Mohandas Narla	2014	Kanti Rai	2008	Robert Kyle
2019	Richard H. Aster	2013	Sir David John Weatherall	2007	Ernest Beutler
2018	Victor Hoffbrand	2012	James George		

## ERNEST BEUTLER LECTURE AND PRIZE

2023	Takehisa Kitazawa and Johnny Mahlangu	2017	Luigi Naldini and Marina Cavazzana	2011	Janet D. Rowley and Brian J. Druker
2022	John Atkinson and Peter Hillmen	2016	Hugues de Thé and Zhu Chen	2010	Barry S. Coller and Joel S. Bennett
2021	Margaret Shipp and Stephen Ansell	2015	Alfred Goldberg and Paul Richardson	2009	Yuet Wai Kan and Thomas Maniatis
2020	Courtney DiNardo and Ari Melnick	2014	Michael R. DeBaun and Robert P. Hebbel		
2019	Sriram Krishnaswamy and Jeffrey I. Weitz	2013	Kenneth Kaushansky and David J. Kuter		
2018	Alan D'Andrea and Neal Young	2012	Bruce R. Blazar and Carl H. June		

## E. DONNALL THOMAS LECTURE AND PRIZE

2023	Katy Rezvani	2012	Timothy J. Ley	2001	Samuel E. Lux, IV
2022	Bruce Blazar	2011	George Q. Daley	2000	David Ginsburg
2021	Connie Westhoff	2010	Leonard I. Zon	1999	Irving Weissman
2020	Toshio Suda	2009	John E. Dick	1998	Stuart H. Orkin
2019	Philip D. Greenberg	2008	Neal S. Young	1997	Robert Rosenberg
2018	Connie J. Eaves	2007	Hal Broxmeyer	1996	Stanley Korsmeyer
2017	James R. Downing	2006	E. Richard Stanley	1995	Charles Esmon
2016	David Scadden	2005	Rainer Storb	1994	Thomas P. Maniatis
2015	Barbara C. Furie and Bruce Furie	2004	Donald Metcalf	1993	Thomas P. Stossel
2014	Tomas Ganz	2003	Ernest Beutler	1992	Stuart Kornfeld
2013	Katherine A. High	2002	Kenneth Mann		

## WILLIAM DAMESHEK PRIZE

2023	Omar Abdel-Wahab	2003	Gary Gilliland	1989	Samuel E. Lux IV
2022	Irene Ghobrial	2002	Catherine Verfaillie	1988	Theodore S. Zimmerman
2021	Elizabeta Nemeth	2001	Brian Druker	1987	Charles Sherr
2020	Adolfo Ferrando	2000	David A. Williams	1986	Stuart Orkin
2019	Emmanuelle Passegué	1999	Salvador Moncada	1985	Thomas F. Deuel
2018	Ross L. Levine	1998	J. Evan Sadler	1984	Barbara C. and Bruce Furie
2017	Benjamin L. Ebert	1997	Björn Dahlbäck	1983	Thomas P. Stossel
2016	Charles Mullighan	1996	Kenneth Kaushansky	1982	Janet D. Rowley
2015	John Byrd	1995	James Ihle	1981	Philip W. Majerus
2014	Scott Armstrong	1994	George J. Broze, Jr.	1979	Yuet Wai Kan
2013	Andrew Weyrich	1993	Owen Witte	1978	Robert D. Rosenberg
2012	Margaret A. Goodell	1992	Richard D. Klausner	1977	Yale Nemerson
2011	Christoph Klein	1991	Makio Ogawa	1976	Robert I. Weed
2010	David T. Scadden	1990	Thalia Papayannopoulou and George Stamatoyannopoulos	1975	Charlotte Friend
2009	Louis M. Staudt			1974	Robert C. Gallo
2008	Kenneth Anderson				
2007	William Vainchenker				
2006	Riccardo Dalla-Favera				
2005	John Dick				
2004	Ronald Levy				

## RECIPIENTS OF AWARDS

### ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2023	Alexis A. Thompson	2020	Edward J. Benz Jr.	2018	Cage S. Johnson and José A. López
2022	James Gavin and David Wilkes	2019	Griffin P. Rodgers	2017	Betty Pace
2021	Deepika Darbari				

### HENRY M. STRATTON MEDAL

2023	Rodger McEver and James B. Bussel	2015	Nancy Speck and Karl Welte	2003	Janet Rowley
2022	Timothy Ley and Robert Montgomery	2014	Geraldine Schechter and Timothy Springer	2002	George Stamatoyannopoulos
2021	Kwaku Ohene-Frempong and Denisa Wagner	2013	Nancy Andrews and Elaine Jaffe	2001	Harold R. Roberts
2020	Maria Domenica Cappellini and Michelle Le Beau	2012	Richard Aster and David Ginsburg	2000	H. Franklin Bunn
2019	William Allen Eaton and Richard A. Larson	2011	Ching-Hon Pui	1999	Helen Ranney
2018	Brunangelo Falini and Freda K. Stevenson	2010	Sanford Shattil	1998	Arthur W. Nienhuis
2017	Josef Tomas Prchal and Sherrill J. Slichter	2009	Connie Eaves	1997	Rainer Storb
2016	J. Evan Sadler and Ayalew Tefferi	2008	Clara Bloomfield	1996	Bernard Forget
		2007	Carlo Croce	1995	David Nathan
		2006	Jack Hirsh	1994	Titus H.J. Huisman
		2005	Barry Collier	1993	Earl W. Davie
		2004	Stanley Korsmeyer	1992	Kenneth G. Mann

### HENRY M. STRATTON LECTURE (1970-1991)

1991	Ralph L. Nachman	1983	Eugene P. Cronkite	1975	E. Donnall Thomas
1990	Malcolm Moore	1982	Ernest A. McCulloch	1974	Ernest Beutler
1989	Aaron J. Marcus	1981	Clement A. Finch	1973	Albert S. Gordon
1988	Robert S. Schwartz	1980	Yuet Wai Kan	1972	Oscar D. Ratnoff
1987	Robert C. Gallo	1979	Henry S. Kaplan	1971	H.G. Kunkel
1986	Bernard Babior	1978	William N. Valentine	1970	W.R. Bruce
1985	Vincent DeVita	1977	Thomas A. Waldmann		
1984	Samuel Rapaport	1976	Wendell F. Rosse		

### ASH MENTOR AWARD

2023	Stephen Sallan and Helen Heslop	2016	Laurence Boxer and Ralph L. Nachman	2010	Mary M. Horowitz and Harvey F. Lodish
2022	Michael Caligiuri and Christopher Flowers	2015	Curt Civin and Craig Kitchens	2009	Arthur Nienhuis and Stuart H. Orkin
2021	Anthony Goldstone and Jonathan Licht	2014	Grover C. Bagby Jr. and John F. DiPersio	2008	George R. Buchanan and Timothy J. Ley
2020	Judith Gasson and Wendy Stock	2013	John Adamson and Stanley Schrier	2007	Edward J. Benz Jr and Harold R. Roberts
2019	Michael R. DeBaun and Leonard I. Zon	2012	Beverly S. Mitchell and Rainer F. Storb	2006	Samuel E. Lux and Deane F. Mosher
2018	John E. Dick and Reed E. Drews	2011	Nancy C. Andrews and Malcolm K. Brenner		
2017	Ronald Hoffman and Oliver W. Press				

## ABSTRACT ACHIEVEMENT AWARDS

### ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

#### UNDERGRADUATE STUDENT

**Rajagopalan Subramaniam**  
Indian Institute of Technology (IIT)

#### MEDICAL STUDENT

**Anagha Sheth, BSc**  
University of Colorado School of Medicine

#### GRADUATE STUDENT

**Zhaofeng Zheng**  
Institute of Hematology & Blood

#### RESIDENT PHYSICIAN

**Moritz Fürstenau, MD**  
University of Cologne

#### POST-DOCTORAL FELLOW

**Mirca Saurty-Seerunghen, PhD**  
Weill Cornell Medicine

## ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

**I-Jun Lau, DPhil, BMBCh**  
University of Oxford

**Maryam Subhan**  
University College London

**Nikolaos Sousos, MD, MSc, PGCert, DPhil**  
Oxford University Hospitals

## ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

**James Kuzich, MBBS, FRACP, FRCPA**  
Peter MacCallum Cancer Centre

## ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan

**Kenki Saito**  
Nara Medical University

**Satoshi Kaito, MD, PhD**  
The University of Tokyo

**Rurika Okuda, MSc, BS**  
Kyoto University

## ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

**Enrico Attardi, MD**  
University of Rome Tor Vergata

**Luca Lanino, MD**  
IRCCS

## ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

**Carlos Bravo-Perez, MD**  
Cleveland Clinic

**Hiroki Mizumaki, MD, PhD**  
National Institutes of Health

## JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

**Matthew Frank, MD, PhD**  
Stanford University

## MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand's disease.

**Lucas Van Gorder**

Children's Hospital of Philadelphia

## ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

**Cristina Astrid Tentori, MD**

IRCCS

## MINORITY GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based Minority Graduate Student Abstract Achievement Awards to select graduate students to acknowledge the accomplishments of and recruit and retain minority graduate students in the field of hematology.

**Charles Ayemoba**

University of Illinois at Chicago

**Claudia Cabrera**

Washington University School of Medicine

**Francisco Marchi**

University of Florida

**Fathima Mohamed**

University of Minnesota

**Corbin Azucenas**

Cincinnati Children's Hospital Medical Center

**Daisy Diaz Rohena**

The University of Texas MD Anderson Cancer Center

**Richard Marrero**

University of Florida

**Justin Thomas**

Fred Hutchinson Cancer Center

**Ginette Balbin-Cuesta**

University of Michigan Medical School

**Ariel Leyte-Vidal**

University of California

**Jonny Mendoza-Castrejon**

Washington University School of Medicine

**Eudorah Vital**

Georgia Institute of Technology and Emory University

## ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year's Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Dor Abelman

Yazan Abu-Shihab

Adebimpe Adelaja

Ijele Adimora

Margo Aertgeerts

Mike Agius

Louise Ahlgren

Gulrayz Ahmed

Roberto Aiolfi

Abigail Ajanel Gomez

Yu Akahoshi

Theresia Akhlaghi

Emmanuella Alawode

Jean-Baptiste Alberge

Mohammad Alhomoud

Konstantinos Aliazis

Stefan Alig

Cecily Allen

Diana Al-Sarayfi

Othman Al-Sawaf

Sultan Alsuhaibani

Zhuo-Yu An

Michael Andersen

Mathew Angelos

Kaitlin Annunzio

Tomohiro Aoki

Michelle Aranha

Mutlu Arat

Mya Arellano

Christopher Arends

Ruby Arora

Sankalp Arora

Esteban Arrieta-Bolanos

Khetwasan Arunphong

Arghavan Ashouri

Frida Bugge Askeland

Ferdows Atiq

Himachandana Atluri

Franziska Auer

Matias Autio

Edward Ayoub

Irfan Azaman

Stefanie Bachl

Maximilian Bader

Marc-Andrea Baertsch

Jie Bai

Zhiliang Bai

Firas Baidoun

Shovik Bandyopadhyay

Subham Bandyopadhyay

Lauren Banner

Mei Bao

Juan Barajas

Sergio Barajas

Manpreet Bariana

Aditya Barve

Fahmin Basher

Naseer Basma

Salman Basrai

Alex Bataller

Benjamin Bateman

Habin Bea

Francisco Beas

Isabelle Becker

J. Beeler

Manali Begur

Salima Benbarche

Philipp Berning

Kalay Bertulfo

Jan Philipp Bewersdorf

Alicia Beyou

Anand Bhagwat

Dipabarna Bhattacharya

Honghao Bi

Viktorija Blumenberg

Prajwal Boddu

Marta Bortolotti

Jonas Bouhlal

Ruayda Bouls

Molly Brakhane

Kelsey Bria

Charlotte Brierley

Robert Briski

Pamela Brito

Maura Bueno

Marco Buttigieg

Madeline Caduc

Xuan Cai

Steven Callori

Virginia Camacho

Wenjing Cao

Bria Carrithers

# ABSTRACT ACHIEVEMENT AWARDS

Claire Cassianni	David Dukenik	Gege Gui	Yue Jin
Gustav Cederquist	Luke Dunaway	Rajesh Gunage	Grace Johnson
Elise Cellerin	Arda Durmaz	Qiuyu Guo	Kanak Joshi
Francesca Cendali	Ugochi Ebinama	Fabio Guolo	Rachel Josselson
Itziar Cenzano	Jan-Niklas Eckardt	Anna Gurevich Shapiro	Anne Juhl
John Chadwick	Jeffrey Edwards	Carmelo Gurnari	Christina Jurotich
Samarpana Chakraborty	Thorir Einarsson Long	Puneeth Guruprasad	Bailee Kain
Christopher Chambliss	Florian Eisele	Gianna Guzzardo	Ilja Kalashnikov
Yu-Hsuan Chang	Dina Elantably	Christopher Haddad	Syeda Ashna Fatima Kamal
Sana Chaudhry	Yasmin Elgammal	Ashley Hadjis	Takahiro Kamiya
Monique Chavez	Alexandra Elias	C. Ryan Hahn	Adam Kanack
Changhan Chen	Harold Elias	Zeeshan Haider	Daiki Karigane
Ding-Wen Chen	Evelyn Pamela Espinoza Morales	Amelia Haj	Corynn Kasap
He Tian (Tony) Chen	Ayo Falade	Aino-Elina Hakkinen	Shobhita Katiyar
Huiqiao Chen	Md Faruque	Adriane Halik	Deeksha Katoch
Xinjie Chen	Ayotola Fatola	Katherine Hampton	Prabhjot Kaur
Yuxiu Chen	Carissa Feliciano	Fengjiao Han	Naomi Kawashima
Zhixiang Chen	Jingjing Feng	Tianxiao Han	Nozomu Kawashima
Luana Chiquetto Paracatu	Qi Feng	Xu Han	Lukas Kazianka
Nicholas Chornenki	Justin Ferdinandus	Xu Han	Sarada Ketharnathan
Yakinthi Chrisochoidou	Marta Fernandes	Shivani Handa	Franz Ketzner
Ilias Christodoulou	Mike Fernandez	Shinpei Harada	Tariq Kewan
Simon Chu	Martina Ferrante	Dunia Hatabah	Aroog Khaliq
Yajing Chu	Ross Firestone	Taha Bartu Hayal	Dhruv Khanduja
Po Yee Chung	Luise Fischer	Jiasen He	Somya Khare
Danielle Cicka	Thais Fischer	Xin He	Eman Khatib-Massalha
Nicoletta Cieri	Jorge Florindez	Pranay Hegde	Wannakorn Khopanlert
Luca Nunzio Cifarelli	Anna Katharina Foerster	Charlotte Hellmich	Hyunjun Kim
Anthony Cirrincione	Colin Fortner	Alberto Hernandez Sanchez	Joseph Kim
Samuel Cockey	Raghda Fouda	Rosario Hernandez-Armengol	Min Young Kim
Ivan Cohen	Dominic Fowler-Shorten	Fieke Hoff	Rockbum Kim
Daniel Cole	Valentina Fragliasso	Quincy Hofsink	Shunsuke Kimura
Cailin Collins	Anna Frandsen	Natalie Holl	Katherine Klein
Sean Corcoran	Mirco Friedrich	Md Akram Hossain	Haley Klimaszewski
David Cordas dos Santos	Yoshiki Furukawa	Andrew Hu	Elizabeth Knauss
Francesco Corrado	Nico Gagelmann	Jennifer Huang	Trine Knudsen
Willem Cox	Saravanan Ganesan	Meixian Huang	Hiroki Kobayashi
David Cruz Hernandez	Juan-Jose Garces	Qiusha Huang	Joost Koedijk
Nataly Cruz-Rodriguez	Elvira Garcia De Paco	Yaojin Huang	Min Jung Koh
Yuqing Dan	Shiliang Ge	Yun Huang	Abhishek Vallabhbbhai Koladiya
Minghao Dang	Leah Gehrs	Zhenli Huang	Hana Komic
Kimberly Davidow	Inga Geirsdottir	Justine Hung	Misato Komori
Romy De Laat-Kremers	Georgina Gener-Ricos	Cameron Hunter	Taisuke Kondo
Ravindu De Silva	Clarissa Gervasoni	Henri Hupe	Tim Kong
Cristiane de Souza	Guido Ghilardi	Stephanie Hurwitz	Yvonne Kong
Jonathan De Wilde	Lourdes Gil-Flores	Kanutte Huse	Anne Marijn Kramer
Kole Degolier	Ashley Gin	Jani Huuhtanen	Michael Kramer
Joanna Deng	Luke Gingell	Betul Ibis	Brian Krum
Lucca Derks	Laura Girardi	Daisuke Ikeda	Evelien Krumb
Aditi Dey	Smith Giri	Shuntaro Ikegawa	Damian Krzyzanowski
Vikram Dhillon	Pia Glogowski	Chiharu Ishikawa	Tadeusz Kubicki
Arjun Dhir	Richard Godby	Yusuke Isshiki	Madhan Srinivasan Kumar
Vinita Dhir	Jordan Goldstein	Satoko Ito	Rathan Kumar
Anna Di Staulo	Willian Gomes	Yuta Ito	Kohei Kume
Aintzane Diaz-Mazkarian	Xubo Gong	Zalaya Ivy	Maria Kumskova
Deepika Dilip	Zimu Gong	Prajish Iyer	Wataru Kuroki
Danai Dima	Fanny Gonzales	Adila Izgutdina	Edward Kwarteng
Peter Dimitrion	Carmen Gonzalez	Kendra Jackson	Hui Si Kwok
Bingjie Ding	Britten Gordon	Johann-Christoph Jann	Emil Kyvsgaard
Weronika Dobrewa	Erica Gotardo	Matthew Jenkins	Xiaolin Lai
Dearbhla Doherty	Anmol Goyal	Yuanyuan Ji	Kentson Lam
Ruochen Dong	David Granadier	Chen Jia	Ivan Landego
Marina Dorigatti Borges	Rosalie Griffin	Bingqian Jiang	Lauren Laufer
Claire Drysdale	Matthew Gromowsky	Dongxu Jiang	Bac Viet Le
Hanna Duan	Amaliris Guerra	Jun Yang Jiang	Catherine Lecat
Julia Dudkiewicz	Camila Guerrero	Nan Jiang	Seonghan Lee

## ABSTRACT ACHIEVEMENT AWARDS

William Lee	Bilal Malik	Aina Oliver-Caldes	Omran Saifi
Yoonkyu Lee	Erica Mamauag	Jon Thorir Oskarsson	Noah Salama
Julien Legrand	Paola Manara	Anna Ossami Saidy	Suruchi Salgar
Allison Lehanka	Srija Manchkanti	Julia Paczkowska	Christopher Sande
Andri Leo Lemarquais	Aashray Mandala	Andrew Palmer	Junya Sango
Thomas Lew	Sacha Belinda Mapombo Choupa	Darren Pan	Hanaisa Sant'Anna
Lisa Leypoldt	Alfredo Marchetti	Lili PAN	Martina Sarchi
Chen Li	Josue Marquez	Nilesh Pandey	Nurefsan Sariipek
Lixia Li	Alexander Marr	Marios Papadimitriou	Samuel Sassine
Menglin Li	Tanner Martinez	Julien Papoin	Ahmed Sayed
Na Li	Esperanza Martin-Sanchez	Dorien Pastoors	Ayman Sayyed
Qin Li	Shinichiro Matsui	Ruchi Patel	Nastassja Scheidegger
Qing Li	Meghana Matur	Akshay Patwardhan	Sven Schimanski
Xueqi Li	Katie Maurer	Jean Pegliasco	Tessa Schmachtel
Yang Li	Michael McCONVILLE	Diego Pereira-Martins	Ann-Kristin Schmalter
Yang Li	Dustin McCurry	Cristina Perez	Caitlin Schneider
Yiwen Li	Danielle McQuinn	Kristen Peterson	Constanze Schneider
Zhengping Li	Rabea Mecklenbrauck	Alexander Pichler	Marissa Schraner
Zhenlong Li	Jose Mejias	Alexandra Pike	Jan Schroder
Ziming Li	Megan Melody	Alfredo Pinedo-Rodriguez	Joseph Schroers-Martin
Emily Liang	Max Mendez-Lopez	Michael Poeschla	Christian Schultze-Florey
Nora Liebers	Ana Menezes	Laura Polcik	Laurianne Scourzic
Katie Lien	Gao Mengge	Kanagaraju Ponnusamy	Inbal Sdayoor
Raphael Lievin	Leo Meriranta	Marianna Ponso	Yuichiro Semba
Elizabeth Lightbody	Lauren Meyer	Mansour Poorebrahim	Jayastu Senapati
Kenneth Lim	Xiaoli Mi	Vera Poort	Hajime Senjo
Guanglan Lin	Mariia Mikhaleva	Bogdan Popescu	Mohan Kumar SenthilKumar
William Lin	Michelle Millions	Patrizia Porazzi	Julieta Sepulveda-Yanez
Zesen Lin	Jelena Milosevic	Lakshmi Bhavani Potluri	Renata Sesti-Costa
Bingyu Liu	Charles Milrod	Narges Pourmandi	Maiko Sezaki
Boya Liu	Rahul Mishra	Yuekun Qi	Devanshee Shah
Jie Liu	Jayna Mistry	Laura Quillen	Krish Shah
Yingyue Liu	Safa Mohamad	Laura Raggi	Rushil Shah
Yu Liu	Anna Montanaro	Kathrine Rallis	Xinhe Shan
Yuchen Liu	Adnan Mookhtiar	Giulia Petra Rappa	Hanqing Shang
Alison Livada	Analy Mora	Christian Rausch	Vignesh Shanmugam
Amaya Llorente-Chavez	Luz Moreno Rueda	Molly Reed	Priyanka Sharma
Marissa Locastro	Kristina Mott	Kai Rejeski	Koustubh Shekar
Alexa Loncharich	Junli Mou	Hongwei Ren	Jaclyn Shelton
Zhangbiao Long	Jan Mueller	Kehan Ren	Young Jun Shim
Izabela Lopes	Umair Munawar	Fausto Alfredo Rios Olais	Shai Shimony
Diego Lopez	Lauren Murphy	Malte Ritter	Melissa Shyian
Yadith Karina Lopez-Garcia	Jurik Mutter	Sofia Rivarola	Jasmeet Sidhu
Joseph Lownik	Greggory Myers	Santiago Riviello-Goya	Silvia Sighinolfi
John Lozada	Keiichi Nakata	Pauline Robbe	Martha Sim
Bin Lu	Henna Nam	Karl Roberts	Florian Simon
Tiange Lu	Ahmad Nanaa	Alyssa Rodriguez	Haley Simpson
Ting Lu	Amna Naqvi	Juan Jose Rodriguez Sevilla	Aakanksha Singh
Danny Luan	Anna Navarro Figueredo	Sergio Rodriguez-Rodriguez	Apeksha Singh
Alexandra Lubin	Kit Neikirk	Alberto Rodriguez-Sanchez	Maria Sirenko
Johannes Lubke	Niraj Neupane	Sæmundur Rognvaldsson	Abigail Skidmore
Ahmed Ludvigsen Al-Mashhadi	Lok Lam Ngai	Gregory Roloff	Sarah Skuli
Sofia Luna	Chi Nguyen	Laurel Romano	Febe Smits
Hanzhi Luo	Daniel Nguyen	James Ropa	Yang Song
Qingyu Luo	Nam Nguyen	Sterling Rosqvist	Nikolaos Spyrou
Efrat Luttwak	Madeline Niederborn	Paula Rothamel	Andrew Srisuwananukorn
Xiurui Lv	Sandra Novoa Jauregui	Pier Rovatti	Ankita Srivastava
Maria Lysandrou	Andres Noyola-Perez	Fernanda Roversi	Livia Stanger
Mona M.Hosseini	Timothy O'Connor	Anna Ruckdeschel	Fabio Steffen
Rui Ma	Yaa Ofori-Marfoh	Leo Ruhnke	Torsten Steinbrunn
Shengling Ma	Olisaemeka Ogbue	Zuzanna Rydzynska	Andrew Stiff
Eduardo Magalhaes	Denis Ohlstrom	Ludovic Saba	Sophia Stock
Tylan Magnusson	Sylvia Okonofua	Kelsey Sack	Naveen Subramanian
Himil Mahadevia	Rurika Okuda	Yasutaka Sadaga	Takeshi Sugio
Kiran Majeti	Fathia Oladipupo	Aditi Saha	Adam Suleman

## ABSTRACT ACHIEVEMENT AWARDS

Fumou Sun	Serhan Unlu	Yu-Hung Wang	Yin Yuan
Jing Sun	Daniela Urueta Portillo	Yun Wang	Saurabh Zanwar
Ruifeng Sun	Marc Usart	Zhifa Wang	Clare Zarka
Ryan Sun	Camille Vaganay	Mustafa Wasifuddin	Martha Zarou
Wenyue Sun	Arti Vaishnav	Isabel Weinhaeuser	Chi Zhang
Xueyan Sun	Sergio Vallejo	Alisha Weiss-Haug	Ellen Zhang
Teodora Supeanu	Yannis Valtis	Tobias Wertheimer	Jingliao Zhang
Keito Suto	Niek Van Der Maas	William Wesson	Lei Zhang
Andrew Ta	Jort Van Der Schans	Jonas Wißkirchen	Menglu Zhang
Jesse Tai	Myrthe van Dijk	Maggie Wong	Michelle Zhang
Amanda Tajik	Karolina Vanickova	Ping Chun Wu	Ningning Zhang
Yuki Takeuchi	Hector Alejandro Vaquera Alfaro	Xia Wu	Xiao-shuai Zhang
Joanne Tan	Giulia Veltri	Ye-Jun Wu	Yaping Zhang
Megane Tanguay	Rathnam Venkat	Michael Wysota	Yi Zhang
Matthew Tanner	Eric Vick	Serene Xavier	Peng Zhao
Ishan Tatake	Junia Vieira dos Santos	Sera Xie	Hao Zheng
Dylan Tatterton	Laura Volta	Tingting Xie	Xinhui Zheng
Samuel Taylor	Sydney Wade	Jane Xu	Chen Zhou
Ana Cristina Tejada Vasquez	Joseph Walden	Ruohao Xu	Jianying Zhou
Semaje Testamark	Christina Waldron	Yaqun Xu	Xiang Zhou
Erik Thiele Orberg	Sarah Waldvogel	Chitresh Yadav	Xinyue Zhou
Zanshe Thompson	Janek Walker	Kyoko Yamaguchi	Yichao Zhou
Sigrun Thorsteinsdottir	Bo Wan	Li-Ping Yang	Yifan Zhou
Kirsten Thus	Visanu Wanchai	Sen Yang	Hongming Zhu
Zheng Tian	Amy Wang	Tingting Yang	Xinyu Zhu
Elizabeth Titova	Dandan Wang	Chun En Yau	Katherine Zhuo
Hunter Tolison	Daniel Wang	Rashmi Yawalkar	Bachisio Ziccheddu
Seda Tolu	Helen Wang	Yongjun Yi	Fu Ziyu
Monika Toma	Jacqueline Wang	Charles Yin	Becky Zon
Zehra Tombul	Junyu Wang	Takao Yogo	Adi Zoref-Lorenz
Ahmet Toprak	Moran Wang	Justin Yoo	Luciana Zuccherato
Dicte Træden	Pan Wang	Masanori Yoshida	Ines Zugasti
Marissa Traets	Shichong Wang	Satoshi Yoshimura	
Jennifer Tran	Song Wang	Chenqi Yu	
Iva Trsova	Ximi Wang	Zhuoya Yu	
Billy Truong	Xin Wang	Junyun Yuan	

# Call for Papers

NEW FROM ASH®



**blood** VTH

vessels, thrombosis & hemostasis

*Blood Vessels, Thrombosis & Hemostasis* seeks to publish high-quality manuscripts focused on clinical and mechanistic aspects of normal and abnormal hemostasis and vascular function. These will include inherited and acquired bleeding and thrombotic disorders, including those involving platelets, as well as disorders involving the venous, arterial, and microvasculature. We seek novel and innovative studies that will have a significant aspect on translational and basic science as well as clinical care. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the *Blood Journals* portfolio, anchored by our high-impact flagship, *Blood*, is a natural home for research in specialty areas of hematology.

## WHY SUBMIT?

*Blood Vessels, Thrombosis & Hemostasis* helps place your research within the reputable and highly visible *Blood Journals* portfolio. By publishing within these journals, you align your research with the long-trusted ASH and *Blood* brands.

## BENEFITS TO AUTHORS:

- ASH & *Blood* Portfolio Visibility
- Fast Peer Review
- Seamless Transfers
- Speed to Publication
- Open Science

ASH is the home for hematology. Long embraced by the hematology community, *Blood Journals* are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a *Blood* journal.

► **Submit your paper now**



**Keith McCrae, MD**  
Editor-in-Chief  
*Cleveland Clinic*  
*Lerner Research Institute*

*Blood Vessels,  
Thrombosis &  
Hemostasis*  
Joins the *Blood  
Journals Portfolio*

# AMERICAN SOCIETY OF HEMATOLOGY 65TH ASH<sup>®</sup> ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 9-12, 2023

## GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society's annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing

and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year's annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in San Diego and the virtual meeting platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact [disabilities@hematology.org](mailto:disabilities@hematology.org).

### TWO WAYS TO ATTEND THE 65TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 65th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in San Diego or participate using ASH's virtual meeting platform. All participants, regardless of location, will have access to the virtual meeting platform built for learning, collaboration, and networking. Most sessions offered at

the in-person meeting will be broadcast simultaneously on the virtual meeting platform, and attendees will have the ability to ask questions and participate in real time.

### REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2024.

Registration is available now at [hematology.org/meetings/annual-meeting/registration-information](https://hematology.org/meetings/annual-meeting/registration-information). Those who have previously registered may upgrade their subscription to extend their access to the meeting's virtual platform at any time by contacting the Registration Center.

#### IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2024. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee.

#### VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate

in real time. The platform will also include on-demand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

- **Real-Time Experience: Access through January 1, 2024**

Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 12, 2024 by viewing the qualifying sessions on the virtual meeting platform.

- **Extended Flexibility: Access through February 1, 2024**

Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.

- **Best Value: Access through March 1, 2024**

Provides maximum flexibility to continue accessing on-demand sessions at the best price per day of access. CME/MOC credits can be claimed through April 12, 2024 by viewing qualifying sessions on the virtual meeting platform.

## GENERAL INFORMATION

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

### LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 26)

Registration Category	In-Person or Real-Time Experience (Virtual access through January 1, 2024)	Extended Flexibility (Virtual access through February 1, 2024)	Best Value (Virtual access through March 1, 2024)
Member (Active and International)	\$850	\$950	\$1,050
Non-Member	\$1,500	\$1,600	\$1,700
Associate or International Member	\$150	\$175	\$200
Medical Student, Graduate Student, or Resident Member	\$150	\$175	\$200
Non-Member in Training	\$250	\$275	\$300
Allied Health Professional	\$750	\$850	\$950
Spouse/Guest (in person only)	\$150	NA	NA
Honorary/Emeritus (before 1/1/15)	\$0	\$50	\$100
Honorary/Emeritus (after 1/1/15)	\$150	\$175	\$200
Non-Profit Patient Advocacy Organization Representative ( <b>Application for approval is required in advance</b> )	\$0	\$0	\$0

### BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

Member .....	Red
Non-Member .....	Green
Associate Member .....	Blue
International Associate Member .....	Blue
Non-Member in Training .....	Blue
Graduate/Medical Student Member .....	Blue
Resident Member .....	Blue
Honorary/Emeritus Member .....	White
Allied Health Professional .....	Purple
Exhibitor Booth Personnel .....	Black
Spouses/Guest .....	Yellow
Media .....	Orange

### BADGES

Returning this year, badges will be mailed in advance of the meeting to North American attendees only. International attendees may pick up their badge at one of several registration locations in San Diego, including at the San Diego International Airport. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## OVERVIEW OF THE MEETING SCHEDULE PREVIEW DAYS: DECEMBER 6-7, 2023

**Beginning December 6, 2023, the ASH annual meeting virtual platform will be available to all registered participants at [annualmeeting.hematology.org](https://annualmeeting.hematology.org)**

All registered attendees are encouraged to log in early to get acquainted with the site's navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

### WHO TO CONTACT

If you are having difficulty accessing the meeting's virtual platform, please contact the ASH Customer Service department by emailing [customerservice@hematology.org](mailto:customerservice@hematology.org) or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

If you have successfully accessed the meeting's virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

## FRIDAY-ONLY PROGRAMMING: December 8, 2023

There are pre-meeting activities scheduled on Friday, December 8, 2023.

- Friday Satellite Symposia
- ASH-a-Palooza
- Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

## OFFICIAL MEETING DAYS: December 9-12, 2023

The 65th ASH Annual Meeting and Exposition will take place December 9-12, 2023 in San Diego, California, and on the meeting's virtual platform. All times listed reflect the Pacific time zone.

<b>Saturday, December 9</b>	Refer to schedule-at-a-glance or the mobile app for specific session times
<b>Sunday, December 10</b>	Refer to schedule-at-a-glance or the mobile app for specific session times
<b>Monday, December 11</b>	Refer to schedule-at-a-glance or the mobile app for specific session times
<b>Tuesday, December 12</b>	All sessions will occur in the general session room beginning at 8:45 a.m. The meeting concludes at 2:15 p.m.

All sessions will be presented at the in-person meeting in San Diego, and unless otherwise noted all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until December 16, 2023.

## GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### CATCH UP DAYS: December 13-14, 2023

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday and Thursday, December 13-14, on the meeting's virtual platform.

#### BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting from December 13 through the end of their virtual meeting registration package.

### NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In San Diego, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues.

ASH's virtual meeting platform makes connecting with colleagues in San Diego and all around the world easy. On the meeting's virtual platform click on Networking to connect with your peers.

### ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting's virtual platform and throughout the convention center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Walls will feature a daily leaderboard

ranking of the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH23, #ASHRunWalk, #ASHKudos, and #ASHHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

### SPEAKER INFORMATION

#### SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in the Sails Pavilion at the San Diego Convention Center. All times are in Pacific time.

##### Speaker Ready Room Hours

Thursday, December 7 . . . . . 3:00 p.m. – 6:00 p.m.  
Friday, December 8 . . . . . 7:00 a.m. – 6:00 p.m.  
Saturday, December 9 . . . . . 7:00 a.m. – 6:00 p.m.  
Sunday, December 10 . . . . . 7:00 a.m. – 6:00 p.m.  
Monday, December 11 . . . . . 7:00 a.m. – 6:00 p.m.  
Tuesday, December 12 . . . . . 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified

for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

6 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation if your presentation is final and requires no modifications.

### CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. **If bias, actual or perceived, occurs during the presentations,**

**session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.**

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity's Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to [CME@hematology.org](mailto:CME@hematology.org).

## CONTINUING MEDICAL EDUCATION INFORMATION

### EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

### ACCREDITATION

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of **80 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with their participation in the live activity.

### CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide **AMA PRA Category 1 Credits™** to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for **AMA PRA Category 1 Credits™**.

### HOW TO OBTAIN A CME CERTIFICATE

A processing fee of \$30 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website ([www.hematology.org](http://www.hematology.org)) by clicking the CME link on the homepage. **The online process for claiming CME credits and printing a CME certificate for the 65th ASH Annual Meeting must be completed no later than April 12, 2024.**

### ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 80 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. **To receive ABIM MOC points for the 65th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 12, 2024.**

### CERTIFICATE OF PARTICIPATION

Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation after completing the Annual Meeting Evaluation Surveys through the ASH website ([www.hematology.org](http://www.hematology.org)) beginning Saturday, December 9, 2023. The online process of **filling out the annual meeting survey and printing the certificate must be completed no later than April 12, 2024. There is no charge to meeting registrants for this service.**

### EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (<http://ebah.org>). For information about claiming EBAH CME for the 65th ASH Annual Meeting email [cme@hematology.org](mailto:cme@hematology.org).

### QUALIFYING ACCREDITED SESSIONS

Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## ATTENDEE SERVICES

### ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in the Sails Pavilion at the San Diego Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or make a donation to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Health Equity Studio, fASHion boutique for the hematologist with style, ASH Live: Remote Session Viewing, ASH Store, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

#### ASH Health Equity Studio

As part of ASH's commitment to promoting and nurturing a diverse and inclusive hematology community, the ASH Health Equity Studio will once again be located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution. These micro-sessions will also be available on the virtual meeting platform.

#### ASH Live: Remote Session Viewing Area

A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session's speakers. **Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.**

#### ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at ([www.hematology.org/Store](http://www.hematology.org/Store)).

#### ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness.

#### Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to

reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website ([www.hematology.org](http://www.hematology.org)) via the mobile application or the Collaboration Room Help Desk in the Sails Pavilion to reserve a Collaboration Room.

#### Collaboration Room Hours

Friday, December 8 . . . . . 7:00 a.m. – 5:45 p.m.  
 Saturday, December 9 . . . 7:00 a.m. – 5:45 p.m.  
 Sunday, December 10 . . . 7:00 a.m. – 5:45 p.m.  
 Monday, December 11 . . . 7:00 a.m. – 5:45 p.m.  
 Tuesday, December 12 . . . 7:00 a.m. – 1:45 p.m.

#### fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, ranging from outerwear, athletic wear, golf polos, hematology specialty socks, bow ties, neck ties, scarves, and kids' apparel, too. Items will be available for purchase in an array of sizes while supplies last.

#### Headshot Alley

Need a new professional headshot? Get one for free at Headshot Alley in ASH Central. Your headshot will be sent to you via email for immediate downloading.

#### Photo Zone

Capture the excitement of the annual meeting with your friends and colleagues by taking a photo in the ASH photo zone, located in ASH Central. Various props and backdrops will be available and will change daily.

#### Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

## ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

#### Ask Red

ASH is continuing the use of AI technology in the form of "Red," your virtual chatbot assistant who helps attendees by answering ASH-specific questions. Red will also be able to connect you with "live" customer service agents that are available to answer questions.

Here are some example questions you can ask Red:

When do the shuttle buses operate?

Where is ASH Central located?

Does ASH offer child care?

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Interactive Technology in Sessions

Second screen technology through Conferences i/o enables attendees to view session slides in real time from most personal devices, including smartphones, tablets, and laptop computers. Conferences i/o allows for better viewing of images that can be difficult to see from the back of the session room and allows the audience to submit questions to the moderators virtually. Some sessions will use this technology for audience polls.

Attendees in participating sessions will be given a unique URL via QR code, which will grant access to view the slides for that session only. The QR code will be displayed at the beginning of the session but may also be found by navigating to the session within the mobile app

## Mobile App

ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2023 annual meeting. The application includes the full text of the abstracts and the articles available in *Hematology 2023* (the ASH Education Program). The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

## PosterCast

While you are in the poster hall, use the free PosterCast app to view five-minute video presentations by the author. This tool is especially useful when away from your computer, laptop or desk, or for viewing posters while the author is not present in the in-person poster hall.

Download the app on your smartphone by searching for "PosterCast" in the App Store or by visiting the PosterCast website and signing in with your ASH credentials.

To use the app, scan the QR code on a participating poster or use the keypad to enter the poster number. You will then be able to view a five-minute video describing the poster's content while you view the poster. A link to the PosterCast recording will also appear within the mobile app for the poster description

## ASH FOUNDATION DONOR LOUNGE

Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of \$250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more information. The Donor Lounge will be located in the Tides Restaurant on Level 1 of the San Diego Convention Center. The Tides Restaurant is located adjacent to Hall A and can be accessed from the Hall A Lobby.

## ASH MANAGEMENT OFFICE

The ASH Staff Office is located in Room 15A on the Mezzanine level of the San Diego Convention Center.

## ASH PARK @ THE PLAZA

ASH Park @ the Plaza will be located in Park Plaza at the San Diego Convention Center. This area will feature early morning yoga, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the San Diego sunshine.

## BUSINESS CENTER

The San Diego Convention Center has a FedEx Office that provides full-service business needs for your convenience located on the ground level across from Hall D. FedEx Office provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

## CHILD CARE ROOM

ASH has, once again, made arrangements with KiddieCorp to provide child-care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 24 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 17.

The cost for child-care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 17 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 8, through Tuesday, December 12.

The child-care room is located in Room 16 on the Mezzanine Level at the San Diego Convention Center.

### Child Care Room Hours

Friday, December 8 . . . . . 6:30 a.m. – 7:30 p.m.  
 Saturday, December 9 . . . 6:30 a.m. – 7:30 p.m.  
 Sunday, December 10 . . . 6:30 a.m. – 8:00 p.m.  
 Monday, December 11 . . . 6:30 a.m. – 8:00 p.m.  
 Tuesday, December 12 . . . 7:30 a.m. – 3:00 p.m.

## COAT/BAG CHECK

Complimentary coat and bag check is available on the Ground Level of the San Diego Convention Center in Box Office A and Hall H Lobby as well as in the East Lobby Lounge of the Marriott Marquis San Diego Marina and the Seaport Foyer at the Manchester Grand Hyatt. Electronic items will not be accepted.

### Coat/Bag Check Hours

Friday, December 8 . . . . . 7:00 a.m. – 8:30 p.m.  
 Saturday, December 9 . . . 7:00 a.m. – 8:00 p.m.  
 Sunday, December 10 . . . 7:00 a.m. – 8:30 p.m.  
 Monday, December 11 . . . 7:00 a.m. – 8:30 p.m.  
 Tuesday, December 12 . . . 7:00 a.m. – 3:30 p.m.

## FRIENDS OF BILL W.

A meeting room for the Friends of Bill W. is located in Conference Room 2 at the Marriott Marquis San Diego Marina in South Tower Level 3.

## HEMATOLOGY MEETUPS

To encourage interaction among attendees, "Hematology Meet Up" areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that

## GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

attendees can coordinate meeting up with each other at a specific location.

### INTERNET STATIONS

Internet Stations are placed throughout the San Diego Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

### LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 14A on the Mezzanine Level of the San Diego Convention Center.

### NURSING MOTHERS' LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the San Diego Convention Center, Hilton San Diego Bayfront, Marriott Marquis San Diego Marina, and Manchester Grand Hyatt. Each nursing mothers' lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Room 16 at the San Diego Convention Center.

### Nursing Mothers' Lounges Locations

#### San Diego Convention Center :

- Hall E Lobby
- Hall B1 Lobby
- Mezzanine Level

#### Manchester Grand Hyatt

- Show Office 6

#### Hilton San Diego Bayfront

- Aqua Level

#### Marriott Marquis San Diego Marina

- Pacific Ballroom Registration Desk

### QUIET ROOMS

Two quiet rooms are located in San Diego Convention Center. Show Office G is designated as the Female Quiet Room and Show Office H is designated as the Male Quiet Room.

### PRESS COMPLEX

The Press Complex, open to registered members of the media, is located on the third level of the Seaport Tower at the Manchester Grand Hyatt.

#### Press Room Hours

- Friday, December 8 . . . . . 9:00 a.m. – 5:00 p.m.
- Saturday, December 9 . . . . . 7:00 a.m. – 6:00 p.m.
- Sunday, December 10 . . . . . 7:00 a.m. – 6:00 p.m.
- Monday, December 11 . . . . . 7:00 a.m. – 6:00 p.m.
- Tuesday, December 12 . . . . . 7:00 a.m. – 1:00 p.m.

### RESTAURANTS/CONCESSIONS

Sodexo Live at the San Diego Convention Center offers a wide variety of dining options, including concessions in the Exhibit Hall and numerous food outlets featuring variety of cuisines. A variety of restaurants are also located near the San Diego Convention Center.

## TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

### VISITOR SAFETY

To stay safe during your visit to San Diego, please follow the tips provided below:

Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).

Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.

Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.

Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.

When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

### SHUTTLE SERVICE

ASH will be providing complimentary shuttle service for more than 70 hotels; additionally, 15 hotels are within walking distance of the San Diego Convention Center .

#### Shuttle Boarding Locations

Routes 1-2

- Marriott Marquis Pacific Ballroom

Routes 3-8

- SDCC Halls A-C

Routes 9-12

- SDCC Halls F-H

Routes 13-16

- Park Blvd. (Near ASH Park @ the Plaza)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Shuttle Hours

Thursday, December 7 . . . . . No shuttle service  
 Friday, December 8 . . . . . 6:30 a.m. – 10:30 p.m.  
 Saturday, December 9 . . . . . 6:30 a.m. – 9:30 p.m.  
 Sunday, December 10 . . . . . 6:30 a.m. – 9:30 p.m.  
 Monday, December 11 . . . . . 6:30 a.m. – 9:30 p.m.  
 Tuesday, December 12 . . . . . 6:30 a.m. – 3:15 p.m.  
 Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

### Service will not be provided for the following hotels, located within walking distance of the San Diego Convention Center:

- Courtyard San Diego Gaslamp/Convention Center
- Embassy Suites San Diego Bay Downtown
- Hard Rock Hotel San Diego
- Hilton San Diego Bayfront
- Hilton San Diego Gaslamp Quarter
- Horton Grand Hotel
- Hotel Indigo San Diego Gaslamp Quarter
- Hotel Z
- Manchester Grand Hyatt
- Margaritaville Hotel San Diego Gaslamp Quarter
- Marriott Marquis San Diego Marina
- Marriott San Diego Gaslamp Quarter
- Omni San Diego
- Pendry San Diego
- Residence Inn San Diego Downtown/Gaslamp Quarter

## AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes between the San Diego Convention Center and the San Diego International Airport during the days and times indicated below.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall C Lobby, Ground Level of the San Diego Convention Center. Tickets cost \$25

## Tickets Sales Hours

Monday, December 11 . . . . . 9:00 a.m. - 7:00 p.m.  
 Tuesday, December 12 . . . . . 7:00 a.m. - 2:45 p.m.

## Shuttle Hours

Monday, December 11 . . . . . 12:00 noon - 6:00 p.m.  
 Tuesday, December 12 . . . . . 9:00 a.m. - 3:00 p.m.

**Departure Location:** San Diego Convention Center, Buses load outside curbside in front of Hall C Lobby, Level 1

## PARKING

On-site private vehicle parking is available at the San Diego Convention Center as well as nearby parking options that serve the Downtown San Diego area. For detailed parking information, visit <https://www.visitsandiego.com/parking>.

## GETTING AROUND

The area's public transportation system - MTS - has routes servicing the San Diego Convention Center with connections to the San Diego International Airport and downtown San Diego. To plan your journey and obtain the latest fares, visit <https://www.sdmts.com/>.

Taking the MTS Trolley is one of the most convenient and least expensive ways to explore the downtown area and the San Diego Convention Center. For maps and fare information, visit the MTS Trolley website, <https://www.sdmts.com/transit-services/trolley>.

FRED: Free Ride Everywhere Downtown is a unique form of transport in San Diego. These electric, open-air vehicles offer completely free rides within their service area throughout downtown San Diego. Service works through a mobile app and can be a great option if the pick-up times align with your schedule. Download the Ride Circuit app to request a ride. Hours of operation can be found at [ridecircuit.com/fred](http://ridecircuit.com/fred).

Taxis in San Diego are billed using a base fare of \$3 with a charge of \$3.30 per mile.

## EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 65th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls B-F in the San Diego Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

### Exhibit Hours

Saturday, December 9 . . . . . 11:00 a.m. – 5:00 p.m.  
 Sunday, December 10 . . . . . 10:00 a.m. – 5:00 p.m.  
 Monday, December 11 . . . . . 10:00 a.m. – 2:00 p.m.

## LUNCH AVAILABLE SUNDAY AND MONDAY

Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the "ticketed" event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall. Lunch will be served from the ASH Café areas located in the back of the exhibit hall.

### Lunch Hours

Sunday, December 10 . . . . . 11:00 a.m. – 12:30 p.m.  
 Monday, December 11 . . . . . 12:00 noon – 1:30 p.m.

## GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### ASH BOOTH (#1215) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1215). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

### CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, and Company Showcases, which feature new research findings, company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All

corporate presentations will take place on the Upper Level of the San Diego Convention Center (Rooms 1-5). Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

#### Theater Hours

<b>Saturday, December 9</b>	11:30 a.m. – 12:30 p.m. 1:30 p.m. – 1:45 p.m. 3:30 p.m. – 3:45 p.m.
<b>Sunday, December 10</b>	8:00 a.m. – 9:00 a.m. 11:30 a.m. – 12:30 p.m. 4:00 p.m. – 4:15 p.m.
<b>Monday, December 11</b>	8:00 a.m. – 9:00 a.m. 12:15 p.m. – 1:15 p.m.

Please see page 139 for detailed Corporate Presentation program information.

## POSTER SESSIONS

Poster sessions are held in Halls G-H of the San Diego Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

#### Saturday, December 9

9:00 a.m. – 7:30 p.m. . . . . . Poster Session I – Viewing  
5:30 p.m. – 7:30 p.m. . . . . . Poster Session I – Presentations

#### Sunday, December 10

9:00 a.m. – 8:00 p.m. . . . . . Poster Session II – Viewing  
6:00 p.m. – 8:00 p.m. . . . . . Poster Session II – Presentations

#### Monday, December 11

9:00 a.m. – 8:00 p.m. . . . . . Poster Session III – Viewing  
6:00 p.m. – 8:00 p.m. . . . . . Poster Session III – Presentations

## SOCIAL EVENTS

### POSTER HALL RECEPTIONS

Saturday, December 9 . . . . . 5:30 p.m. – 7:30 p.m.  
Sunday, December 10 . . . . . 6:00 p.m. – 8:00 p.m.  
Monday, December 11 . . . . . 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2023 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

### ASH FOUNDATION RUN/WALK

**Sunday, December 10, 2023, 7:00 a.m. – 9:00 a.m.**

Fifth Avenue Landing (on the Embarcadero and marina side of the convention center toward the Hilton San Diego Bayfront Hotel)

Begin your day in a fun, healthy, and philanthropic way by participating in the 10th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 10. Participants may run or walk through the designated event course in scenic San Diego, choosing either a 3K or 5K route. Not attending in person this year? Don't worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Minority Recruitment Initiative Fund. ASH and the ASH Foundation may opt to designate a portion of, or all corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at <https://www.hematology.org/foundation/run-walk>

## MEETING RULES AND REGULATIONS

## CODE OF CONDUCT

ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact [customerservice@hematology.org](mailto:customerservice@hematology.org) as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

## MEETING AND SESSION PARTICIPATION

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the San Diego Convention Center:

- 1. I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE SAN DIEGO CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY.** I agree, for myself and any heirs, not to sue ASH or the San Diego Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.
- I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge, since the recipient would not have completed the requirement to show proof of vaccination to ASH before a badge is issued. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

## PARTICIPATION OF FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries..

## ANNUAL MEETING DATA COLLECTION

As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:

American Society of Hematology

- Privacy Policy ([hematology.org/about/privacy-policy](https://hematology.org/about/privacy-policy))
- Terms of Service ([hematology.org/about/terms-of-service](https://hematology.org/about/terms-of-service))

SPARGO (ASH Registration and Housing provider)

- Privacy Policy (<https://spargoinc.com/privacy-statement>)

Freeman (Virtual Meeting Platform provider)

- Privacy Policy (<https://www.freeman.com/privacy-policy/>)
- Terms of Service (<https://www.freeman.com/terms/>)

Attendees who have questions or concerns can contact [ashregistration@spargoinc.com](mailto:ashregistration@spargoinc.com).

## PROHIBITED SESSION ROOM BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

## CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

## RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH's ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact [ashregistration@spargoinc.com](mailto:ashregistration@spargoinc.com).

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

### A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

### B. Photographs and Audio Recording

**Limited Right to Share:** Except as provided in Sections A and B.2 of this Policy ([hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2](http://hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2)), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at <http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode>). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

**Attribution:** an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;

**Non-Commercial:** an attendee may not use the Meeting Materials for commercial purposes; and

**No Derivatives:** if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.

**Poster and Exhibit Hall Presentations:** Attendees of the ASH annual meeting may take photographs and make recordings of Meeting Materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. **Attendees are strictly prohibited from sharing Meeting Materials associated with Poster Presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such Meeting Materials.**

### C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of meeting materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees. Flash photography is strictly prohibited.

### D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of meeting materials, including live streaming audio or video recordings, is strictly prohibited.

### E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

### F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to use and distribute the registrant's image or voice in photographs, videotapes, audiotapes, or other electronic media pertaining to the ASH annual meeting events and activities.

# DIVERSITY, EQUITY, AND INCLUSION AT ASH®

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care

communities. ASH's efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 65th ASH Annual Meeting to help improve diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

## ASH HEALTH EQUITY STUDIO

**Saturday, Sunday, Monday**

**Sails Pavilion, San Diego Convention Center**

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

## PROMOTING MINORITIES IN HEMATOLOGY ORAL PRESENTATIONS AND RECEPTION (FOR IN-PERSON PARTICIPANTS)

**Saturday 6:30 p.m. – 9:00 p.m.**

**Marina Ballroom G, Marriott Marquis San Diego Marina**

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, Minority Resident Hematology Award, ASH Minority Graduate Award, and the ASH Minority Fellowship Award program participants. A special reception will follow the presentations to mark the 20th anniversary of the ASH Minority Recruitment Initiative.

## MATERNAL HEALTH – FERTILITY PRESERVATION IN HEMATOLOGY CARE

**Sunday 9:30 a.m. – 11:00 a.m.**

**Ballroom 20AB, San Diego Convention Center**

Both patients with hematologic conditions and their hematologists face a complex set of challenges when considering options for fertility preservation. With new technologies available and a broader understanding of the need for fertility preservation, there are more opportunities available. This session will explore why there has been such a marked increase in demand for these options, what exactly the options and techniques available are and what both hematologists and their patients need to expect in success rates, complications and demands on their already busy schedules..

## SPECIAL SCIENTIFIC SESSION ON RACE AND SCIENCE

**Sunday 9:30 a.m. – 11:00 a.m.**

**Hall A, San Diego Convention Center**

Race and Science: Bench to Bedside to the Community. Will address DEI as it relates to basic through clinical research. The following two questions will be the core focus of the discussion: (1) How do we ensure that research is generalizable; and (2) What are the critical DEI questions that need to be addressed in the different domains of research (basic, translational, and clinical).

# DIVERSITY, EQUITY, AND INCLUSION AT ASH

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## HEALTH EQUITY ROUNDS LUNCH (FOR IN-PERSON PARTICIPANTS)

**Sunday 11:15 a.m. – 12:15 p.m. Sapphire Ballroom CD, Hilton San Deigo Bayfront**

The Health Equity Rounds are interactive in-person, case-based discussions with interdisciplinary panels, including hematologists, health equity/public health experts, patients, and patient advocates, to discuss health equity issues within hematology.

## WAKE UP TO DEI NETWORKING BREAKFAST (FOR IN-PERSON PARTICIPANTS)

**Monday 7:00 a.m. – 8:30 a.m. Marina Ballroom, Marriott Marquis San Diego Marina**

This will be a networking gathering to allow the communities that fall within the Diversity, Equity, and Inclusion (DEI) umbrella a space to gather across communities and get to know each other. The event will include remarks from a member of the ASH Committee on Diversity, Equity, and Inclusion.

## AI IN HEMATOLOGY: WHERE DO YOU STAND IN 2023?

**Monday 10:30 a.m. – 12:00 p.m. Room 11, San Diego Convention Center**

Artificial intelligence (AI) and related technologies are rapidly gaining traction in a variety of industries, including healthcare. The integration of AI and machine learning (ML) has the potential to revolutionize the way we approach research and patient care in hematology, from diagnosis to prognosis and treatment selection. This session will delve into the current state of AI and ML in diagnostic hematology and clinical research. It will highlight the various ways in which AI and ML are being used in hematology, such as developing diagnostic tools and novel drug targets. Additionally, the session will discuss the use of AI and ML in prognostic models, which can help predict the outcome of a patient's disease, as well as personalized treatment plans. Finally, the session will discuss the complexity and the importance of AI ethics.

## WOMEN IN HEMATOLOGY NETWORKING RECEPTION (FOR IN-PERSON PARTICIPANTS)



**Monday 7:30 p.m. – 9:30 p.m. Coronado Ballroom & Terrace, Manchester Grand Hyatt San Diego**

The networking reception provides a space where all can gather in an informal environment, interact with peers, connect with role models and potential mentors, and become inspired and empowered to overcome the challenges women face in hematology.

# NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education's (ACCME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any

presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform and an up-to-date list of sessions will also be available.

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

## Non-CME Sessions

Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

### General Sessions

- Best of ASH
- Ernest Beutler Lecture and Prize
- Late-Breaking Abstracts Session
- Plenary Scientific Session

### Scientific Program Sessions

- The Evolution of Multiple Myeloma: From Inside-Out
- Next Generation of Gene-Based Therapies for Bleeding Disorders
- JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy

### Special Interest Sessions

- ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease
- ASH Foundation Run/Walk
- Blood Advances Meet the Editors
- Blood Advances Presents: How to Peer Review a Scientific Paper
- Blood and Beyond
- Blood Presents: How to Get Published in a Peer Review Journal

### Health Equity Rounds Lunch

### Hemostasis and Thrombosis Community Networking Reception

### Meet the Blood Editors

### Promoting Minorities in Hematology: Presentations and Reception

### Women in Hematology Networking Dinner

### Wake up to DEI Networking Breakfast

### Spotlight Sessions

### The Evolution of Multiple Myeloma: From Inside-Out

### Next Generation of Gene-Based Therapies for Bleeding Disorders

### Non-CME Programs

All sessions in the following programs are not accredited for CME credit:

### ASH Health Equity Studio

### ASH Poster Walks

### ASH Wellness Studio

### ASH-a-Palooza Events

### Company Showcases

### Industry Theaters

### Oral and Poster Abstracts

### Scientific Workshops

### Product Theaters

### Trainee Activities and Services

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

➤ For your patients

**Learn more about  
dosing information  
for KEYTRUDA<sup>®</sup>  
(pembrolizumab)**

For more information, visit [keytrudahcp.com/dosing](https://keytrudahcp.com/dosing)



Copyright © 2022 Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates. All rights reserved.  
US-KEY-05032 03/22 [keytrudahcp.com/dosing](https://keytrudahcp.com/dosing)





# AMERICAN SOCIETY OF HEMATOLOGY 65TH ASH<sup>®</sup> ANNUAL MEETING AND EXPOSITION

## DAY-AT-A-GLANCE

Friday, December 8, 2023

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### THURSDAY, DECEMBER 7, 2023

5:30 a.m.-10:00 p.m.	Registration at the Airport (for in-person participants)	3:00 p.m.-7:00 p.m.	Registration at the Convention Center (for in-person participants)
San Diego International Airport		Ballroom 20 Lobby	

### FRIDAY, DECEMBER 8, 2023

5:30 a.m.-10:00 p.m.	Registration at the Airport (for in-person participants)	<i>BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)</i> <b>Omni San Diego, Grand Ballroom 4</b>
San Diego International Airport		
7:00 a.m.-6:00 p.m.	Learn, Engage, and Relax in ASH Central (for in-person participants)	<i>Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease</i> <b>Ballroom 20CD</b>
Sails Pavilion		
7:00 a.m.-6:00 p.m.	Registration at the Convention Center (for in-person participants)	<i>Medical Crossfire<sup>®</sup>: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies</i> <b>Room 6B</b>
Ballroom 20 Lobby		<i>Myelodysplastic Syndromes 2023: What's New?</i> <b>Marriott Marquis San Diego Marina, San Diego Ballroom AB</b>
7:00 a.m.-6:00 p.m.	Registration at the Grand Hyatt (for in-person participants)	<i>Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today</i> <b>Room 6A</b>
Manchester Grand Hyatt San Diego, Hotel Main Lobby		<i>Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care with Potent CAR-T and Bispecific Options</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17</b>
7:00 a.m.-6:00 p.m.	Registration at the Marriott Marquis (for in-person participants)	
Marriott Marquis San Diego Marina, East Lobby Lounge		
7:00 a.m.-10:00 a.m.	Satellite Symposia (for in-person participants)	
		9:00 a.m.-12:00 p.m. Training Program Directors Workshop (for in-person participants)
		Hilton San Diego Bayfront, Indigo 204
		11:00 a.m.-2:00 p.m. Satellite Symposia
<i>Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice</i> <b>Room 6CF</b>		<i>A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes</i> <b>Marriott Marquis San Diego Marina, San Diego Ballroom AB</b>
<i>Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22</b>		<i>An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22</b>

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

*BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)*

**Omni San Diego, Grand Ballroom**

*CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration*

**Room 30 A-E**

*Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management*

**Ballroom 20CD**

*Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!*

**Room 6A**

*Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma*

**Room 6DE**

*Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

*Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

*Multiple Myeloma: Clinical Challenges for the Community Clinician*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

*Optimizing Myelofibrosis Management with Current and Emerging Therapies*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

*Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

*Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?*

**Room 6B**

*Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications*

**Ballroom 20AB**

**12:45 p.m.-5:00 p.m. ASH-a-Palooza (Open to Trainees Only)**

**Petco Park**

*Opening Song and Welcome*

*ASH Talks*

*Blood Drops*

*Blood Buddies*

**1:00 p.m.-1:20 p.m. ASH-a-Palooza (Open to Trainees Only)**

*ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities*

**Petco Park, Sections 112 and 114**

**2:00 p.m.-5:00 p.m.**

**Scientific Workshops**

*Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology*

**Room 33**

*Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology*

**Room 28 A-D**

*Background to Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure*

**Room 29**

*Scientific Workshop on Hematology and Aging*

**Room 11**

*Scientific Workshop on the Interplay between Coagulation and Malignancy*

**Room 25**

*Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Worms to Patients*

**Room 24**

*Scientific Workshop on Myeloid Development*

**Room 6CF**

*Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies*

**Room 7**

*Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities*

**Room 8**

**2:10 p.m.-2:30 p.m.**

**ASH-a-Palooza (Open to Trainees Only)**

*ASH Talk #2 - Approaches to Team Management*

**Petco Park, Sections 112 and 114 Petco**

**3:00 p.m.-6:00 p.m.**

**Satellite Symposia**

*A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*Achieving "Next-Level" Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

*Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease*

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

*Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care*

**Room 30 A-E**

*Advancing cTTP Care Through Integration of the Latest Clinical Evidence*

**Ballroom 20AB**

*AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

*Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome*

**Room 6DE**

*An Expert Guide to What's New and What's Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

*BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)*

**Omni San Diego, Grand Ballroom**

*Case Challenges in Myelofibrosis for the Community Clinician*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

*Changing the Path of Myelofibrosis: Envisioning a Brighter Future for Our Patients*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

*Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

*Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients' Lifespans*

**Room 6B**

*Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

*Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care*

**Room 6A**

*Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents*

**Ballroom 20CD**

**3:20 p.m.-3:30 p.m.**

**ASH-a-Poolza: President's Remarks  
(Open to Trainees Only)**

**Petco Park, Sections 112 and 114**

**3:30 p.m.-4:15 p.m.**

**ASH-a-Palooza: Blood Wars - Jeopardy!  
(Open to Trainees Only)**

**Petco Park, Sections 112 and 114**

**5:00 p.m.-7:00 p.m.**

**Trainee Welcome Reception  
(Open to Trainees Only)**

**Petco Park, Left Field**

**7:00 p.m.-10:00 p.m.**

**Satellite Symposia**

*BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)*

**Omni San Diego, Grand Ballroom**

*Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

## SATURDAY, DECEMBER 9, 2023

**7:00 a.m.-7:45 a.m.**

**ASH Wellness Studio  
(for in-person participants)**

*ASH Yoga*

**ASH Park @ The Plaza**

**7:00 a.m.-6:00 p.m.**

**Learn, Engage, and Relax in ASH Central  
(for in-person participants)**

**Sails Pavilion**

**7:00 a.m.-6:00 p.m.**

**Registration at the Convention Center  
(for in-person participants)**

**Ballroom 20 Lobby**

**7:00 a.m.-6:00 p.m.**

**Registration at the Grand Hyatt  
(for in-person participants)**

**Manchester Grand Hyatt San Diego, Hotel Main Lobby**

**7:00 a.m.-6:00 p.m.**

**Registration at the Marriott Marquis  
(for in-person participants)**

**Marriott Marquis San Diego Marina, East Lobby Lounge**

**8:00 a.m.-9:00 a.m.**

**Coffee and Collaboration in ASH Central  
(for in-person participants)**

**Sails Pavilion**

*Day-At-A-Glance*

**8:00 a.m.-9:00 a.m.**

**How I Treat: Bringing Science to Clinical Dilemmas (Ticketed Sessions, for in-person participants)**

*Acquired Hemophilia A Diagnosis and Management*

**Hilton San Diego Bayfront, Aqua Salon AB**

*Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL)*

**Hilton San Diego Bayfront, Aqua Salon F**

*Advances in Myeloproliferative Neoplasms Affecting Management*

**Hilton San Diego Bayfront, Aqua Salon D**

*Hematologists and the Care of Pregnant Women*

**Hilton San Diego Bayfront, Aqua 310**

*Patients with Acute Myeloid Leukemia*

**Hilton San Diego Bayfront, Aqua Salon C**

**8:00 a.m.-9:00 a.m.**

**Meet the Scientist (Ticketed Sessions, for in-person participants)**

*Co-Operativity in the Pathogenesis of Myeloid Malignancies*

**Hilton San Diego Bayfront, Aqua Salon E**

*Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle*

**Hilton San Diego Bayfront, Aqua 313**

*Iron and Heme in Stem Cell Maintenance and Erythropoiesis*

**Hilton San Diego Bayfront, Aqua 311**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Genome Engineering for Enhanced Blood Cancer Immunotherapy  
Hilton San Diego Bayfront, Aqua 313

Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies  
Hilton San Diego Bayfront, Aqua 300

9:00 a.m.-9:30 a.m. Coffee Break in Poster Hall  
(for in-person participants)

Halls G-H

9:00 a.m.-9:30 a.m. Health Equity Studio

Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health  
Sails Pavilion - ASH Health Equity Studio

9:00 a.m.-7:30 p.m. Poster Session I - Viewing

Halls G-H

9:05 a.m.-9:15 a.m. ASH Wellness Studio  
(for in-person participants)

What's Restoring You?  
Sails Pavilion - ASH Wellness Studio

9:15 a.m.-9:25 a.m. ASH Wellness Studio  
(for in-person participants)

An Oasis in Chaos  
Sails Pavilion - ASH Wellness Studio

9:30 a.m.-10:45 a.m. Education Sessions

Acquired Hemophilia A Diagnosis and Management  
Room 28 A-D

Are We Personalizing MDS Therapy in 2023?  
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

CAR T Cells in ALL: Bridge or Definitive Therapy?  
Room 6B

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?  
Room 6CF

What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?  
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

9:30 a.m.-10:45 a.m. Scientific Sessions

Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes  
Room 7

Next Generation of Gene-Based Therapies for Bleeding Disorders  
Room 31

The Evolution of Multiple Myeloma: From Inside-Out  
Manchester Grand Hyatt San Diego, Grand Hall C

9:30 a.m.-11:00 a.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation  
Room 25

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease  
Room 29

321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies  
Room 33

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders  
Room 30

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress  
Room 24

603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression  
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies  
Ballroom 20CD

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma  
Manchester Grand Hyatt San Diego, Grand Hall D

616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML  
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response  
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL  
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies  
Ballroom 20AB

641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation  
Manchester Grand Hyatt San Diego, Grand Hall B

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment  
Manchester Grand Hyatt San Diego, Harbor Ballroom

652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications  
Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights  
Room 6DE

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data

Room 6A

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Improving Outcomes by Reducing Transplant-Related Complications

Room 11

802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology

Marriott Marquis San Diego Marina, San Diego Ballroom AB

902. Health Services and Quality Improvement: Lymphoid Malignancies: Making a Splash In Outcomes Data

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

904. Outcomes Research: Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

9:30 a.m.-11:00 a.m. Special Session on Sickle Cell Disease Centers

Hall A

10:00 a.m.-11:00 a.m. Blood Journals Studio (for in-person participants)

Meet the Blood Advances Editors  
Halls G-H - Blood Journals Studio

11:00 a.m.-11:30 a.m. Health Equity Studio

Community Partnerships: An Essential Component to Advance Health Equity  
Sails Pavilion - ASH Health Equity Studio

11:00 a.m.-12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ The Plaza

11:00 a.m.-12:30 p.m. Open Time for Lunch

11:00 a.m.-5:00 p.m. Exhibits Open

Halls B-F

11:05 a.m.-11:15 a.m. ASH Wellness Studio (for in-person participants)

Fix the Way You Sit  
Sails Pavilion - ASH Wellness Studio

11:15 a.m.-12:15 p.m. Blood Presents: How to get Published in a Peer Review Journal (for in-person participants)

Room 24

11:15 a.m.-12:15 p.m. ASH Grassroots Network Lunch (for in-person participants)

Marriott Marquis San Diego Marina, Marina Ballroom DE

11:15 a.m.-12:15 p.m. Career Development Lunch (Open to Trainees Only)

Hilton San Diego Bayfront, Sapphire Ballroom ABCD

11:20 a.m.-11:30 a.m. ASH Wellness Studio (for in-person participants)

Life-Saving Lessons from Plant-Based Eaters  
Sails Pavilion - ASH Wellness Studio

11:30 a.m.-12:30 p.m. Industry Theaters

BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape  
Room 5A

COVID-19: Protecting Vulnerable Populations  
Room 5B

GSK oncology: breaking barriers for patients with multiple myeloma  
Room 1B

Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors  
Room 1A

11:30 a.m.-12:30 p.m. Product Theaters

Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types  
Room 3

Learn more about a CAR T cell therapy for relapsed/refractory multiple myeloma (RRMM)  
Room 2

The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocytosis (ISM)  
Room 4

11:35 a.m.-11:45 a.m. ASH Wellness Studio (for in-person participants)

Feel Better in Your Body  
Sails Pavilion - ASH Wellness Studio

12:30 p.m.-1:30 p.m. Ham-Wasserman Lecture

Hall A

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**1:30 p.m.-1:45 p.m.**

**Company Showcases**

*Galapagos' 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model*

**Room 5A**

*Showcase on Galleri®, a multi-cancer early detection test*

**Room 5B**

**1:30 p.m.-2:00 p.m.**

**Coffee Break in Exhibit Hall  
(for in-person participants)**

**Halls B-F**

**1:30 p.m.-2:00 p.m.**

**Health Equity Studio  
(for in-person participants)**

*How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective*

**Sails Pavilion - ASH Health Equity Studio**

**1:35 p.m.-1:45 p.m.**

**ASH Wellness Studio  
(for in-person participants)**

*Finding Stillness in the Busyness*

**Sails Pavilion - ASH Wellness Studio**

**1:45 p.m.-1:55 p.m.**

**ASH Wellness Studio  
(for in-person participants)**

*The Real Purpose of Your Purpose*

**Sails Pavilion - ASH Wellness Studio**

**2:00 p.m.-3:15 p.m.**

**Scientific Symposia**

*Alternative Immune Effector Cells*

**Room 6DE**

**2:00 p.m.-3:15 p.m.**

**Education Program**

*How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?*

**Ballroom 20CD**

*Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult*

**Room 24**

*Ongoing Challenges in the Management of VTE*

**Room 29**

*Transfusion Support in Sickle Cell Disease*

**Room 28 A-D**

**2:00 p.m.-3:15 p.m.**

**Scientific Sessions**

*Co-Operativity in the Pathogenesis of Myeloid Malignancies*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*Emerging Methodologies to Investigate Platelet Biology*

**Room 25**

*Spatial Genomic & Epigenomic Profiling in Hematology*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**2:00 p.m.-3:30 p.m.**

**Distinguished Abstract Achievement  
Awards Ceremony**

**Halls G-H - Blood Journals Studio**

**2:00 p.m.-3:30 p.m.**

**Oral Abstract Sessions**

*101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease*

**Room 33**

*114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors*

**Room 31**

*203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity*

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

*616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents*

**Room 6A**

*617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

*621. Lymphomas: Translational: Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc.*

**Ballroom 20AB**

*622. Lymphomas: Translational: Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma*

**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

*624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas*

**Manchester Grand Hyatt San Diego, Grand Hall B**

*627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients with Aggressive Lymphomas*

**Manchester Grand Hyatt San Diego, Grand Hall C**

*637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

*642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation*

**Manchester Grand Hyatt San Diego, Grand Hall D**

*653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma*

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

*654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines: The Spectrum of Plasma Cell Disorders*

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

*704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies*

**Room 6B**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors  
**Room 6CF**

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship from Clinical Trials And Observations  
**Room 7**

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology  
**Room 30**

901. Health Services and Quality Improvement: Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovative Care in CAR-T Therapy  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

903. Health Services and Quality Improvement: Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies  
**Hall A**

905. Outcomes Research: Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

**2:00 p.m.-3:30 p.m. Special Symposium on Quality - Identifying and Addressing Underuse in Hematologic Care**

**Room 11**

**3:30 p.m.-3:45 p.m. Company Showcases**

Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies  
**Room 5B**

Reimagining Cancer Care at Syndax: Clinical Development of Targeted Therapies  
**Room 5A**

**3:30 p.m.-4:00 p.m. Coffee Break in Exhibit Hall (for in-person participants)**

**Halls B-F**

**3:30 p.m.-4:00 p.m. Health Equity Studio (for in-person participants)**

Using Research to Advance Equity in the LGBTQIA+ Space  
**Sails Pavilion - ASH Health Equity Studio**

**3:35 p.m.-3:45 p.m. ASH Wellness Studio (for in-person participants)**

Workday Tension Timeout  
**Sails Pavilion - ASH Wellness Studio**

**3:45 p.m.-3:55 p.m. ASH Wellness Studio (for in-person participants)**

Eating With a Full Mind or Mindfully  
**Sails Pavilion - ASH Wellness Studio**

**4:00 p.m.-5:00 p.m. ASH Poster Walks (for in-person participants)**

ASH Poster Walk on Hemostasis and Thrombosis hosted by Blood VTH  
**Halls G-H - Blood Journals Studio**

**4:00 p.m.-5:15 p.m. Education Program**

Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

Hematologic Toxicity of Immunotherapies  
**Room 6DE**

How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

**Ballroom 20CD**

Why Am I Getting Paged at 2AM? Microangiopathic Emergencies  
**Room 29**

**4:00 p.m.-5:15 p.m. Scientific Sessions**

Iron and Heme in Stem Cell Maintenance and Erythropoiesis  
**Room 24**

Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis  
**Room 31**

Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.  
**Room 25**

**4:00 p.m.-5:30 p.m. Oral Sessions**

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease  
**Room 28 A-D**

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias  
**Room 33**

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care  
**Room 30**

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control  
**Room 6CF**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL

**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas

**Manchester Grand Hyatt San Diego, Grand Hall B**

627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents

**Manchester Grand Hyatt San Diego, Grand Hall C**

636. Myelodysplastic Syndromes: Basic and Translational: Molecular Drivers and Therapeutic Implications

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL

**Manchester Grand Hyatt San Diego, Grand Hall D**

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

701. Experimental Transplantation: Basic and Translational: GVHD, Intestinal Immunity, and the Gut Microbiome

**Room 7**

703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights

**Room 6A**

705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity

**Room 6B**

723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes

**Room 11**

901. Health Services and Quality Improvement: Non-Malignant Conditions: Access to Quality Care in Classical Hematology

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

903. Health Services and Quality Improvement: Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

905. Outcomes Research: Lymphoid Malignancies: Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma

**Hall A**

906. Outcomes Research: Myeloid Malignancies: Risk Factors and Health Disparities

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

**4:00 p.m.-5:35 p.m.**

**Scientific Sessions**

*What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies*  
**Ballroom 20AB**

*Ontogeny and Myeloid Disorders of Childhood*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

**5:00 p.m.-5:30 p.m.**

**Blood Journals Studio (for in-person participants)**

*Meet the Blood VTH Editor-in-Chief*

**Halls G-H - Blood Journals Studio**

**5:30 p.m.-7:30 p.m.**

**Welcome Reception in Poster Hall (for in-person participants)**

**Halls G-H**

**5:30 p.m.-7:30 p.m.**

**Poster Session I - Presentations**

**Halls G-H**

101. Red Cells and Erythropoiesis, Excluding Iron

102. Iron Homeostasis and Biology

112. Thalassemia and Globin Gene Regulation

113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational

114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

201. Granulocytes, Monocytes, and Macrophages

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational

311. Disorders of Platelet Number or Function: Clinical and Epidemiological

321. Coagulation and Fibrinolysis: Basic and Translational

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological

331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological

332. Thrombosis and Anticoagulation: Clinical and Epidemiological

401. Blood Transfusion

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational

503. Clonal Hematopoiesis, Aging and Inflammation

506. Bone Marrow Microenvironment

508. Bone Marrow Failure: Acquired

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

602. Myeloid Oncogenesis: Basic

603. Lymphoid Oncogenesis: Basic

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological

613. Acute Myeloid Leukemias: Clinical and Epidemiological

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

- 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
- 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
- 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
- 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
- 621. Lymphomas: Translational: Molecular and Genetic
- 622. Lymphomas: Translational: Non-Genetic
- 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
- 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological
- 626. Aggressive Lymphomas: Prospective Therapeutic Trials
- 627. Aggressive Lymphomas: Clinical and Epidemiological
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological
- 636. Myelodysplastic Syndromes: Basic and Translational
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological
- 641. Chronic Lymphocytic Leukemias: Basic and Translational
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
- 652. Multiple Myeloma: Clinical and Epidemiological
- 653. Multiple Myeloma: Prospective Therapeutic Trials
- 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
- 701. Experimental Transplantation: Basic and Translational
- 703. Cellular Immunotherapies: Basic and Translational
- 704. Cellular Immunotherapies: Early Phase and Investigational Therapies

- 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies
- 711. Cell Collection and Processing
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
- 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
- 723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence
- 731. Autologous Transplantation: Clinical and Epidemiological
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
- 801. Gene Therapies
- 802. Chemical Biology and Experimental Therapeutics
- 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology
- 901. Health Services and Quality Improvement: Non-Malignant Conditions
- 902. Health Services and Quality Improvement: Lymphoid Malignancies
- 903. Health Services and Quality Improvement: Myeloid Malignancies
- 904. Outcomes Research: Non-Malignant Conditions
- 905. Outcomes Research: Lymphoid Malignancies
- 906. Outcomes Research: Myeloid Malignancies

**6:30 p.m.-8:00 p.m. Promoting Minorities in Hematology (PMH) Oral Presentations (for in-person participants)**

**Marriott Marquis San Diego Marina, Marina Ballrooms D-F**

**8:00 p.m.-9:00 p.m. Promoting Minorities in Hematology (PMH) MRI Anniversary Reception (for in-person participants)**

**Marriott Marquis San Diego Marina, Marina Ballroom G**

**SUNDAY, DECEMBER 10, 2023**

**7:00 a.m.-9:00 a.m. ASH Foundation Run/Walk**  
**San Diego Bayfront Park and South Embarcadero**

**7:00 a.m.-5:00 p.m. Registration at the Convention Center (for in-person participants)**  
**Ballroom 20 Lobby**

**7:00 a.m.-6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)**  
**Sails Pavilion**

**7:30 a.m.-9:30 a.m. Medical Educators Symposium**  
**Hilton San Diego Bayfront, Sapphire Ballroom AB**

**8:00 a.m.-9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)**

**Sails Pavilion**

**8:00 a.m.-9:00 a.m. How I Treat: Bringing Science to Clinical Dilemmas (Ticketed sessions, for in-person participants)**

*Cellular Therapy for Lymphoma*  
**Hilton San Diego Bayfront, Aqua Salon D**

*Early Management of Acute Promyelocytic Leukemia (APML)*  
**Hilton San Diego Bayfront, Aqua Salon F**

*Ongoing Challenges in the Management of VTE*  
**Hilton San Diego Bayfront, Aqua Salon AB**

*T-Cell Redirection Therapy for Multiple Myeloma*  
**Hilton San Diego Bayfront, Aqua Salon E**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**8:00 a.m.-9:00 a.m. Industry Theaters**

*Classical Hematology: Looking into the Future*  
**Room 1B**

*The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy*  
**Room 1A**

**8:00 a.m.-9:00 a.m. Product Theaters**

*A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer*  
**Room 2**

*APHEXDA (motixafortide): Learn about this new FDA approved treatment option*  
**Room 3**

*Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician's Perspective and a Patient's Experience*  
**Room 4**

*Exploring Time Off Treatment with a BCL-2 Inhibitor*  
**Room 5B**

*Unveiling a Subcutaneous Therapy for 3L+ DLBCL*  
**Room 5A**

**8:00 a.m.-9:00 a.m. Meet the Scientist (Ticketed sessions, for in-person participants)**

*Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (For In-person Participants)*  
**Hilton San Diego Bayfront, Aqua 300**

*Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes*  
**Hilton San Diego Bayfront, Aqua 314**

*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*  
**Hilton San Diego Bayfront, Aqua 300**

*Research in Complications Sickle Cell Disease*  
**Hilton San Diego Bayfront, Aqua 313**

*The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression*  
**Hilton San Diego Bayfront, Aqua 311**

**9:00 a.m.-9:30 a.m. Coffee Break in Poster Hall (for in-person participants)**

Halls G-H

**9:00 a.m.-9:30 a.m. Health Equity Studio (for in-person participants)**

*Systemic Racism in Hematology*  
**Sails Pavilion - ASH Health Equity Studio**

**9:00 a.m.-8:00 p.m. Poster Session II - Viewing**

Halls G-H

**9:05 a.m.-9:15 a.m. ASH Wellness Studio (for in-person participants)**

*How to Quiet the Mind Chatter*  
**Sails Pavilion - ASH Wellness Studio**

**9:15 a.m.-9:25 a.m. ASH Wellness Studio (for in-person participants)**

*Family First - 7 Steps to Living Well*  
**Sails Pavilion - ASH Wellness Studio**

**9:30 a.m.-10:45 a.m. Scientific Symposia**

*The Impact of the Microbiota on Immunotherapy of Hematological Malignancies*  
**Room 25**

*Understanding Sickle Cell Pathophysiology*  
**Room 33**

**9:30 a.m.-10:45 a.m. Education Sessions**

*Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?*  
**Room 11**

*Hemostasis in Patients With Severe Liver Disease*  
**Room 31**

*How Do We Enhance Results in Rare Hematologic Malignancies?*  
**Room 29**

*How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?*  
**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

*The Iron Revolution!*  
**Room 28 A-D**

*What Are the Advances in Myeloproliferative Neoplasms Affecting Management?*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

**9:30 a.m.-11:00 a.m. Oral Abstracts Sessions**

*311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes*  
**Room 30**

*501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness*  
**Room 24**

*602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies*  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

*605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias*  
**Manchester Grand Hyatt San Diego, Grand Hall B**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

622. *Lymphomas: Translational: Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma*

**Manchester Grand Hyatt San Diego, Grand Hall C**

626. *Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma*

**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

627. *Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient*

**Manchester Grand Hyatt San Diego, Grand Hall D**

632. *Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs*

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

701. *Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution*

**Room 6B**

703. *Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies*

**Room 6A**

721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

722. *Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

801. *Gene Therapies: New Approaches From Bench to Bedside*

**Ballroom 20CD**

904. *Outcomes Research: Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

905. *Outcomes Research: Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology*

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

9:30 a.m.-11:00 a.m. **2023 ASH Guideline Implementation Champions**

**Room 7**

9:30 a.m.-11:00 a.m. **Maternal Health: Fertility Preservation in Hematology Care**

**Ballroom 20AB**

9:30 a.m.-11:00 a.m. **Special Scientific Session on Race and Science: Bench to Bedside to the Community**

**Hall A**

9:30 a.m.-11:05 a.m. **Scientific Sessions**

*Scientific Committee on Immunology and Host Defense|Scientific Committee on Transplantation Biology & Cellular Therapies: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy*  
**Room 6CF**

10:00 a.m.-11:00 a.m. **Meet the Blood Editors**

**Halls G-H - Blood Journals Studio**

10:00 a.m.-5:00 p.m. **Exhibits Open**

**Halls B-F**

11:00 a.m.-11:30 a.m. **Health Equity Studio (for in-person participants)**

*Legally Intentional: Microlearning Session on Systemic Racism*  
**Sails Pavilion - ASH Health Equity Studio**

11:00 a.m.-12:30 p.m. **Complimentary Light Lunch in the Exhibit Hall (for in-person participants)**

**Halls B-F**

11:00 a.m.-12:30 p.m. **Live Music and Outdoor Lunch Seating (for in-person participants)**

**ASH Park @ The Plaza**

11:05 a.m.-11:15 a.m. **ASH Wellness Studio (for in-person participants)**

*The Real Purpose of Your Purpose*  
**Sails Pavilion - ASH Wellness Studio**

11:15 a.m.-12:15 p.m. **Blood Advances Presents: How to Peer Review a Scientific Paper**

**Room 24**

11:15 a.m.-12:15 p.m. **Health Equity Rounds Lunch (for in-person participants)**

**Hilton San Diego Bayfront, Sapphire Ballroom CD**

11:15 a.m.-12:15 p.m. **Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia (Open to Trainees Only)**

**Room 33**

11:15 a.m.-12:15 p.m. **Trainee Didactic Session: The International Trainee Journey (Open to Trainees Only)**

**Room 31**

11:15 a.m.-12:30 p.m. **ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?**

**Marriott Marquis San Diego Marina, Marina Ballroom DE**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**11:20 a.m.-11:30 a.m. ASH Wellness Studio (for in-person participants)**

*Straight Spine, Big Smile*  
**Sails Pavilion - ASH Wellness Studio**

**11:30 a.m.-12:30 p.m. Product Theaters**

*A Complement Inhibitor for PNH*  
**Room 5B**

*A Discussion on a Treatment Option for Sickle Cell Disease*  
**Room 5A**

*Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody*  
**Room 1B**

*Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.*  
**Room 2**

*Learn more about a new FDA-approved treatment, OJJAARA (momelotinib)*  
**Room 4**

*Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL*  
**Room 3**

*Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases*  
**Room 1A**

**11:35 a.m.-11:45 a.m. ASH Wellness Studio (for in-person participants)**

*Stress Doesn't Exist*  
**Sails Pavilion - ASH Wellness Studio**

**12:00 p.m.-1:30 p.m. Oral Abstracts Sessions**

*301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis*  
**Room 28 A-D**

*322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan*  
**Room 29**

*506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease*  
**Room 11**

*612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL*  
**Manchester Grand Hyatt San Diego, Grand Hall B**

*621. Lymphomas: Translational : Molecular and Genetic: Signaling Pathways and MRD in Lymphoma*  
**Manchester Grand Hyatt San Diego, Harbor Ballroom**

*652. Multiple Myeloma: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance - Novel Insights on the Relevance of Gammopathies and Misc.*

**Manchester Grand Hyatt San Diego, Grand Hall C**

*654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril: Novel Diagnostics to Treatments for Amyloidosis*

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

*905. Outcomes Research: Lymphoid Malignancies: Outcomes Research in Myeloma: What's New?*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

*906. Outcomes Research: Myeloid Malignancies: Real-World Treatment Patterns and Outcomes*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

**12:30 p.m.-1:30 p.m. ASH-EHA Joint Symposium**

**Hall A**

**1:30 p.m.-2:00 p.m. Health Equity Studio (for in-person participants)**

*Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health*

**Sails Pavilion - ASH Health Equity Studio**

**1:30 p.m.-2:00 p.m. Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award**

**Hall A**

**1:30 p.m.-4:00 p.m. Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)**

**Room 28 A-D**

**1:30 p.m.-4:00 p.m. Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)**

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

**1:30 p.m.-4:00 p.m. Simulcast of Announcement of Awards and Plenary Scientific Session (for in-person participants)**

**Manchester Grand Hyatt San Diego, Grand Hall B**

**2:00 p.m.-4:00 p.m. Plenary Scientific Session**

*Plenary Scientific Session*  
**Hall A**

**4:00 p.m.-4:15 p.m. Company Showcases**

*Halia Therapeutics- Targeting the Chronic Inflammatory Bone Marrow Microenvironment*  
**Room 5B**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

4:00 p.m.-4:30 p.m.	<b>Coffee Break in Exhibit Hall (for in-person participants)</b>	4:30 p.m.-6:00 p.m.	<b>Oral Abstract Sessions</b>
<b>Halls B-F</b>		112. <i>Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia</i> <b>Room 31</b>	
4:00 p.m.-4:30 p.m. <b>Health Equity Studio (for in-person participants)</b>		113. <i>Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans</i> <b>Room 33</b>	
Community Partnerships: An Essential Component to Advance Health Equity <b>Sails Pavilion - ASH Health Equity Studio</b>		332. <i>Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care</i> <b>Room 28 A-D</b>	
4:05 p.m.-4:15 p.m. <b>ASH Wellness Studio (for in-person participants)</b>		508. <i>Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials</i> <b>Room 7</b>	
The Greatest Medicine...The Right Tribe! <b>Sails Pavilion - ASH Wellness Studio</b>		602. <i>Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells</i> <b>Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13</b>	
4:15 p.m.-4:25 p.m. <b>ASH Wellness Studio (for in-person participants)</b>		604. <i>Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19</b>	
Fix the Way You Sit <b>Sails Pavilion - ASH Wellness Studio</b>		613. <i>Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26</b>	
4:30 p.m.-5:30 p.m. <b>ASH Poster Walks (for in-person participants)</b>		618. <i>Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment</i> <b>Manchester Grand Hyatt San Diego, Grand Hall D</b>	
ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia <b>Halls G-H - Blood Journals Studio</b>		623. <i>Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy</i> <b>Manchester Grand Hyatt San Diego, Grand Hall C</b>	
4:30 p.m.-5:45 p.m. <b>Education Sessions</b>		624. <i>Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma</i> <b>Manchester Grand Hyatt San Diego, Grand Hall B</b>	
Have We Optimized Therapy Yet for Patients with AML? <b>Room 6CF</b>		627. <i>Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas</i> <b>Ballroom 20AB</b>	
Hematologists and the Care of Pregnant Women <b>Room 25</b>		634. <i>Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies</i> <b>Ballroom 20CD</b>	
Hot Topics in Blood Donation: Donor Risks and Social Justice <b>Hall A</b>		634. <i>Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers</i> <b>Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22</b>	
How Do We Tackle Remaining Clinical Challenges in CML? <b>Marriott Marquis San Diego Marina, San Diego Ballroom AB</b>		642. <i>Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia</i> <b>Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD</b>	
4:30 p.m.-5:45 p.m. <b>Education Spotlight Sessions</b>		651. <i>Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States</i> <b>Manchester Grand Hyatt San Diego, Harbor Ballroom</b>	
Debate: PCC or Andexanet alfa for Managing Bleeding in Patients in Oral Xa Inhibitors? <b>Room 29</b>		652. <i>Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma</i> <b>Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH</b>	
Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials <b>Room 6A</b>			
4:30 p.m.-5:45 p.m. <b>Scientific Spotlight Sessions</b>			
Immunometabolism as a Tool to Advance Cell Therapy <b>Room 11</b>			
Tackling Greater Burden of Multiple Myeloma in African American Patients <b>Room 6B</b>			

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

722. *Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

901. *Health Services and Quality Improvement: Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

905. *Outcomes Research: Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

**4:30 p.m.-6:00 p.m. Blood and Beyond: Un-Walling Health and Well-Being: Shared Destinies at the San Diego-Tijuana Border**

**Room 24**

**4:30 p.m.-6:30 p.m. Systems-Based Hematology Education and Networking Session: Hematology E-Consultation**

**Room 30**

**5:30 p.m.-6:00 p.m. Meet the *Blood Neoplasia* Editor-in-Chief (for in-person participants)**

**Halls G-H - Blood Journals Studio**

**6:00 p.m.-8:00 p.m. Poster Session II - Presentations (for in-person participants)**

**Halls G-H**

- 101. *Red Cells and Erythropoiesis, Excluding Iron Poster II*
- 102. *Iron Homeostasis and Biology Poster II*
- 112. *Thalassemia and Globin Gene Regulation Poster II*
- 113. *Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Poster II*
- 114. *Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological Poster II*
- 201. *Granulocytes, Monocytes, and Macrophages Poster II*
- 203. *Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Poster II*
- 301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational Poster II*
- 311. *Disorders of Platelet Number or Function: Clinical and Epidemiological Poster II*
- 321. *Coagulation and Fibrinolysis: Basic and Translational Poster II*
- 322. *Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Poster II*
- 331. *Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological Poster II*
- 332. *Thrombosis and Anticoagulation: Clinical and Epidemiological Poster II*
- 401. *Blood Transfusion Poster II*

501. *Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational Poster II*

503. *Clonal Hematopoiesis, Aging and Inflammation Poster II*

506. *Bone Marrow Microenvironment Poster II*

508. *Bone Marrow Failure: Acquired Poster II*

509. *Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Poster II*

602. *Myeloid Oncogenesis: Basic Poster II*

603. *Lymphoid Oncogenesis: Basic Poster II*

604. *Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Poster II*

605. *Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Poster II*

612. *Acute Lymphoblastic Leukemias: Clinical and Epidemiological Poster II*

613. *Acute Myeloid Leukemias: Clinical and Epidemiological Poster II*

614. *Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II*

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II*

616. *Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Poster II*

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster II*

618. *Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster II*

621. *Lymphomas: Translational: Molecular and Genetic Poster II*

622. *Lymphomas: Translational: Non-Genetic Poster II*

623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Poster II*

624. *Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological I*

626. *Aggressive Lymphomas: Prospective Therapeutic Trials Poster II*

627. *Aggressive Lymphomas: Clinical and Epidemiological Poster II*

631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Poster III*

632. *Chronic Myeloid Leukemia: Clinical and Epidemiological Poster II*

634. *Myeloproliferative Syndromes: Clinical and Epidemiological Poster II*

636. *Myelodysplastic Syndromes—Basic and Translational Poster II*

637. *Myelodysplastic Syndromes : Clinical and Epidemiological Poster II*

641. *Chronic Lymphocytic Leukemias: Basic and Translational Poster II*

642. *Chronic Lymphocytic Leukemia: Clinical and Epidemiological Poster II*

651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Poster II*

652. *Multiple Myeloma: Clinical and Epidemiological Poster II*

653. *Multiple Myeloma: Prospective Therapeutic Trials Poster II*

654. *MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Poster II*

701. *Experimental Transplantation: Basic and Translational Poster II*

703. *Cellular Immunotherapies: Basic and Translational Poster II*

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies Poster II*

705. *Cellular Immunotherapies: Late Phase and Commercially Available Therapies Poster II*

711. *Cell Collection and Processing Poster II*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

- 721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities Poster II*
- 722. *Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster II*
- 723. *Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence Poster II*
- 731. *Autologous Transplantation: Clinical and Epidemiological Poster II*
- 732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Poster II*
- 801. *Gene Therapies Poster II*
- 802. *Chemical Biology and Experimental Therapeutics Poster II*

- 803. *Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster II*
- 901. *Health Services and Quality Improvement: Non-Malignant Conditions Poster II*
- 902. *Health Services and Quality Improvement: Lymphoid Malignancies Poster II*
- 903. *Health Services and Quality Improvement: Myeloid Malignancies Poster II*
- 904. *Outcomes Research: Non-Malignant Conditions Poster II*
- 905. *Outcomes Research: Lymphoid Malignancies Poster II*
- 906. *Outcomes Research: Myeloid Malignancies Poster II*

MONDAY, DECEMBER 11, 2023

**7:00 a.m.-7:45 a.m. ASH Wellness Studio (for in-person participants)**

ASH Yoga  
ASH Park @ The Plaza

**7:00 a.m.-8:30 a.m. Wake Up To DEI Networking Breakfast (for in-person participants)**

Marriott Marquis San Diego Marina, Marina Ballroom

**7:00 a.m.-5:00 p.m. Registration at the Convention Center (for in-person participants)**

Ballroom 20 Lobby

**7:00 a.m.-6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)**

Sails Pavilion

**8:00 a.m.-9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)**

Sails Pavilion

**8:00 a.m.-9:00 a.m. Product Theaters**

*A new, first-in-class treatment for RRMM patients*  
Room 5B

*Achieving Higher Factor VIII Levels in Hemophilia A*  
Room 3

*An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma*  
Room 1B

*Latest Advancement in Allogeneic Hematopoietic Cell Transplantation*  
Room 5A

**8:15 a.m.-8:45 a.m. Health Equity Studio (for in-person participants)**

*How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective*  
Sails Pavilion - ASH Health Equity Studio

**9:00 a.m.-10:00 a.m. E. Donnell Thomas Lecture and Prize**

Hall A

**9:00 a.m.-8:00 p.m. Poster Session III - Viewing**

Halls G-H

**10:00 a.m.-10:30 a.m. Coffee Break in Exhibit Hall (for in-person participants)**

Halls B-F

**10:00 a.m.-10:30 a.m. Health Equity Studio (for in-person participants)**

*Using Research to Advance Equity in the LGBTQIA+ Space*  
Sails Pavilion - ASH Health Equity Studio

**10:00 a.m.-11:00 a.m. Meet the Blood Advances Editors (for in-person participants)**

Halls G-H - Blood Journals Studio

**10:00 a.m.-2:00 p.m. Exhibits Open**

Halls B-F

**10:05 a.m.-10:15 a.m. ASH Wellness Studio (for in-person participants)**

*What's Restoring You?*  
Sails Pavilion - ASH Wellness Studio

**10:15 a.m.-10:25 a.m. ASH Wellness Studio (for in-person participants)**

*Eating With a Full Mind or Mindfully*  
Sails Pavilion - ASH Wellness Studio

**10:30 a.m.-11:45 a.m. Education Sessions**

*Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias*  
Room 28 A-D

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

*How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies*

**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

**10:30 a.m.-11:45 a.m. Scientific Sessions**

*Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome*

**Room 31**

**10:30 a.m.-11:45 a.m. Scientific Spotlight Sessions (for in-person participants)**

*Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma*

**Manchester Grand Hyatt San Diego, Grand Hall D**

**10:30 a.m.-12:00 p.m. Oral Abstract Sessions**

*201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes*

**Room 24**

*301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis*

**Room 30**

*311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia*

**Hall A**

*331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations*

**Room 29**

*401. Blood Transfusion: Advances in Transfusion Medicine*

**Room 33**

*508. Bone Marrow Failure: Acquired: Immune AA and VEXAS: Biology, Diagnosis and Treatment*

**Room 6DE**

*602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

*603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

*613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication*

**Room 6B**

*615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL*

**Room 6A**

*623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents*

**Manchester Grand Hyatt San Diego, Grand Hall B**

*631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context*

**Ballroom 20AB**

*634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs*

**Ballroom 20CD**

*651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia*

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

*652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma*

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

*703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

*704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas*

**Room 6CF**

*722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

*731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

*901. Health Services and Quality Improvement: Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

**10:30 a.m.-12:00 p.m. AI in Hematology: Where Do You Stand in 2023?**

**Room 11**

**10:30 a.m.-12:00 p.m. ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults**

**Manchester Grand Hyatt San Diego, Grand Hall C**

**10:30 a.m.-12:00 p.m. Junior Faculty Career Development Session**

**Room 25**

**11:00 a.m.-12:00 p.m. Blood Advances in a Different Vein: Live (for in-person participants)**

**Halls G-H - Blood Journals Studio**

**12:00 p.m.-12:30 p.m. Health Equity Studio (for in-person participants)**

*Systemic Racism in Hematology*  
**Sails Pavilion - ASH Health Equity Studio**

**12:00 p.m.-1:00 p.m. The ABCs of Publishing for Authors (for in-person participants)**

**Halls G-H - Blood Journals Studio**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

12:00 p.m.-1:30 p.m.	Complimentary Light Lunch in the Exhibit Hall (for in-person participants)	12:35 p.m.-12:45 p.m.	ASH Wellness Studio (for in-person participants)
Halls B-F		An Oasis in Chaos Sails Pavilion - ASH Wellness Studio	
12:00 p.m.-1:30 p.m.	Live Music and Outdoor Lunch Seating (for in-person participants)	1:00 p.m.-1:30 p.m.	Health Equity Studio
ASH Park @ The Plaza		Legally Intentional: Microlearning Session on Systemic Racism Sails Pavilion - ASH Health Equity Studio	
12:05 p.m.-12:15 p.m.	ASH Wellness Studio (for in-person participants)	1:30 p.m.-2:30 p.m.	Ernest Beutler Lecture and Prize
Feel Better in Your Body Sails Pavilion - ASH Wellness Studio		Hall A	
12:15 p.m.-1:15 p.m.	Industry Theaters	2:30 p.m.-2:45 p.m.	Coffee Break in Poster Hall (for in-person participants)
Emerging AstraZeneca Hematology Pipeline Room 5B		Halls G-H	
Gilead and Kite Oncology Pipeline Room 1A		2:35 p.m.-2:45 p.m.	ASH Wellness Studio (for in-person participants)
In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease Room 5A		Protective Power of Plants Sails Pavilion - ASH Wellness Studio	
12:15 p.m.-1:15 p.m.	Product Theaters	2:45 p.m.-4:00 p.m.	Scientific Symposia
An FDA approved treatment option for anemia in LR-MDS Room 3		Multi-Omics Driven Precision Hematology Room 30	
CARVYKTI® Product Summary for Healthcare Providers Room 1B		2:45 p.m.-4:00 p.m.	Education Sessions
Outcomes and Economic Impact of Treatment with CABLIV® (caplacizumab-yhdp) Room 4		Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL? Manchester Grand Hyatt San Diego, Grand Hall B	
12:15 p.m.-1:15 p.m.	ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions	What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together Ballroom 20AB	
Room 7		2:45 p.m.-4:00 p.m.	Scientific Sessions
12:15 p.m.-1:15 p.m.	Trainee Didactic Session: Show Me the Money - Funding Your Research (Open to Trainees Only)	Interplay of Coagulation and Complement in Transfusion Medicine Room 29	
Room 31		2:45 p.m.-4:00 p.m.	Education Spotlight Sessions (for in-person participants)
12:15 p.m.-1:15 p.m.	Trainee Didactic Session: What to Ask For in an Interview (Open to Trainees Only)	Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL Room 7	
Room 33		What is a "Normal" Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Hall A	
12:20 p.m.-12:30 p.m.	ASH Wellness Studio (for in-person participants)	Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes Room 11	
Workday Tension Timeout Sails Pavilion - ASH Wellness Studio			

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**2:45 p.m.-4:00 p.m. Scientific Spotlight Session  
(for in-person participants)**

*The Mysteries of Factor XI*  
**Room 31**

**2:45 p.m.-4:15 p.m. Oral Abstract Sessions**

114. *Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation*  
**Room 28 A-D**

311. *Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations*  
**Room 25**

332. *Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism*  
**Room 33**

503. *Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries*  
**Room 24**

613. *Acute Myeloid Leukemias: Clinical and Epidemiological: AML : De Novo and Myelodysplasia-Related*  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

614. *Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL*  
**Manchester Grand Hyatt San Diego, Grand Hall C**

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML*  
**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features*  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

618. *Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis*  
**Manchester Grand Hyatt San Diego, Grand Hall D**

621. *Lymphomas: Translational: Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics*  
**Room 6DE**

626. *Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas*  
**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery*  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

632. *Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches*  
**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

651. *Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions*  
**Manchester Grand Hyatt San Diego, Harbor Ballroom**

652. *Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes*  
**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

703. *Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers*  
**Room 6B**

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies*  
**Room 6A**

732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation*  
**Ballroom 20CD**

803. *Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology*  
**Room 6CF**

902. *Health Services and Quality Improvement: Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

906. *Outcomes Research: Myeloid Malignancies: Symptom Burden and Supportive Therapies*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

**3:00 p.m.-4:00 p.m. Meet the Blood Editors  
(for in-person participants)**

**Halls G-H - Blood Journals Studio**

**4:30 p.m.-5:45 p.m. Education Sessions**

*Alphabet Soup - Challenging Consults on the Pediatric Units*  
**Room 11**

*Hematologists as Lifesavers: Inpatient Hematology Emergencies*  
**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6**

*How Can We Manage High-Risk Hematologic Malignancies in the Community?*  
**Manchester Grand Hyatt San Diego, Grand Hall B**

*Improving Outcomes for Individuals With Sickle Cell Disease: Are We Moving the Needle?*  
**Room 29**

**4:30 p.m.-6:00 p.m. Scientific Symposia**

*Special Symposium on the Basic Science in Hemostasis and Thrombosis*  
**Room 30**

**4:30 p.m.-6:00 p.m. Oral Abstracts Sessions**

102. *Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis*  
**Room 25**

114. *Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future*  
**Room 31**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

201. *Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias*

**Room 33**

503. *Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations*

**Room 24**

509. *Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc.*

**Room 7**

602. *Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13**

613. *Acute Myeloid Leukemias: Clinical and Epidemiological: AML: Molecular Targets, Ethnicity, and AI*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26**

614. *Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL*

**Manchester Grand Hyatt San Diego, Grand Hall D**

615. *Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML*

**Marriott Marquis San Diego Marina, San Diego Ballroom AB**

617. *Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17**

623. *Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy*

**Manchester Grand Hyatt San Diego, Grand Hall C**

627. *Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL*

**Manchester Grand Hyatt San Diego, Harbor Ballroom**

631. *Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22**

637. *Myelodysplastic Syndromes: Clinical and Epidemiological: Genomic Classification and Prognostication of MDS*

**Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19**

652. *Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma*

**Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH**

653. *Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma*

**Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD**

703. *Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies*

**Room 6B**

704. *Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas*

**Room 6A**

705. *Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence*

**Room 6CF**

711. *Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells*

**Room 6DE**

721. *Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool*

**Ballroom 20AB**

732. *Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection*

**Ballroom 20CD**

801. *Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders*

**Hall A**

904. *Outcomes Research: Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9**

905. *Outcomes Research: Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma*

**Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4**

4:30 p.m.-6:00 p.m.

**ASH Guidelines on Venous Thromboembolism (VTE): What's New**

**Room 28 A-D**

6:00 p.m.-7:30 p.m.

**ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)**

**East Terrace (Upper Level)**

6:00 p.m.-8:00 p.m.

**Poster Hall Reception (for in-person participants)**

**Halls G-H**

6:00 p.m.-8:00 p.m.

**Poster Session III - Presentations**

**Halls G-H**

6:00 p.m.-8:00 p.m.

**Poster Session - Presentations**

**Halls G-H**

101. *Red Cells and Erythropoiesis, Excluding Iron Poster III*

102. *Iron Homeostasis and Biology Poster III*

112. *Thalassemia and Globin Gene Regulation Poster III*

113. *Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational Poster III*

114. *Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological Poster III*

201. *Granulocytes, Monocytes, and Macrophages Poster III*

203. *Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Poster III*

301. *Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational Poster III*

311. *Disorders of Platelet Number or Function: Clinical and Epidemiological Poster III*

321. *Coagulation and Fibrinolysis: Basic and Translational Poster III*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological Poster III
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological Poster III
332. Thrombosis and Anticoagulation: Clinical and Epidemiological Poster III
401. Blood Transfusion Poster III
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational Poster III
503. Clonal Hematopoiesis, Aging and Inflammation Poster III
506. Bone Marrow Microenvironment Poster III
508. Bone Marrow Failure: Acquired Poster III
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital Poster III
602. Myeloid Oncogenesis: Basic Poster III
603. Lymphoid Oncogenesis: Basic Poster III
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Poster III
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Poster III
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological Poster III
613. Acute Myeloid Leukemias: Clinical and Epidemiological Poster III
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Poster III
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster III
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Poster III
621. Lymphomas: Translational: Molecular and Genetic Poster III
622. Lymphomas: Translational: Non-Genetic Poster III
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological Poster III
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological Poster III
626. Aggressive Lymphomas: Prospective Therapeutic Trials Poster III
627. Aggressive Lymphomas: Clinical and Epidemiological Poster III
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Poster III
632. Chronic Myeloid Leukemia: Clinical and Epidemiological Poster III
634. Myeloproliferative Syndromes: Clinical and Epidemiological Poster III
636. Myelodysplastic Syndromes: Basic and Translational Poster III
637. Myelodysplastic Syndromes: Clinical and Epidemiological Poster III
641. Chronic Lymphocytic Leukemias: Basic and Translational Poster III
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological Poster III
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Poster III
652. Multiple Myeloma: Clinical and Epidemiological Poster III
653. Multiple Myeloma: Prospective Therapeutic Trials Poster III
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Poster III
701. Experimental Transplantation: Basic and Translational Poster III
703. Cellular Immunotherapies: Basic and Translational Poster III
704. Cellular Immunotherapies: Early Phase and Investigational Therapies Poster III
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies Poster III
711. Cell Collection and Processing Poster III
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities Poster III
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence Poster III
731. Autologous Transplantation: Clinical and Epidemiological Poster III
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies Poster III
801. Gene Therapies Poster III
802. Chemical Biology and Experimental Therapeutics Poster III
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Poster III
901. Health Services and Quality Improvement - Non-Malignant Conditions Poster III
902. Health Services and Quality Improvement - Lymphoid Malignancies Poster III
903. Health Services and Quality Improvement: Myeloid Malignancies Poster III
904. Outcomes Research : Non-Malignant Conditions Poster III
905. Outcomes Research: Lymphoid Malignancies Poster III
906. Outcomes Research: Myeloid Malignancies Poster III

**6:00 p.m.-8:00 p.m.**      **ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)**

**Room 28E & Plaza Terrace**

**7:30 p.m.-9:30 p.m.**      **Women In Hematology Networking Event (for in-person participants)**

**Manchester Grand Hyatt San Diego, Coronado Ballroom & Terrace**

## TUESDAY, DECEMBER 12, 2023

**7:00 a.m.-1:30 p.m.**      **Registration at the Convention Center (for in-person participants)**

**Ballroom 20 Lobby**

**7:00 a.m.-6:00 p.m.**      **Learn, Engage, and Relax in ASH Central (for in-person participants)**

**Sails Pavilion**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

8:15 a.m.-11:30 a.m.	Coffee and Late-Breaking Abstracts
Hall A	
8:45 a.m.-9:00 a.m.	Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals
Hall A	
9:00 a.m.-10:30 a.m.	Coffee Available in General Session Room (for in-person participants)
Hall A	

9:00 a.m.-10:30 a.m.	Late-Breaking Abstracts Session
Hall A	
11:00 a.m.-12:30 p.m.	Presidential Symposium
Hall A	
12:30 p.m.-2:00 p.m.	Best of ASH
Hall A	
2:00 p.m.-2:15 p.m.	Business Meeting
Hall A	

WEDNESDAY, DECEMBER 13, 2023

10:00 a.m.-11:00 a.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia Virtual Program	
5:00 p.m.-6:00 p.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on What's Hot in Sickle Cell Disease Clinical Research in 2023 Virtual Program	

10:00 a.m.-11:00 a.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology Virtual Program	
5:00 p.m.-6:00 p.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on Time to Examine Time Toxicity in Hematology Virtual Program	

THURSDAY, DECEMBER 14, 2023

10:00 a.m.-11:00 a.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology Virtual Program	
5:00 p.m.-6:00 p.m. Pacific time	ASH Poster Walks (Virtual Program)
ASH Poster Walk on Time to Examine Time Toxicity in Hematology Virtual Program	



# American Society of Hematology

Helping hematologists conquer blood diseases worldwide



## BLOOD AND BEYOND

### UN-WALLING HEALTH AND WELL-BEING: SHARED DESTINIES AT THE SAN DIEGO-TIJUANA BORDER

The editors of the *Blood* journal take this opportunity to highlight the intersection of hematology and the humanities in a session entitled Blood and Beyond. For this year, in complement to the celebration of the 20th anniversary of ASH's Minority Recruitment Initiative, the session: Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border will be presented by Teddy Cruz and Fonna Forman and will consider the intersection of diversity, equity and inclusion, migration and social policy.

#### ASH® 2023 Annual Meeting in San Diego

Sunday, December 10, 2023

4:30 PM – 6:00 PM

SDCC, Room 24

► Register to attend this session in-person, or via the Virtual Platform/Webcast\*

[hematology.org/annual-meeting](https://hematology.org/annual-meeting)

\*Requires ASH 2023 registration or webcast purchase



Teddy Cruz and Fonna Forman are principals in Estudio Teddy Cruz + Fonna Forman, a research-based political and architectural practice in San Diego transgressing conventional boundaries between theory and practice, and merging the fields of architecture and urbanism, political theory, and urban policy.

#### SPEAKERS:

**Teddy Cruz (MDes Harvard), Professor,** Public Culture and Urbanism, Visual Arts Department, University of California, San Diego

**Fonna Forman (JD, PhD Chicago), Professor,** Political Science and Founding Director of the Center on Global Justice, University of California, San Diego

#### CO-CHAIRS:

**Nancy Berliner, MD,** Brigham and Women's Hospital, Boston, MA

**Alison Walker, MD, MPH, MBA,** Moffet Cancer Center, Tampa, FL

# 2023 FRIDAY SATELLITE SYMPOSIA

Preceding the 65th ASH Annual Meeting and Exposition

Join our panels of

## LEADING EXPERTS FOR ENGAGING DISCUSSIONS

at the **Friday Satellite Symposia on December 8!**

TURN OVER TO EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!



## MAKE A DIFFERENCE!

For each in-person attendee, we will be donating \$10 to Make-A-Wish Foundation



Make-A-Wish®

To learn more visit

[gotoper.com/friday23](https://gotoper.com/friday23)





# EXPLORE OUR FRIDAY SATELLITE SYMPOSIA!

## BREAKFAST SERVED AT 6:30 AM PT



Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies



Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We Are Moving Care Forward Today

## BRUNCH SERVED AT 10:30 AM PT



Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL



Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients With Cancer-Related Anemia?



Show Me the Data®: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?



Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations, and Beyond!

## HAPPY HOUR SERVED AT 2:30 PM PT



Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes From Frontline to R/R



Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care




Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients' Life Spans

## DINNER SERVED AT 6:30 PM PT



How Do We Treat GvHD Today...And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease



**SCAN HERE**  
TO LEARN MORE



# GENERAL SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential

Symposium. Many of the General Sessions also honor distinguished leaders in the field through awards and special lectures

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SATURDAY

### Ham-Wasserman Lecture

**Saturday 12:30 p.m. – 1:30 p.m.**  
Hall A

*Thrombocytopenia Due to Platelet Activation Syndromes: HIT and Beyond*

#### Chair:

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

#### Speakers:

ANDREAS GREINACHER, MD, University of Greifswald, Greifswald, Germany

## SUNDAY

### ASH-EHA Joint Symposium

**Sunday 12:30 p.m. – 1:30 p.m.**  
Hall A

*Stem Cell Transcriptomics in the Niche*

#### Co-Chairs:

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

ANTONIO MEDINA ALMEIDA, MD, PhD, President, European Hematology Association Universidade Catolica Portuguesa, Rio de Mouro, Portugal Hospital da Luz Lisboa, Lisbon, Portugal

#### Speakers:

ALEXANDER MEDVINSKY, PhD, The University of Edinburgh, Edinburgh, Scotland, UK  
*The Role of the Stem Cell Niche in the Development of Definitive Hematopoietic Stem Cells*

LINHENG LI, PhD, Stowers Institute for Medical Research, Kansas City, MO  
*Microenvironmental Regulation of Stem Cells and Wnt/PI3K-Akt Signaling in Leukemia Stem Cell Immune Escape*

**Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award**

**Sunday 1:30 p.m. – 2:00 p.m.**  
Hall A

#### Chair:

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

### Plenary Scientific Session

**Sunday 2:00 p.m. – 4:00 p.m.**  
Hall A

#### Co-Chairs:

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

NARLA MOHANDAS, DSc, New York Blood Center, New York, NY

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## MONDAY

## E. Donnell Thomas Lecture and Prize

**Monday 9:00 a.m. – 10:00 a.m.**  
Hall A

**Chair:**

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speaker:**

KATAYOUN REZVANI, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, TX  
*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*

Ernest Beutler Lecture and Prize (non-CME)

**Monday 1:30 p.m. – 2:30 p.m.**  
Hall A

*Non-Replacement Therapy in Hemophilia Management: The Evolution of FVIII Mimetics from Basic Science to Clinical Translation*

**Chair:**

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**

TAKEHISA KITAZAWA, DMV, PhD, Chugai Pharmaceutical, Totsuka-Ku, Japan  
*Basic Science*

JOHNNY MAHLANGU, MBBCh, MMed, University of the Witwatersrand, Johannesburg, South Africa  
*Clinical/Translational Science*

## TUESDAY

Announcement of Awards:  
William Dameshek Prize and  
Henry M. Stratton Medals

**Tuesday 8:45 a.m. – 9:00 a.m.**  
Hall A

**Chair:**

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

## Late-Breaking Abstracts Session

**Tuesday 9:00 a.m. – 10:30 a.m.**  
Hall A

**Co-Chairs:**

JEAN M. CONNORS, MD, Dana-Farber Cancer Institute, Boston, MA

AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD

## Presidential Symposium

**Tuesday 11:00 a.m. – 12:30 p.m.**  
Hall A

*The Complement System and Targeted Therapies*

**Chair:**

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

**Speakers:**

LUBKA T. ROUMENINA, PhD, Centre De Recherche Des Cordeliers, Paris, France  
*Complement and Innate Immunity*

CLAUDIA KEMPER, PhD, National Heart, Lung, and Blood Institute, Bethesda, MD  
*Intracellular Complement and Adoptive Immunity*

ELENI GAVRIILAKI, MD, PhD, George Papanicolaou General Hospital, Thessaloniki, Greece  
*Targeting Complement to Treat Hematologic Disease*

Best of ASH 

**Tuesday 12:30 p.m. – 2:00 p.m.**  
Hall A

**Co-Chairs:**

ELIZABETA NEMETH, PhD, University of California, Los Angeles, Los Angeles, CA

KOJO S.J. ELENITOBA-JOHNSON, MD, Memorial Sloan Kettering Cancer Center, New York, NY

# SPECIAL INTEREST SESSIONS

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## FRIDAY

### Training Directors' Workshop (for in-person participants)

**Friday**      **9:00 a.m. – 12:00 p.m.**  
**Indigo 204**  
**Hilton San Diego Bayfront**

#### Chair:

SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

#### Speakers:

TAMARA J. DUNN, MD,  
Stanford University, Stanford, CA  
*Diversity, Equity, and Inclusion  
Considerations & Recruitment*

MARTHA ARELLANO, MD, Emory University School of Medicine, Atlanta, GA  
*Diversity, Equity, and Inclusion  
Considerations & Recruitment*

SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN  
*Combatting Virtual Learning*

GERALD HSU, MD, PHD, University of California, San Francisco, San Francisco, CA  
*Combatting Virtual Learning*

JESSICA M. STEMPEL, MD, Yale School of Medicine, New Haven, CT  
*Combatting the Stigma of Being an  
International Medical Graduate*

PALLAWI TORKA, MD, Memorial Sloan Kettering Cancer Center, New York, NY  
*Combatting the Stigma of Being an  
International Medical Graduate*

### ASH Wellness Studio, Sails Pavilion <sup>(non-CME)</sup> (for in-person participants)

7:00 a.m. - 7:45 a.m.	ASH Yoga (ASH Park @ the Plaza)
9:05 a.m. - 9:15 a.m.	What's Restoring You
9:15 a.m. - 9:25 a.m.	An Oasis in Chaos
11:05 a.m. - 11:15 a.m.	Fix the Way You Sit
11:20 a.m. - 11:30 a.m.	Life-Saving Lessons from Plant-Based Eaters
11:35 a.m. - 11:45 a.m.	Feel Better in Your Body
1:35 p.m. - 1:45 p.m.	Finding Stillness in the Busyness
1:45 p.m. - 1:55 p.m.	The Real Purpose of Your Purpose
3:35 p.m. - 3:45 p.m.	Workday Tension Timeout
3:45 p.m. - 3:55 p.m.	Eating With a Full Mind or Mindfully

### Health Equity Studio, Sails Pavilion <sup>(non-CME)</sup>

9:00 a.m. - 9:30 a.m.	Outcome Disparities in Hematologic Diseases: The Importance of Social Determinants of Health
11:00 a.m. - 11:30 a.m.	Community Partnerships: An Essential Component to Advance Health Equity
1:30 p.m. - 2:00 p.m.	How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective
3:30 p.m. - 4:00 p.m.	Using Research to Advance Equity in the LGBTQIA+ Space

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Blood Journals Studio, Halls G-H**   
(for in-person participants)

10:00 a.m. - 11:00 a.m.	Meet the Blood Advances Editors
2:00 p.m. - 3:30 p.m.	Distinguished Abstract Achievement Awards Ceremony
5:00 p.m. - 5:30 p.m.	Meet the <i>Blood VTH</i> Editor-in-Chief

## SATURDAY

**Special Session on  
Sickle Cell Disease Centers**

**Saturday 9:30 a.m. – 11:00 a.m.**  
**Hall A**  
**San Diego Convention Center**

**Co-Chairs:**

PAYAL DESAI, MD, Atrium Health, Charlotte, NC

JULIE KANTER, MD, University of Alabama at Birmingham, Birmingham, AL

**Speakers:**

SOPHIE LANZKRON, MD, Johns Hopkins Medical Institute, Baltimore, MD  
*Maximizing Revenue from an Infusion Center*

JULIE KANTER, MD, University of Alabama at Birmingham, Birmingham, AL  
*Partnering With Your Hospital On 340B*

ALEXIS KRISTINE LEONARD, MD, St. Jude Children's Research Hospital, Germantown, TN  
*Getting Ready to Provide Genetic Therapies*

**ASH Grassroots Network Lunch**  
(for in-person participants) 

**Saturday 11:15 a.m. – 12:15 p.m.**  
**Marina Ballroom DE**  
**Marriott Marquis San Diego Marina**

**Chair:**

JENNIFER HOLTER-CHAKRABARTY, MD, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK

**Blood Presents: How to get Published  
in a Peer Review Journal**  
(for in-person participants)  

**Saturday 11:15 a.m. – 12:15 p.m.**  
**Room 24**  
**San Diego Convention Center**

**Panelists:**

NANCY BERLINER, MD, Brigham and Women's Hospital, Boston, MA

ANDREW W. ROBERTS, MBBS, PhD, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Australia

**Special Symposium on Quality -  
Identifying and Addressing Underuse  
in Hematologic Care**

**Saturday 2:00 p.m. – 3:30 p.m.**  
**Room 11**  
**San Diego Convention Center**

**Co-Chairs:**

MING Y YEONG LIM, MBBSCHIR, University of Utah, Salt Lake City, UT

JACOB COGAN, MD, University of Minnesota, Minneapolis, MN

**Speakers:**

GEOFFREY BARNES, MD, MSc, University of Michigan, Ann Arbor, MI  
*IVC Filter Retrieval*

ALEXANDRA POWER-HAYS, MD, Cincinnati Children's Hospital, Cincinnati, OH  
*Hydroxyurea in Sickle Cell Disease*

ALLISON BURNETT, PHARM.D., University of New Mexico Health Sciences Center, Albuquerque, NM  
*Patient Education Prior to Anticoagulation*

**Promoting Minorities in Hematology (PMH)  
Oral Presentations**  
(for in-person participants)

**Saturday 6:30 p.m. – 9:00 p.m.**  
**Marina Ballrooms D-F**  
**Marriott Marquis San Diego Marina**

**Promoting Minorities in Hematology (PMH)  
MRI Anniversary Reception**  
(for in-person participants)

**Saturday 8:00 p.m. – 9:00 p.m.**  
**Marian Ballroom G**  
**Marriott Marquis San Diego Marina**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**ASH Wellness Studio, Sails Pavilion** (non-CME)  
(for in-person participants)

9:05 a.m. - 9:15 a.m.	How to Quiet the Mind Chatter
9:15 a.m. - 9:25 a.m.	Family First – 7 Steps to Living Well
11:05 a.m. - 11:15 a.m.	The Real Purpose of Your Purpose
11:20 a.m. - 11:30 a.m.	Straight Spine, Big Smile
11:35 a.m. - 11:45 a.m.	Stress Doesn't Exist
4:05 p.m. - 4:15 p.m.	The Greatest Medicine...The Right Tribe!
4:15 p.m. - 4:25 p.m.	Fix the Way You Sit

**Health Equity Studio, Sails Pavilion** (non-CME)

9:00 a.m. - 9:30 a.m.	Systemic Racism in Hematology
11:00 a.m. - 11:30 a.m.	Legally Intentional: Microlearning Session on Systemic Racism
1:30 p.m. - 2:00 p.m.	Epidemiology of Social Determinants of Health: Inequities and Outcomes of Hematologic Diseases
4:00 p.m. - 4:30 p.m.	Community Partnerships: An Essential Component to Advance Health Equity

**Blood Journals Studio, Halls G-H** (non-CME)  
(for in-person participants)

10:00 a.m. - 11:00 a.m.	Meet the Blood Advances Editors
5:30 p.m. - 6:00 p.m.	Meet the <i>Blood Neoplasia</i> Editor-in-Chief

## SUNDAY

### Medical Educators' Symposium

**Sunday 7:30 a.m. – 9:30 a.m.**  
**Sapphire Ballroom AB**  
**Hilton San Diego Bayfront**

#### Chair:

PALLAWI TORKA, MD, Memorial Sloan Kettering Cancer Center, New York, NY

#### Speakers:

ANGELA C. WEYAND, MD, University of Michigan, Ann Arbor, MI

*General Session 1: Utilizing Social Media in Learning*

ALFRED I. LEE, MD, PhD, Yale University School of Medicine, New Haven, CT

*General Session 2: Making the Most of Virtual Teaching*

SCOTT MOERDLER, MD, Children's Hospital at Montefiore, New Brunswick, NJ

*General Session 2: Making the Most of Virtual Teaching*

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN

*General Session 3: Diversity, Equity, and Inclusion in Educational Material Development*

ERIN G. REID, MD, MS, Moores University of California, San Diego Cancer Center, La Jolla, CA  
*Breakout 1: Technology and Medical Education: Remote Learning*

RITA PASCHAL, MD, University of Alabama at Birmingham Medical Center, Birmingham, AL  
*Breakout 2: How to be a Good Mentor*

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN  
*Breakout 3: DEI and Implicit Bias in Case Development*

ARIELA L. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Philadelphia, PA  
*Breakout 4: Teaching Across the Learner Spectrum and Integrating APPs*

ALICE MA, MD, FACP, University of North Carolina at Chapel Hill, Chapel Hill, NC  
*Breakout 5: Giving Good Feedback to Trainees*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## 2023 ASH Guideline Implementation Champions

**Sunday** 9:30 a.m. – 11:00 a.m.  
Room 7  
San Diego Convention Center

### Co-Chairs:

RACHEL P. ROSOVSKY, MD, MPH, Massachusetts General Hospital, Boston, MA

AMY BILLET, MD, Dana-Farber Cancer Institute, Wilmington, DE

### Speakers:

CHRISTINA MARIE RUIZ, MD, University of California San Diego School of Medicine, San Diego, CA  
*Improving the Outpatient Pain Management Plan for Patients with Sickle Cell Disease with Innovative Pain Action Plan*

GABRIELLA NGUYEN, MD, Children's Health, University of Texas Southwestern, Dallas, TX  
*Steering Change with Compass: Clinical Pathway to Optimize the Management of Pediatric Acute Stroke in Sickle Cell Disease*

## Maternal Health: Fertility Preservation in Hematology Care

**Sunday** 9:30 a.m. – 11:00 a.m.  
Ballroom 20AB  
San Diego Convention Center

### Chair:

SARAH O'BRIEN, MD, MSc, Nationwide Children's Hospital, Columbus, OH

### Speakers:

ERICA MARSH, MD, MSCI, FACOG, University of Michigan, Ann Arbor, MI  
*Fertility Health Equity and the Fertility Preservation Process*

ALISON LOREN, MD, MSCE, University of Pennsylvania, Philadelphia, PA  
*Fertility Care for Patients with Hematologic Conditions*

MINDY CHRISTIANSON, MD, MBA, Cleveland Clinic, Cleveland, OH  
*Fertility Care for Physicians*

## Special Scientific Session on Race and Science: Bench to Bedside to the Community

**Sunday** 9:30 a.m. – 11:00 a.m.  
Hall A  
San Diego Convention Center

### Co-Chairs:

ELIZABETHA NEMETH, PhD, University of California, Los Angeles, Los Angeles, CA

ALISON R. WALKER, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH

NADINE J BARRETT, PhD, MS, MA, Duke University School of Medicine, Durham, NC

### Speakers:

SHONTA CHAMBERS, MSW, Patient Advocate Foundation, Hampton, VA  
*Community and Patient Advocate Perspective*

SAAD Z. USMANI, MD, Memorial Sloan Kettering Cancer Center, New York, NY  
*Clinical Trial Perspective*

NICOLE GORMLEY, MD, Food and Drug Administration, Bethesda, MD  
*Regulatory Perspective*

ALISA S. WOLBERG, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC  
*Basic Science Perspective*

## Blood Advances Presents: How to Peer Review a Scientific Paper (non-CME)

**Sunday** 11:15 a.m. – 12:15 p.m.  
Room 24  
San Diego Convention Center

## ASH Clinicians in Practice (ACIP) Lunch - How Can We Provide Sustainable Care to Hematology Patients?

**Sunday** 11:15 a.m. – 12:30 p.m.  
Marina Ballroom DE  
Marriott Marquis San Diego Marina

### Chair:

CHANCELLOR DONALD, MD, Tulane University School of Medicine, New Orleans, LA

### Speakers:

AARON GOODMAN, MD, University of California, San Diego, San Diego, CA  
*Financial Toxicity: How to Determine Value of Hematology Treatments for Patients?*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SHANNON WALKER, MD, Vanderbilt University, Nashville, TN

*How can Artificial Intelligence Improve the Practice of Hematology in Providing Sustainable Care in Pediatrics?*

BENJAMIN F. TILLMAN, MD, Vanderbilt University, Nashville, TN

*How can Artificial Intelligence Improve the Practice of Hematology in Providing Sustainable Care?*

DAVID ANDORSKY, MD, Rocky Mountain Cancer Centers, Boulder, CO

*Can Guidelines and Pathways Help Determine Value of Treatments for Hematology Patients?*

### Health Equity Rounds Lunch (for in-person participants) (non-CME)

**Sunday 11:15 a.m. – 12:15 p.m.**  
**Sapphire Ballroom CD**  
**Hilton San Diego Bayfront**

#### Moderator:

YVONNE EFEBERA, MD, Ohio Health, Columbus, OH

#### Speakers:

SHAKIRA J. GRANT, MBBS, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC  
*Health Workforce Diversity and Equity*

SRINIVAS DEVARAKONDA, MD, The Ohio State University, Columbus, OH  
*Health Workforce Diversity and Equity*

### Blood and Beyond (non-CME)

**Sunday 4:30 p.m. – 6:00 p.m.**  
**Room 24**  
**San Diego Convention Center**

#### Co-Chairs:

NANCY BERLINER, MD, Brigham and Women's Hospital, Boston, MA

ALISON R. WALKER, MD, Moffitt Cancer Center, Tampa FL

#### Speakers:

TEDDY CRUZ, MDES, Estudio Teddy Cruz + Fonna Forman, University of California, San Diego, San Diego, CA

FONNA FORMAN, PhD, Estudio TeddyCruz + Fonna Forman, University of California, San Diego, San Diego, CA

Un-walling Health and Well-Being: Shared destinies at the San Diego-Tijuana Border

*Considering the intersection of diversity, equity and inclusion, migration and social policy, Fonna Forman and Teddy Cruz will discuss the eco-social impacts of increasing migration across the US-Mexico border region, and how the UCSD Center on Global Justice is responding to the challenge in Tijuana. This includes the construction of emergency housing and the coordination of education, vocational training, employment, cultural activity, and health services.*

### Systems-Based Hematology Education and Networking Session: Hematology E-Consultation

**Sunday 4:30 p.m. – 6:30 p.m.**  
**Room 30**  
**San Diego Convention Center**

#### Chair:

MARC STUART ZUMBERG, MD, University of Florida, Gainesville, FL

#### Speakers:

SANDHYA R. PANCH, MD, Fred Hutchinson Cancer Center, Seattle, WA  
*Start up, Resource Allocation, Insurance, and Work Flow for Hematology E-Consultation*

SURBHI SHAH, MD, Mayo Clinic, Scottsdale, AZ  
*Lessons Learned in Hematology E-Consultation: Advantages, Disadvantages, and Applicability to Other Academic Centers and Smaller Institutions*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**ASH Wellness Studio, Sails Pavilion** (non-CME)  
(for in-person participants)

7:00 a.m. - 7:45 a.m.	ASH Yoga (ASH Park @ the Plaza)
10:05 a.m. - 10:15 a.m.	What's Restoring You
10:15 a.m. - 10:25 a.m.	Eating With a Full Mind or Mindfully
12:05 p.m. - 12:15 p.m.	Feel Better in Your Body
12:20 p.m. - 12:30 p.m.	Workday Tension Timeout
12:35 p.m. - 12:45 p.m.	An Oasis in Chaos
2:35 p.m. - 2:45 p.m.	Protective Power of Plants

**Health Equity Studio, Sails Pavilion** (non-CME)

8:15 a.m. - 8:45 a.m.	How to Support LGBTQIA Patients, Trainees, and Colleagues: A Whole Person Perspective
10:00 a.m. - 10:30 a.m.	Using Research to Advance Equity in the LGBTQIA+ Space
12:00 p.m. - 12:30 p.m.	Systemic Racism in Hematology
1:00 p.m. - 1:30 p.m.	Legally Intentional: Microlearning Session on Systemic Racism

**Blood Journals Studio, Halls G-H** (non-CME)  
(for in-person participants)

10:00 a.m. - 11:00 a.m.	Meet the <i>Blood Advances</i> Editors
11:00 a.m. - 12:00 p.m.	<i>Blood Advances</i> in a Different Vein: Live
12:00 p.m. - 1:00 p.m.	The ABCs of Publishing for Authors
3:00 p.m. - 4:00 p.m.	Meet the <i>Blood</i> Editors

## MONDAY

### Wake Up to DEI Networking Breakfast (for in-person participants) (non-CME)

**Monday 7:00 a.m. – 8:30 a.m.**  
**Marina Ballroom**  
**Marriott Marquis San Diego Marina**

### AI in Hematology: Where Do You Stand in 2023?

**Monday 10:30 a.m. – 12:00 p.m.**  
**Room 11**  
**San Diego Convention Center**

#### Chair:

TORSTEN HAFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany

#### Speakers:

WEIDA TONG, PhD, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR

*Can AI Be Used in Drug Discovery?*

YATES COLEY, PhD, Kaiser Permanente Washington Health Research Institute, Seattle, WA

### *AI Ethics: More Complex Than What You Think*

MATTHEW LUNGREN, MD, MPH, Microsoft+Nuanca Communications, Burlington, MA  
*The Application of Artificial Intelligence in Medical Imaging: Lessons Learned from Radiology, Ophthalmology and Oncology*

TORSTEN HAFERLACH, MD, PhD, Munich Leukemia Laboratory, Munich, Germany  
*The Future Is Now: AI in the Hematology Clinic*

### ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

**Monday 10:30 a.m. – 12:00 p.m.**  
**Grand Hall C Manchester**  
**Grand Hyatt San Diego**

#### Chair:

MATTHEW C. CHEUNG, MD, MSc, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

WENDY STOCK, MD, The University of Chicago, Chicago, IL  
*Initial Therapy for ALL in Adolescents and Young Adults*

JULIE WOLFSON, MD, MSHS, The University of Alabama at Birmingham, Birmingham, AL  
*Initial Therapy for ALL in Adolescents and Young Adults*

KRISTEN M. O'DWYER, MD, University of Rochester Medical Center, Rochester, NY  
*Management of Remission and Relapse of ALL in Adolescents and Young Adults*

SUMIT GUPTA, MD, PhD, Hospital for Sick Children, Toronto, ON, Canada  
*Management of Remission and Relapse of ALL in Adolescents and Young Adults*

ALESSANDRA FERRAJOLI, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
*Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in Patients with Hematological Malignancies*

### ASH Guidelines on Venous Thromboembolism (VTE): What's New

**Monday 4:30 p.m. – 6:00 p.m.**  
**Room 28 A-D,**  
**San Diego Convention Center**

**Chair:**

ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

**Speakers:**

SASKIA MIDDELDORP, MD, PhD, Academic Medical Center, Nijmegen, Netherlands  
*ASH Guidelines on Thrombophilia*

DEBORAH SIEGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada  
*Next Steps for ASH Guidelines on Use of Anticoagulation in Patients with COVID-19*

SUELY M. REZENDE, MD, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil  
*Updates on Adaptation of ASH VTE Guidelines for Latin America*

### Junior Faculty Career Development Session

**Monday 10:30 a.m. – 12:00 p.m.**  
**Room 25**  
**San Diego Convention Center**

**Chair:**

SANJAY MOHAN, MD, MSCI, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

**Speakers:**

OYEBIMPE ADESINA, MD, MS, University of California, Davis, Sacramento, CA  
*Individual Career Development Awards- K23/K08*

CASSANDRA JOSEPHSON, Children's Healthcare of Atlanta, Atlanta, GA  
*Individual Career Development Awards- K07*

SRINIVAS DEVARAKONDA, MD, The Ohio State University, Columbus, OH  
*Funding Your Medical Education Research*

### ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants)

**Monday 6:00 p.m. – 7:30 p.m.**  
**East Terrace (Upper Level),**  
**San Diego Convention Center**

### ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants)

**Monday 6:15 p.m. – 8:15 p.m.**  
**Room 28 A-D & Plaza Terrace,**  
**San Diego Convention Center**

### ASH Choosing Wisely® Campaign: 2023 ASH Choosing Wisely Champions

**Monday 12:15 p.m. – 1:15 p.m.**  
**Room 7**  
**San Diego Convention Center**

**Chair:**

MING Y. YEONG LIM, MBChir, University of Utah, Salt Lake City, UT

**Speakers:**

VILMARIE RODRIGUEZ, MD, Nationwide Children's Hospital, The Ohio State University, Columbus, OH  
*Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia*

### Women In Hematology Networking Event (for in-person participants)

**Monday 7:30 p.m. – 9:30 p.m.**  
**Coronado Ballroom & Terrace,**  
**Manchester Grand Hyatt, San Diego**

**Moderators:**

ARIELA L. MARSHALL, MD, Dana-Farber Cancer Institute, Inc., Rochester, MN

TAMARA J. DUNN, MD, Stanford University, Stanford, CA

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Panelists:**

ALEXIS A. THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

KONSTANZE DÖHNER, University Hospital of Ulm, Ulm, Germany

**Speakers:**

VILMARIE RODRIGUEZ, MD, Nationwide Children's Hospital, The Ohio State University, Columbus, OH  
*Rebida: Reduction of Blood Transfusions for Iron Deficiency Anemia*

ALESSANDRA FERRAJOLI, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
*Usefulness of a Treatment Algorithm for the Management of Abnormal Uterine Bleeding in*

AYMAN ALHEJAZI, MD, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia

*Outpatient Versus Inpatient Delivery of Intensive Chemotherapy for Patients with Hematological Neoplasms: A 5-Year Experience from a Tertiary Center*

### ASH Guidelines on Venous Thromboembolism (VTE): What's New

**Monday 4:30 p.m. – 6:00 p.m.**  
**Room 28 A-D, San Diego Convention Center**

**Chair:**

ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

**Speakers:**

SASKIA MIDDELDORP, MD, PhD, Academic Medical Center, Nijmegen, Netherlands  
*ASH Guidelines on Thrombophilia*

DEBORAH SIEGAL, MD, MSc, University of Ottawa, Ottawa, ON, Canada  
*Next Steps for ASH Guidelines on Use of Anticoagulation in Patients with COVID-19*

SUELY M. REZENDE, MD, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil  
*Updates on Adaptation of ASH VTE Guidelines for Latin America*

### ASH Hemostasis and Thrombosis Community Networking Reception (for in-person participants) (non-CME)

**Monday 6:00 p.m. – 7:30 p.m.**  
**East Terrace (Upper Level), San Diego Convention Center**

### ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease (for in-person participants) (non-CME)

**Monday 6:00 p.m. – 8:00 p.m.**  
**Room 28E & Plaza Terrace, San Diego Convention Center**

### Women in Hematology Networking Event (for in-person participants) (non-CME)

**Monday 7:30 p.m. – 9:30 p.m.**  
**Coronado Ballroom & Terrace, Manchester Grand Hyatt San Diego**

# TRAINEE ACTIVITIES

ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience. The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows.

These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## FRIDAY

### ASH-a-Palooza

**Friday** 12:45 p.m. – 5:00 p.m.  
Petco Park

This is ASH's premier trainee event complete with micro-learning sessions, mentorship opportunities, and more! It is only open to trainees wearing a blue badge. Blood Buddies are one-on-one, ten-minute sessions to discuss career tracks and seek advice for faculty members.

### ASH Talk Opening Song and Welcome



**Friday** 12:45 p.m. – 1:00 p.m.  
Sections 112 and 114  
Petco Park

#### Speaker:

RAYNE H. ROUCE, MD, Clinical Care Center-Texas Children's Hospital, Houston, TX

### ASH Talk #1 - Imposter Syndrome/DEI/Pay Disparities

**Friday** 1:00 p.m. – 1:20 p.m.  
Sections 112 and 114  
Petco Park

#### Chair:

MAYA ABDALLAH, MD, Boston University, Boston, MA

#### Speaker:

JULIE SILVER, MD, Harvard Medical School, Boston, MA

### Blood Buddies (In-Person)

**Friday** 1:30 p.m. – 2:00 p.m., 2:40 p.m. – 3:10 p.m., 4:35 p.m. – 5:00 p.m.  
Petco Park, Sections 122 and 124

#### Adult Clinical Classical Hematology

MOREY BLINDER, MD, Washington University, Saint Louis, MO

MARC CARRIER, MD, The Ottawa Hospital, Ottawa, ON, Canada

JULIE KANTER, MD, University of Alabama At Birmingham, Birmingham, AL

ALICE MA, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

SANA SAIF UR REHMAN, MD, Washington University in St. Louis, St. Louis, MO

#### Adult Clinical Malignant Hematology

JULIE E CHANG, MD, University of Wisconsin, Madison, WI

ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA

MATTHEW L. ULRICKSON, MD, MD Anderson Medical Center/Banner Health, Gilbert, AZ

ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

AMY YUAN WANG, MD, MPH, University of Chicago, Chicago, IL

#### BMT Peds and Adult

EMILY K. CURRAN, MD, University of Chicago, Cincinnati, OH

HANY ELMARIAH, MD, MS, Moffitt Cancer Center, Tampa, FL

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

DEEPA JAGADEESH, MD, Cleveland Clinic, Solon, OH  
 Sajad Khazal, MD Anderson Medical Center, Houston, TX  
 SATYAJIT KOSURI, MD, University of Chicago, Chicago, IL  
 KRISTIN M. PAGE, MD, Medical College of Wisconsin, Milwaukee, WI  
 RESHMA RAMLAL, MD, University of Kentucky, Lexington, KY  
 SANTOSH L. SARAF, MD, University of Illinois, Chicago, IL  
 ADRIANNA VLACHOS, MD, Steven and Alexandra Cohen Children's Medical Center, New York, NY

### Diversity, Equity, and Inclusion (DEI)

MAUREEN OKAM ACHEBE, MD, MPH, Hematology Division Brigham and Women's, Boston, MA  
 LEON BERNAL-MIZRACHI, MD, Emory University School of Medicine, Atlanta, GA  
 LANETTA BRONTÉ-HALL, MD, MPH, MSPH, Foundation for Sickle Cell Disease Research, Hollywood, FL  
 CHANCELLOR DONALD, MD, Tulane University School of Medicine, New Orleans, LA  
 TITILOPE FASIPE, MD, PhD, Texas Children's Cancer & Hematology Centers, Rosharon, TX  
 PATRICK T. MCGANN, MD, PhD, Children's Hospital Medical Center, Providence, RI  
 JONATHAN MOREIRA, MD, Northwestern University, Chicago, IL  
 KERICE A. PINKNEY, MD, Joe DiMaggio Children's Hospital, Hollywood, FL  
 DEIRDRA TERRELL, PhD, University of Oklahoma Health Sciences Ctr, Oklahoma City, OK  
 ANGELA C. WEYAND, MD, University of Michigan Medical School, Ann Arbor, MI

### Medical Education

ALEX A. BOUCHER, MD, University of Minnesota Medical School, Plymouth, MN  
 CAROLINE CROMWELL, MD, Mount Sinai School of Medicine, New York, NY  
 USHA PEREPU, MBBS, MRCP, University of Iowa, Iowa City, IA  
 ALEXANDRA P. WOLANSKYJ-SPINNER, MD, Mayo Clinic, Rochester, MN  
 IDA WONG-SEFIDAN, MD, University of California San Diego, San Diego, CA

### Pediatric Clinical Malignant Hematology

AIMEE C. TALLEUR, MD, St. Jude Children's Research Hospital, Memphis, TN  
 KARA M. KELLY, MD, Roswell Park Cancer Center, Buffalo, NY

LESLIE KERSUN, MD, MSED, Children's Hospital of Philadelphia, Swarthmore, PA  
 JENNIFER MCNEER, MD, MS, University of Utah, Salt Lake City, UT  
 ANDREW E. PLACE, MD, PhD, Dana-Farber Cancer Institute, Inc., Boston, MA  
 RAYNE ROUCE, MD, Texas Children's Hospital, Houston, TX

### Pediatric Clinical Classical Hematology

E. LEILA JEROME CLAY, MD, Novo Nordisk, Tampa, FL  
 MELANIE E. FIELDS, MD, The Washington University, Saint Louis, MO  
 LEWIS HSU, MD, PhD, University of Illinois, Chicago, IL  
 SEETHAL A. JACOB, MD, MS, Riley Hospital For Children, Indianapolis, IN  
 AKSHAT JAIN, MD, MPH, North Shore LIJ, Redlands, CA  
 JEFFREY D. LEBENSBURGER, DO, The University of Alabama, Birmingham, AL

### Quality Improvement

ADAM F. BINDER, MD, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA  
 RACHAEL F. GRACE, MD, The Children's Hospital Corporation, Boston, MA  
 ALLISON A. KING, MD, PhD, MPH, Washington University, St. Louis, MO  
 JORDAN K. SCHAEFER, MD, University of Michigan, Ann Arbor, MI

### Blood Drops

**Friday** 1:30 p.m. – 1:40 p.m., 1:50 p.m. – 2:00 p.m.  
**Left Field Concourse**  
**Petco Park**

### Diversity, Equity, and Inclusion

ALEX F. HERRERA, MD, City of Hope, Duarte, CA

### Hematology Opportunities for the Next Generation (HONORS)

BRITTANEY-BELLE ELIZABETH GORDON, MD, University of North Carolina, Chapel Hill, NC

### Malignant Hematology

ALISON W. LOREN, MD, Penn Medicine Perelman Center for Advanced Medicine, Philadelphia, PA

### MEI

PAMELA B. ALLEN, MD, Emory University, Decatur, GA

### PhD

WEI TONG, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Research Training Award Fellows (RTAF)

RAMZI ABBoud, MD, Washington University School of Medicine, Clayton, MO

### Sickle Cell Disease

LUKE R. SMART, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

### Quality Improvement

MING Y. YEONG LIM, MBBCHIR, University of Utah, Salt Lake City, UT

### Wellness

JACQUELINE C. BARRIENTOS, MD, MS, Mount Sinai Medical Center, Miami Beach, Florida

## ASH Talk #2 - Approaches to Team Management

(non-CME)

**Friday** 2:10 p.m. – 2:30 p.m.  
Sections 112 and 114  
Petco Park

### Chair:

MAYA ABDALLAH, MD, Boston University, Boston, MA

### Speaker:

IFEYINWA OSUNKWO, MD, Novo Nordisk Rare Disease, Waltham, MA

## Blood Drops (non-CME)

**Friday** 2:40 p.m. – 2:50 p.m., 3:00 p.m. – 3:10 p.m.  
Left Field Concourse  
Petco Park

### Diversity, Equity, and Inclusion

ALISON W. LOREN, MD, Perelman Center for Advanced Medicine, Philadelphia, PA

### Hematology Opportunities for the Next Generation (HONORS)

GEORGIOS E. CHRISTAKOPOULOS, MD, University of Minnesota Medical School, Masonic Children's Hospital, Memphis, TN

### Malignant Hematology

HIRA MIAN, MD, McMaster University, Hamilton, ON, Canada

### PhD

ZE ZHENG, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI

### Physician-Scientist Award (Phy-Sci)

CHRISTINA SNIDER, MD, Cleveland Clinic Lerner College of Medicine, Nashville, TN

### Quality Improvement

ELIZABETH J. SHPALL, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

### Scholar

STEPHEN S. CHUNG, MD, UT Southwestern Medical Center, Dallas, TX

### Sickle Cell Disease

DEEPIKA S. DARBARI, MD, Children's National Center for Cancer and Blood Disorders, Washington, DC

### Translational Research Training in Hematology (TRTH)

ANNA M. EIRING, PhD, Texas Tech University Health Science Center, El Paso, TX

### Wellness

LESLIE R. ELLIS, MD, MSHPEd, Wake Forest University School of Medicine, Winston Salem, NC

## President's Remarks

**Friday** 3:20 p.m. – 3:30 p.m.  
Sections 112 and 114  
Petco Park

ROBERT BRODSKY, MD, President, American Society of Hematology, Johns Hopkins University, Baltimore, MD

## Blood Wars - Jeopardy!

**Friday** 3:30 p.m. – 4:15 p.m.  
Sections 112 and 114  
Petco Park

## Blood Drop (non-CME)

**Friday** 4:35 p.m. – 4:45 p.m., 4:50 p.m. – 5:00 p.m.  
Left Field Concourse  
Petco Park

### CRTI

SURBHI SIDANA, MD, Stanford University, Stanford, CA

### Diversity, Equity, and Inclusion

ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

### Malignant Hematology

KAH POH (MELISSA) LOH, MBBCH BAO, MS, University of Rochester Medical Center, Rochester, NY

### MMSAP

NATASHA STANLEY, DO, Children's Hospital of Philadelphia, Philadelphia, PA

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**PhD**

HEATHER O'LEARY, PhD, Northeast Ohio Medical University, Rootstown, OH

**Sickle Cell Disease**

JEFFREY D. LEBENSBURGER, DO, The University of Alabama, Birmingham, AL

**Physician-Scientist Award (Phy-Sci)**

ALEXANDER F. M. CRAIG, MPhil, Stanford University Medical Center, Stanford, CA

**Wellness**

RONAK H. MISTRY, DO, Vanderbilt University Medical Center, Nashville, TN

**Quality Improvement**

ALLISON A. KING, MD, PhD, MPH, Washington University in St. Louis, St. Louis, MO

## SATURDAY

**Career Development Lunch** 

**Saturday 11:15 a.m. – 12:15 p.m.**  
Hilton San Diego Bayfront  
Sapphire Ballroom ABCD

This session will provide an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

A boxed lunch is provided. There will be one hematology leader, assigned with a topic, at a table where trainees are welcome to eat lunch and chat about that topic.

**Adult and Pediatric BMT**

DARIA V BABUSHOK, MD, PhD, University of Pennsylvania, Merion Station, PA

SHARON SAVAGE, MD, National Cancer Institute, NIH, Bethesda, MD

KRIS MICHAEL MAHADEO, MD, MD Anderson Medical Center, Houston, TX

ADRIANNA VLACHOS, MD, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY

**Adult Clinical Classical Hematology**

OYEBIMPE ADESINA, MD, MS, University of California Davis, Mountain View, CA

BETH MARTIN-KOOL, MD, Stanford University, Palo Alto, CA

ANNA L. PARKS, MD, University of Utah, Salt Lake City, UT

LAYLA VAN DOREN, MD, Yale School of Medicine, New Haven, CT

**Adult Clinical Malignant Hematology**

BRANDON BLUE, MD, Moffitt Cancer Center, Tampa, FL

KIERON DUNLEAVY, MD, Georgetown University, Washington, DC

MARLISE R. LUSKIN, MD, Dana-Farber Cancer Institute, Boston, MA

KENDRA SWEET, MD, Moffitt Cancer Center, Tampa, FL

**Clinical Careers in Hematology (Private Practice Careers)**

JOHN M. BURKE, MD, Rocky Mountain Cancer Centers, Aurora, CO

KAREN CHEE, MD, University of California, San Francisco, CA

PAUL FISHKIN, MD, Illinois Cancer Care, Peoria, IL

EMILY MEIER, MD, MSc, Pfizer, South San Francisco, CA

**Geriatric Hematology**

CHARITY I. OYEDEJI, MD, Duke University, Durham, NC

ASHLEY E ROSKO, MD, The Ohio State University, Columbus, OH

**Global Hematology**

LUIS ENRIQUE MALPICA CASTILLO, MD, University of Texas MD, Anderson cancer Center, Pearland, TX

DIEGO VILA CLE, MD, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil

ALETTE INATI, MD, Rafik Hariri University Hospital, Tripoli, Lebanon

**Government Careers (NIH and FDA)**

ANGELO DE CLARO, MD, Food and Drug Administration, Silver Spring, MD

LAUREL MENAPACE, MD, Sanofi, Washington, DC

WILLIAM MERRITT, Germantown, MD

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Industry Careers

GREGORY J. KATO, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

IFEYINWA OSUNKWO, MD, Novo Nordisk Rare Disease, Waltham, MA

WEILI SUN, MD, PhD, Janssen Pharmaceutical, Los Angeles

### Laboratory and Translational Hematology

EUGENE KHANDROS, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

BRIDGET MARCELLINO, MD, PhD, Mount Sinai School of Medicine, New York, NY

SEONGSEOK YUM, MD, PhD, University of Arizona, Tuscon, AZ

### Lifespan Hematology

SEETHAL A JACOB, MD, MS, Riley Hospital for Children, Indianapolis, IL

JULIE KANTER, MD, University of Alabama, Birmingham, AL

### Maternal Health

ARIELA L. MARSHALL, MD, Mayo Clinic, Rochester, MN

BETHANY T. SAMUELSON BANNOW, MD, Oregon Health and Science University, Portland, OR

### Medical Educators in Hematology

TAMARA J. DUNN, MD, Stanford University, Stanford, CA

ANNIE IM, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

JENNIE LAW, MD, University of Maryland Greenbaum Cancer Center, Baltimore, MD

COURTNEY NICOLE MILLER-CHISM, MD, Baylor College of Medicine, Houston, TX

### Medical Informatics & Artificial Intelligence

LARS BULLINGER, MD, Charité Universitätsmedizin Berlin, Berlin, Germany

RONI SHOVAL, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

### Pediatric Clinical Hematology

ALEX A BOUCHER, MD, University of Minnesota, Minneapolis, MN

PETER GORDON, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

KARA M. KELLY, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

GUY YOUNG, MD, University of Southern California Keck School of Medicine, Children's Hospital of Los Angeles, Los Angeles, CA

### PhD Careers

GABRIEL GHIAUR, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

ANDREW VOLK, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

### Systems-Based Hematology

HARRIET A. BERING, MD, Harvard Vanguard Medical Associates, Lexington, MA

NATHAN T. CONNELL, MD, MPH, Brigham and Woman's Hospital, Boston, MA

## SUNDAY – MONDAY

### Trainee Didactic Sessions

Offered during lunch on Sunday and Monday, the Trainee Didactic Sessions are designed to offer trainees an overview of timely and relevant career-oriented issues.

### Trainee Didactic Session: A Road Less Traveled - Careers Outside of Academia

**Sunday** 11:15 a.m. – 12:15 p.m.  
Room 33  
San Diego Convention Center

### Chair:

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

### Speakers:

AMBER YATES, MD, Agios Pharmaceuticals, Houston, TX

TIMOTHY KUBAL, MD, MBA, Moffitt Cancer Center, Tampa, FL

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Trainee Didactic Session: Show Me the Money - Funding Your Research

**Monday** 12:15 p.m. – 1:15 p.m.  
Room 31  
San Diego Convention Center

#### Chair:

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

#### Speakers:

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

CASSANDRA JOSEPHSON, MD, Johns Hopkins University, St Petersburg, FL

### Trainee Didactic Session: The International Trainee Journey

**Sunday** 11:15 a.m. – 12:15 p.m.  
Room 31  
San Diego Convention Center

#### Chair:

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

#### Speakers:

ELOISA RIVA, MD, MEd, Hospital Británico, Montevideo, Uruguay

ANDRES GOMEZ-DE LEON, MD, Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico

### Trainee Didactic Session: What to Ask for in an Interview

**Monday** 12:15 p.m. – 1:15 p.m.  
Room 33  
San Diego Convention Center

#### Chair:

IFEYINWA OSUNKWO, MD, Novo Nordisk, Waltham, MA

#### Speakers:


ALISON R. WALKER, MD, MPH, MBA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

ZE ZHENG, MBBS, PhD, Medical College of Wisconsin, Milwaukee, WI



# Covalent Menin Inhibition

*unlocking powerful potential*



## Covalency aims to achieve:

- Higher Selectivity
- Deeper Target Engagement
- Greater Therapeutic Window
- Durability

Biomea Fusion is developing BMF-219, an investigational, oral, covalent menin inhibitor, currently being evaluated in multiple clinical trials. We are enrolling patients with known menin inhibitor sensitive mutations in various heme malignancies, KRAS mutant solid tumors, as well as adults with diabetes.

A **COVALENT** small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of novel covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.

**Visit us at the 2023 ASH Annual Meeting Booth #3223.**

To learn more about Biomea Fusion's covalent menin inhibitor (BMF-219) clinical trials, contact us at 1-844-245-0490, [clinicaltrials@biomeafusion.com](mailto:clinicaltrials@biomeafusion.com) or visit [clinicaltrials.gov](https://clinicaltrials.gov).



We Aim to Cure™



# EDUCATION SESSIONS

The Education Program will be held from Saturday, December 9 – Monday, December 11. A question-and-answer period will occur following the conclusion of all the session's presentations. Chapters based on these sessions will be published in *Hematology 2023*, the ASH Education Program.

## Education Program Co-Chairs:

Jean M. Connors, MD, Dana-Farber Cancer Institute, Boston, MA

Amy E. DeZern, MD, Johns Hopkins University, Baltimore, MD

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Acquired Hemophilia A Diagnosis and Management

**Saturday 9:30 a.m. – 10:45 a.m.**  
**Room 28 A-D**  
**San Diego Convention Center**

### Chair:

ANDREAS TIEDE, MD, Hannover Medical School, Hannover, Germany

### Speakers:

SEAN PLATTON, MSc, CSci, FIBMS, Barts Health NHS Trust, London, England  
*Diagnosis and Laboratory Monitoring of Acquired Hemophilia A*

ANDREAS TIEDE, MD, Hannover Medical School, Hannover, Germany  
*Immunotherapy of Acquired Hemophilia A*

REBECCA KRUSE-JARRES, MD, MPH, Puget Sound Blood Center, Seattle, WA  
*The Role of Efficizumab in Acquired Hemophilia A*

## Are We Personalizing MDS Therapy in 2023?

**Saturday 9:30 a.m. – 10:45 a.m.**  
**Marriott Grand Ballroom 5-6**  
**Marriott Marquis San Diego Marina**

### Chair:

DAVID A. SALLMAN, MD, H. Lee Moffitt Cancer Center, Tampa, FL

### Speakers:

RENA R. XIAN, MD, Johns Hopkins University, Baltimore, MD  
*How to Classify Risk Based On Clinical and Molecular Modeling: Integrating molecular markers in the risk assessment of myelodysplastic syndrome*

MARIE SEBERT, MD, PhD, Institution, Paris, France  
*Next-Generation Therapy for Lower Risk MDS*

DAVID A. SALLMAN, MD, H. Lee Moffitt Cancer Center, Tampa, FL  
*Frontline Treatment Options for Higher Risk MDS: Can We Move Past Azacitidine?*

## CAR T Cells in ALL: Bridge or Definitive Therapy?

**Saturday 9:30 a.m. – 10:45 a.m.**  
**Room 6B**  
**San Diego Convention Center**

### Chair:

ALICE BERTAINA, MD, PhD, Stanford University, Palo Alto, CA

### Speakers:

NIRALI N. SHAH, M.D., National Institutes of Health, Bethesda, MD  
*Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL*

ALICE BERTAINA, MD, PhD, Stanford University, Palo Alto, CA  
*Stem Cell Transplantation for ALL: You've Always Got a Donor, Why Not Always Use It?*

STEPHEN GOTTSCHALK, MD, St. Jude's Children's Research Hospital, Memphis, TN  
*Preventing Relapse after CD19-CAR T-cell Therapy for Pediatric ALL: Role of Transplant and Enhanced CAR T cells*

## How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

**Saturday 9:30 a.m. – 10:45 a.m.**  
**Room 6CF**  
**San Diego Convention Center**

### Chair:

MANALI K. KAMDAR, MD, MBBS, University of Colorado, Denver, CO

### Speakers:

ANNA MARIA SUREDA BALARI, MD, PhD, INSTITUT CATALA D'ONCOLOGIA, BARCELONA, SPAIN  
*CAR T-Cell Therapy in Aggressive Lymphomas- Identifying Prognostic and Predictive Markers*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

LORETTA J. NASTOUPIL, MD, MD Anderson Cancer Center, Houston, TX  
*Management of Aggressive Lymphoma After CAR T-Cell Therapy Failure*

MANALI K. KAMDAR, MD, MBBS, University of Colorado, Denver, CO  
*Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas*

### What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?

**Saturday 9:30 a.m. – 10:45 a.m.**  
**Pacific Ballroom Salons 15-17**  
**Marriott Marquis San Diego Marina**

#### Chair:

ALISON R. WALKER, MD, MPH, MBA, The Ohio State University Medical Center, Powell, OH

#### Speakers:

JACQUELINE CLOOS, PhD, VU University Medical Center, Amsterdam, Netherlands  
*Understanding Differential Technologies for Detection of MRD and How to Incorporate into Clinical Practice*

MARION SUBKLEWE, MD, Ludwig-Maximilians-University of Munich, Muenchen, Bavaria, Germany  
*Novel Immunotherapies in the Treatment of AML, Is There a Hope?*

ALISON R. WALKER, MD, MPH, MBA, The Ohio State University Medical Ctr., Powell, OH  
*Novel Therapies upon Failure of HMA + Venetoclax*

### How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Ballroom 20CD**  
**San Diego Convention Center**

#### Chair:

CHAITRA S. UJJANI, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA

#### Speakers:

CHAITRA S. UJJANI, MD, Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA  
*Dual Targeted Regimens for the Front-line Treatment of CLL*

JOANNA M. RHODES, MD, Rutgers Cancer Institute, Hoboken, NJ  
*MRD Directed Therapy in CLL- Ready for Primetime?*

TOBY EYRE, Oxford University Hospitals NHS Foundation Trust, Headington, United Kingdom  
*Richters Transformation- Is There Light at the End of this Tunnel?*

### Inherited Bone Marrow Failure Syndromes - From Pediatrics to Adult

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Room 24**  
**San Diego Convention Center**

#### Chair:

EMMA M. GROARKE, MD, National Institutes of Health, Bethesda, MD

#### Speakers:

EMMA M. GROARKE, MD, National Institutes of Health, Bethesda, MD  
*When to Consider Inherited Marrow Failure Syndromes in Adults*

TIMOTHY S. OLSON, MD, PhD, Children's Hospital of Philadelphia, Merion Station, PA  
*Management of Fanconi Anemia Beyond Childhood*

MARENA R. NIEWISCH, MD, Hannover Medical School, Hannover, Germany  
*Clinical Manifestations of Telomere Biology Disorders in Adults*

### Ongoing Challenges in the Management of VTE

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Room 29**  
**San Diego Convention Center**

#### Chair:

KENNETH A. BAUER, MD, Beth Israel Deaconess Medical Center, Boston, MA

#### Speakers:

KENNETH A. BAUER, MD, Beth Israel Deaconess Medical Center, Boston, MA  
*Talk #1 The Do's, Don'ts, and Nuances of Thrombophilia Testing*

CECILIA BECATTINI, MD, University of Perugia, Perugia, Italy  
*Provoked vs Minimally Provoked vs Unprovoked VTE—Does it Matter?*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

KEITH R. McCRAE, MD, Cleveland Clinic, Cleveland, OH  
*How to Diagnose and Manage Antiphospholipid Syndrome*

### Transfusion Support in Sickle Cell Disease

**Saturday** 2:00 p.m. – 3:15 p.m.  
Room 28 A-D  
San Diego Convention Center

#### Chair:

FRANCE PIRENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France

#### Speakers:

ANOOSHA HABIBI, MD, Henri-Mondor University Hospital- UPEC, Creteil Cedex, France  
*Managing Pregnancy in Patients with Sickle Cell Disease from a Transfusion Perspective*

SHANNON KELLY, Vitalant Research Institute (formerly Blood Systems Research Institute), San Francisco, CA  
*Suppressing HbS With Chronic Exchange Transfusions*

FRANCE PIRENNE, MD, PhD, Université Paris-Est Créteil Hospital, Creteil, France  
*Alloimmunization and Hyperhemolysis in Sickle Cell Disease*

### Graft Versus Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

**Saturday** 4:00 p.m. – 5:15 p.m.  
San Diego Ballroom AB  
Marriott Marquis San Diego Marina

#### Chair:

MUNA QAYED, MD, Emory University, Atlanta, GA

#### Speakers:

KIRK R. SCHULTZ, B.C. Children's Hospital, Vancouver, BC, Canada  
*Planning GVHD Preemptive Therapy: Risk factors, Biomarkers, and Prognostic Scores*

MUNA QAYED, MD, Emory University, Atlanta, GA  
*Novel Approaches to Acute GVHD Prevention*

IDOROENYI AMANAM, MD, City of Hope, Duarte, CA  
*Chronic GVHD: Review Advances in Prevention, Novel Endpoints and Targeted Strategies*

### Hematologic Toxicity of Immunotherapies

**Saturday** 4:00 p.m. – 5:15 p.m.  
Room 6DE  
San Diego Convention Center

#### Chair:

FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL

#### Speakers:

FREDERICK L. LOCKE, MD, Moffitt Cancer Center, Tampa, FL  
*CAR-T*

MICHAEL KROLL, MD, MD Anderson Cancer Center, Houston, TX  
*Checkpoint Inhibitors*

MARTIN HUTCHINGS, MD, PhD, Rigshospitalet, Copenhagen, Denmark  
*Bispecific Antibody Therapies*

### How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

**Saturday** 4:00 p.m. – 5:15 p.m.  
Ballroom 20CD  
San Diego Convention Center

#### Chair:

ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ

#### Speakers:

ANDREW M. EVENS, DO, MBA, MMSc, Rutgers Cancer Institute New Jersey, New Brunswick, NJ  
*Hodgkin Lymphoma Treatment for Older Persons in the Modern Era*

SAIRAH AHMED, MD, The University of Texas M D Anderson Cancer Center, Houston, TX  
*Management of Limited Stage Hodgkin Lymphoma*

NATALIE S. GROVER, MD, University of North Carolina, Chapel Hill, NC  
*The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post-Brentuximab and Checkpoint Inhibitor Failure*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Why Am I Getting Paged at 2AM? Microangiopathic Emergencies

**Saturday** 4:00 p.m. – 5:15 p.m.  
Room 29  
San Diego Convention Center

#### Chair:

SHRUTI CHATURVEDI, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD

#### Speakers:

JENNIFER JURY MCINTOSH, DO, Medical College of Wisconsin, Milwaukee, WI  
*Labor and Delivery: DIC, HELLP, Pre-eclampsia*

SHRUTI CHATURVEDI, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD  
*Medical Consult—aHUS, TTP—How to Distinguish and What to Do*

BEVERLEY JANE HUNT, MD, FMCPATH, FRCP, King's College, London, England  
*Consumptive Coagulopathy in the ICU*

### Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

**Sunday** 9:30 a.m. – 10:45 a.m.  
Room 11  
San Diego Convention Center

#### Chair:

SUNEET AGARWAL, MD, PhD, Children's Hospital Boston, Boston, MA

#### Speakers:

KRISTEN E. SCHRATZ, MD, Johns Hopkins Hospital, Baltimore, MD  
*Clonal Evolution in Inherited Marrow Failure Syndromes Predicts Disease Progression*

SUNEET AGARWAL, MD, PhD, Children's Hospital Boston, Boston, MA  
*Minimal Intensity Conditioning Strategies for Bone Marrow Failure – Is It Time for “Preventative” Transplants?*

KASIANI MYERS, MD, Cincinnati Children's Hospital, Cincinnati, OH  
*Post-transplant Complications in Patients With Marrow Failure Syndromes—Are We Improving Long-Term Outcomes?*

### Hemostasis in Patients with Severe Liver Disease

**Sunday** 9:30 a.m. – 10:45 a.m.  
Room 31  
San Diego Convention Center

#### Chair:

LARA N. ROBERTS, MD, MBBS, King's College Hospital, London, England

#### Speakers:

TON LISMAN, PhD, University Medical Centre Groningen, Groningen, Netherlands  
*How to Assess Hemostasis in Patients with Severe Liver Disease*

LARA N. ROBERTS, MD, MBBS, King's College Hospital, London, England  
*How to Manage Hemostasis in Patients with Liver Disease During Interventions*

WALTER AGENO, MD, University of Insubria, Varese, Italy  
*How to Manage Splanchnic Vein Thrombosis in Patients with Liver Disease*

### How Do We Enhance Results in Rare Hematologic Malignancies?

**Sunday** 9:30 a.m. – 10:45 a.m.  
Room 29  
San Diego Convention Center

#### Chair:

ANITA D'SOUZA, MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI

#### Speakers:

OUSSAMA ABLA, MD, Hospital for Sick Children, Toronto, ON, Canada  
*Langerhans Cell Histiocytosis: Promises and Caveats of Targeted Therapies in High-risk and CNS Disease*

DEEPTI H. RADIA, MD, FRCPATH, Guy's and St. Thomas' Hospital, London, United Kingdom  
*Mastocytosis Demystified*

ANITA D'SOUZA, MD, MS, The Medical College of Wisconsin Inc, Milwaukee, WI  
*Amyloid Consults Do Not Have to be Vexing*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

**Sunday** 9:30 a.m. – 10:45 a.m.  
Seaport Ballroom EFGH  
Manchester Grand Hyatt San Diego

### Chair:

FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy

### Speakers:

FRANCESCA GAY, MD, PhD, University of Torino, Torino, Italy  
*A Rational Approach to Functionally High-Risk Myeloma*

MONIQUE A. HARTLEY-BROWN, MD, Dana-Farber Cancer Institute, Boston, MA  
*Considerations for Next Therapy After ANTI CD38 Monoclonal Antibodies Used as First Line*

ADAM D. COHEN, The Trustees of The University of Pennsylvania, Philadelphia, PA  
*Options at the Time of Relapse After ANTI BCMA Therapy*

## The Iron Revolution!

**Sunday** 9:30 a.m. – 10:45 a.m.  
Room 28 A-D  
San Diego Convention Center

### Chair:

THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR

### Speakers:

THOMAS G. DELOUGHERY, MD, Oregon Health and Science University, Portland, OR  
*Sex, Lies, and Iron Deficiency: A Call to Change Ferritin Reference Ranges*

MICHAEL AUERBACH, MD, Auerbach Hem-Onc Associates, Inc., Baltimore, MD  
*IV Iron Formulations and Use in Adults*

JACQUELYN POWERS, MD, Baylor College of Medicine/ Texas Children's Hospital, Houston, TX  
*Intravenous Iron Therapy in Pediatrics: Who Should Get It and When Is the Right Time?*

## What Are the Advances in Myeloproliferative Neoplasms Affecting Management?

**Sunday** 9:30 a.m. – 10:45 a.m.  
Marriott Grand Ballroom 5-6  
Marriott Marquis San Diego Marina

### Chair:

JEANNE PALMER, MD, Mayo Clinic - Arizona, Scottsdale, AZ

### Speakers:

DOUGLAS TREMBLAY, MD, Icahn School of Medicine at Mount Sinai, New York, NY  
*Cytoreduction for ET and PV: Who, What, When, and How?*

HARINDER GILL, MD, MBBS, FRCP, FRCPath, The University of Hong Kong, Hong Kong  
*Evolving landscape of JAK Inhibition in Myelofibrosis: Monotherapy and Combinations*

JEANNE PALMER, MD, Mayo Clinic, Arizona, Scottsdale, AZ  
*Are Transplant Indications Changing for MF?*

## Have We Optimized Therapy Yet for Patients with AML?

**Sunday** 4:30 p.m. – 5:45 p.m.  
Room 6CF  
San Diego Convention Center

### Chair:

TARA L. LIN, MD, The University of Kansas Medical Center, Westwood, KS

### Speakers:

CHRISTOPH RÖLLIG, MD, MSc, University Hospital Dresden, Dresden, Germany  
*Improving Long-Term Outcomes with Intensive Induction Chemotherapy for Patients with AML*

TARA L. LIN, MD, The University of Kansas Medical Center, Westwood, KS  
*The Approach of HMA + ven With or Without BMT for All patients*

JUSTIN M. WATTS, MD, Miami, Coral Gables, FL  
*The Future Paradigm of HMA + ven or Targeted Inhibitor Approaches: Sequencing or Triplet Combinations in AML Therapy*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Hematologists and the Care of Pregnant Women

**Sunday** 4:30 p.m. – 5:45 p.m.  
Room 25  
San Diego Convention Center

### Chair:

FIONNUALA NI AINLE, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

### Speakers:

ADAM K. LEWKOWITZ, MD, Brown University School of Medicine, Women & Infants Hospital In Rhode Island, Providence, RI  
*Identifying and Treating Iron Deficiency in Pregnancy*

ANDRA H. JAMES, MD, Duke University School of Medicine, Durham, NC  
*Management of Pregnant Women Who Have Bleeding Disorders*

FIONNUALA NI AINLE, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland  
*Prevention, Diagnosis and Management of PE & DVT in Pregnant Women*

## Hot Topics in Blood Donation: Donor Risks and Social Justice

**Sunday** 4:30 p.m. – 5:45 p.m.  
Hall A  
San Diego Convention Center

### Chair:

RICHARD M. KAUFMAN, MD, Brigham and Women's Hospital, Boston, MA

### Speakers:

MINDY GOLDMAN, MD, Canadian Blood Services, Ottawa, ON, Canada  
*MSM and Blood Donation: Shifting to Individualized Risk Assessment*

DARJA KARPOVA, MD, Washington University in St. Louis, Saint Louis, MO  
*Clonal hematopoiesis in Frequent Whole Blood Donors*

RICHARD M. KAUFMAN, MD, Brigham and Women's Hospital, Boston, MA  
*T-cell Lymphopenia in Frequent Platelet Donors*

## How Do We Tackle Remaining Clinical Challenges in CML?

**Sunday** 4:30 p.m. – 5:45 p.m.  
San Diego Ballroom AB  
Marriott Marquis San Diego Marina

### Chair:

NARANIE SHANMUGANATHAN, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia

### Speakers:

NARANIE SHANMUGANATHAN, MBBS, FRACP, FRCPA, PhD, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia  
*Accelerated phase CML--de Novo and Transformed*

SIMONA SOVERINI, PhD, University of Bologna School of Medicine, Castel Maggiore, Bologna, Italy  
*Resistance Mutations in CML and How We Approach Them*

MASSIMO BRECCIA, Hematology-Sapienza University, Rome, Italy  
*Atypical CML-Diagnosis and Treatment*

## Energizing the Red Cell: Novel Therapies for Hereditary Hemolytic Anemias

**Monday** 10:30 a.m. – 11:45 a.m.  
Room 28 A-D  
San Diego Convention Center

### Chair:

RACHAEL F. GRACE, MD, The Children's Hospital Corporation, Boston, MA

### Speakers:

RACHAEL F. GRACE, MD, The Children's Hospital Corporation, Boston, MA  
*PK Activators in Pyruvate Kinase Deficiency*

EDUARD J. VAN BEERS, MD, PhD, University Medical Centre Utrecht, Utrecht, Netherlands  
*PK Activators for Sickle Cell Disease*

KEVIN H.M. KUO, MD, FRCPC, MSc, University of Toronto, Toronto, ON, Canada  
*PK Activators for Thalassemia*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies

**Monday** 10:30 a.m. – 11:45 a.m.  
Seaport Ballroom ABCD  
Manchester Grand Hyatt San Diego

### Chair:

NIZAR J. BAHLIS, MD, University of Calgary, Alberta, Canada

### Speakers:

NIZAR J. BAHLIS, MD, University of Calgary, Alberta, Canada  
*Current Use of Bispecific Antibodies to Treat Multiple Myeloma*

SHAM MAILANKODY, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY  
*Current Use of CAR T-Cells to Treat Multiple Myeloma*

SURBHI SIDANA, MD, Stanford University, Stanford, CA  
*Managing Side Effects: Guidance for Use of Immunotherapies in Multiple Myeloma*

## Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL?

**Monday** 2:45 p.m. – 4:00 p.m.  
Grand Hall B  
Manchester Grand Hyatt San Diego

### Chair:

TAMARA P. MILLER, MD, MSCE, Emory University, Decatur, GA

### Speakers:

JOHN C. MOLINA, MD, MEd, , Shaker Heights, OH  
*Leveraging Health Care Technology to Improve Health Outcomes and Reduce Outcome Disparities in AYA Leukemia*

TAMARA P. MILLER, MD, MSCE, Emory University, Decatur, GA  
*Adolescent and Young Adults (AYA) Versus Pediatric Patients: Survival, Risks and Barriers to Enrollment*

EMILY K. CURRAN, MD, University of Cincinnati, Cincinnati, OH  
*Acute Lymphoblastic Leukemia in Young Adults: Which Treatment?*

## What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

**Monday** 2:45 p.m. – 4:00 p.m.  
Ballroom 20AB  
San Diego Convention Center

### Chair:

RONI SHOVAL, MD, PhD, Memorial Sloan-Kettering, New York, NY

### Speakers:

REENA JAYANI, MD, Vanderbilt University Medical Center, Nashville, TN  
*How Old Is Too Old? Frailty and Geriatric Assessments of Older Patients Undergoing Allogeneic HCT*

RONI SHOVAL, MD, PhD, Memorial Sloan-Kettering, New York, NY  
*The Sum of the Parts: What We Can and Cannot Learn from Comorbidity Scores in Allogeneic Transplantation*

ASMITA MISHRA, MD, MBA, Moffitt Cancer Center, Tampa, FL  
*Approaches to Optimize Outcomes in Transplant Recipients*

## Alphabet Soup - Challenging Consults on the Pediatric Units

**Monday** 4:30 p.m. – 5:45 p.m.  
Room 11  
San Diego Convention Center

### Chair:

NICOLE KUCINE, MD, MS, Weill Cornell Medical College, New York, NY

### Speakers:

ASHISH KUMAR, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH  
*Inflamed – HLH, MAS, or Something Else?*

NICOLE KUCINE, MD, MS, Weill Cornell Medical College, New York, NY  
*Too Many White Cells – TAM, JMML, or Something Else?*

CLIFFORD M. TAKEMOTO, MD, St Jude's Children's Research Hospital, Memphis, TN  
*Where Have All the Platelets Gone – HIT, DIC, or Something Else?*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Hematologists as Lifesavers: Inpatient Hematology Emergencies

**Monday 4:30 p.m. – 5:45 p.m.**  
**Marriott Grand Ballroom 5-6**  
**Marriott Marquis San Diego Marina**

### Chair:

STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL

### Speakers:

MARTIN S. TALLMAN, MD, Northwestern University, Highland Park, IL

*How to Avoid Early Mortality in APL*

STEVEN FEIN, MD, MPH, Heme Onc Call, Miami, FL  
*How to manage ITP with life-threatening bleeding*

ADI ZOREF-LORENZ, MD, Hematology Institute, Meir Medical Center, Kfar Saba, Israel  
*Inpatient Recognition and Management of HLH*

## How Can We Manage High-Risk Hematologic Malignancies in the Community?

**Monday 4:30 p.m. – 5:45 p.m.**  
**Grand Hall B**  
**Manchester Grand Hyatt San Diego**

### Chair:

DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA

### Speakers:

DIPTI PATEL-DONNELLY, MD, Virginia Cancer Specialists, McLean, VA

*Acute Leukemias and Complicated Lymphomas: Pearls to Optimize Management When Patients Stay Local*

JESUS G. BERDEJA, MD, Sarah Cannon Center For Blood Cancers, Nashville, TN  
*Multiple Myeloma: A Paradigm for Blending Community and Academic Care*

RUEMU EJEDAFETA BIRHIRAY, MD, Hem.-Onc. of Indiana, PC, Indianapolis, IN  
*Clinical Research in the Community*

## Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?

**Monday 4:30 p.m. – 5:45 p.m.**  
**Room 29**  
**San Diego Convention Center**

### Chair:

COURTNEY FITZHUGH, National Institutes of Health (Hematology), Bethesda, MD

### Speakers:

KENNETH I. ATAGA, MD, University of Tennessee Health Sciences Center, Memphis, Nashville, TN  
*Using Disease Modifying Therapies in Sickle Cell Disease*

ADETOLA A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN  
*The Range of Haploidentical Transplant Protocols in Sickle Cell Disease: All Haplos Are Not Created Equally*

JOHN F. TISDALE, MD, National Institutes of Health Molecular & Clinical Hematology, Bethesda, MD  
*Gene Therapy for Sickle Cell Disease*



# NEW IN 2023 • IN-PERSON EVENT ONLY



**blood**® journals  
STUDIO

**AT THE 65TH ASH®  
ANNUAL MEETING  
& EXPOSITION**



We invite you to attend the sessions below at the **Blood Journals Studio** or stop by to meet journal staff during the poster hall hours  
**LOCATED IN THE POSTER HALL, G-H**

TIME*	SATURDAY, DECEMBER 9	
10:00 AM	Meet the <i>Blood Advances</i> Editors	Alisa Wolberg, PhD; Constantine Tam, MBBS, MD
2:00 PM	Distinguished Abstract Achievement Award Ceremony	
4:00 PM	ASH Poster Walk on Hemostasis and Thrombosis hosted by <i>Blood Vessels, Thrombosis &amp; Hemostasis (VTH)</i>	Lisa Baumann Kreuziger, MD, MS, Versiti, Menomonee Falls, WI; Harvey Roweth, PhD, BSc, Brigham and Women's Hospital, Boston, MA; Marie Hollenhorst, MD, PhD, Brigham and Women's Hospital, Boston, MA, Harvard Medical School, Boston, MA Organized by: <b>ASH SCIENTIFIC AFFAIRS</b>
5:00 PM	Meet the <i>Blood VTH</i> Editor-in-Chief	Keith McCrae, MD, Editor-in-Chief, <i>Blood VTH</i>
SUNDAY, DECEMBER 10		
10:00 AM	Meet the <i>Blood</i> Editors	Helen Heslop, MD; Bertie Göttgens, DPhil
4:30 PM	ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by <i>Blood Neoplasia</i>	Klaus Metzeler, MD, University of Leipzig, Germany Organized by: <b>ASH SCIENTIFIC AFFAIRS</b>
5:30 PM	Meet the <i>Blood Neoplasia</i> Editor-in-Chief	Jonathan Licht, MD, Editor-in-Chief, <i>Blood Neoplasia</i>
MONDAY, DECEMBER 11		
10:00 AM	Meet the <i>Blood Advances</i> Editors	Geoffrey R. Hill, MD, FRCPA, FRACP; Olatoyosi Odenike, MD
11:00 AM	Best Practices for Peer Review: <i>ASH Clinical News</i> interviews <i>Blood Advances</i> Editors	Aaron T. Gerds, MD, <i>ASH Clinical News</i> Editor-in-Chief Catherine M. Bollard, MD, Editor-in-Chief, <i>Blood Advances</i> ; Andrew S. Weyrich, PhD, Deputy Editor, <i>Blood Advances</i>
12:00 PM	The ABCs of Publishing for Authors: <i>The Hematologist</i> interviews the <i>Blood</i> Editors	Shaji Kumar, MD, Editor-in-Chief, <i>The Hematologist</i> ; Nancy Berliner, MD, Editor-in-Chief, <i>Blood</i> ; Andrew Roberts, MBBS, PhD, Deputy Editor, <i>Blood</i>
3:00 PM	Meet the <i>Blood</i> Editors	Erica Wood, MBBS; Philippe Armand, MD, PhD

\* Pacific Daylight Time (PDT)

# EDUCATION SPOTLIGHT SESSIONS

These sessions are intended to provide an in-depth review on specific scientific topics. This year, speakers will discuss current challenges and controversies in two exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 90-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SUNDAY

### Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?

**Sunday 4:30 p.m. – 5:45 p.m.**  
Room 29, San Diego Convention Center

#### Chair:

DAVID GARCIA, MD, University of Washington, Seattle, WA

#### Speakers:

SAM SCHULMAN, MD, PhD, McMaster University, Hamilton, Ontario, Canada  
*PCC Should Be Used to Reverse Xai Anticoagulants*

DEBORAH SIEGAL, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada  
*Andexanet Should Be Used to Reverse Xai Anticoagulants*

### Where the Bench Meets the Bedside: Laboratory Correlates in Clinical Trials

**Sunday 4:30 p.m. – 5:45 p.m.**  
Room 6A, San Diego Convention Center

#### Chair:

JUSTIN TAYLOR, MD, University of Miami, Miami, FL

#### Speakers:

VALERIA SANTINI, AOU Careggi-University of Florence, Firenze, Italy  
*Laboratory Scientists Don't Care*

JUSTIN TAYLOR, MD, University of Miami, Miami, FL  
*Clinicians Don't Care*

## MONDAY

### Managing Previvorship in Hematology: Clinical Approaches to CCUS and MBL

**Monday 2:45 p.m. – 4:00 p.m.**  
Room 7, San Diego Convention Center

#### Chair:

GREGORY A. ABEL, MD, MPH, DFCI, Boston, M

#### Speakers:

ZHUOER XIE, MD, MS, Lutz, FL  
*CCUS is Increasingly Significant in Clinical Practice*

PAOLO GHIA, MD, PhD, Vita-Salute San Raffaele University, Milano, Italy  
*Monoclonal B-cell Lymphocytosis: at a Crossroad Between Disease and Senescence*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### What is a "Normal" Neutrophil Count? The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution

**Monday** 2:45 p.m. – 4:00 p.m.  
Hall A, San Diego Convention Center

#### Chair:

MAUREEN OKAM ACHEBE, MD, MPH, Hematology  
Division Brigham and Women's, Boston, MA

#### Speakers:

LAUREN E. MERZ, MD, MSc, Dana-Farber Cancer  
Institute, Boston, MA

*Duffy-null Associated Neutrophil Counts--  
What is Normal*

JOHN MARK SLOAN, MD, Boston Medical Center,  
Boston, MA

*Clinical Implications of the Duffy Antigen*

### Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes

**Monday** 2:45 p.m. – 4:00 p.m.  
Room 11, San Diego Convention Center

#### Chair:

DEAN ANTHONY LEE, MD, PhD, The Research Institute  
at Nationwide Children's Hospital, Columbus, OH

#### Speakers:

CARLOS A. RAMOS, MD, The Methodist Hospital,  
Houston, TX

*Off-the-shelf  $\alpha\beta$ - or NK-T Cells for Cancer Therapy*

JONATHAN P. H. FISHER, University College London,  
London, United Kingdom

*Engineering T cells: A New Tool for Cancer  
Immunotherapy*

# HOW I TREAT: BRINGING SCIENCE TO CLINICAL DILEMMAS

These sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

ASH Active, International, Associate, International Associate, Resident, or Graduate/Medical Student Member	\$50
Non-Member	\$75
Associate, International Associate, Resident, or Graduate/Medical Student, or Honorary/Emeritus Member	\$50
Non-Member in Training	\$50
Allied Health Professional	\$50

### Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket. Training will be required to purchase a ticket.

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

## SATURDAY

### Acquired Hemophilia A Diagnosis and Management (for in-person participants)

<b>Saturday</b>	<b>8:00 a.m. – 9:00 a.m.</b> <b>Aqua Salon AB</b> <b>Hilton San Diego Bayfront</b>
-----------------	--

**SPEAKER:**

ANDREAS TIEDE, MD, Hannover Medical School, Hannover, Germany

### Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) (for in-person participants)

<b>Saturday</b>	<b>8:00 a.m. – 9:00 a.m.</b> <b>Aqua Salon F</b> <b>Hilton San Diego Bayfront</b>
-----------------	---

**Speaker:**

JOHN C. MOLINA, MD, MEd, National Cancer Institute, Shaker Heights, OH

### Advances in Myeloproliferative Neoplasms Affecting Management (for in-person participants)

<b>Saturday</b>	<b>8:00 a.m. – 9:00 a.m.</b> <b>Aqua Salon D</b> <b>Hilton San Diego Bayfront</b>
-----------------	---

**Speaker:**

JEANNE PALMER, MD, Mayo Clinic, Scottsdale, AZ

### Hematologists and the Care of Pregnant Women (for in-person participants)

<b>Saturday</b>	<b>8:00 a.m. – 9:00 a.m.</b> <b>Aqua 310</b> <b>Hilton San Diego Bayfront</b>
-----------------	---

**Speaker:**

FIONNUALA NI AINLE, MD, PhD, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Patients with Acute Myeloid Leukemia (for in-person participants)**

**Saturday 8:00 a.m. – 9:00 p.m.**  
**Aqua Salon C**  
**Hilton San Diego Bayfront**

**Speaker:**

CHRISTOPH RÖLLIG, MD, MSc, University Hospital, Dresden, Germany

SUNDAY

**Cellular Therapy for Lymphoma (for in-person participants)**

**Sunday 8:00 a.m. – 9:00 a.m.**  
**Aqua Salon D**  
**Hilton San Diego Bayfront**

**Speaker:**

LORETTA J. NASTOUPIL, MD, MD Anderson Cancer Center, Houston, TX

**Ongoing Challenges in the Management of VTE (for in-person participants)**

**Sunday 8:00 a.m. – 9:00 a.m.**  
**Aqua Salon AB**  
**Hilton San Diego Bayfront**

**Speaker:**

KENNETH A. BAUER, MD, Beth Israel Deaconess Medical Center, Boston, MA

**Early Management of Acute Promyelocytic Leukemia (APML) (for in-person participants)**

**Sunday 8:00 a.m. – 9:00 a.m.**  
**Aqua Salon F**  
**Hilton San Diego Bayfront**

**Speaker:**

MARTIN TALLMAN, MD, Northwestern University Feinberg School of Medicine, Highland Park, IL

**T-Cell Redirection Therapy for Multiple Myeloma (for in-person participants)**

**Sunday 8:00 a.m. – 9:00 a.m.**  
**Aqua Salon E**  
**Hilton San Diego Bayfront**

**Speaker:**

SURBHI SIDANA, MD, Stanford University, Stanford, CA

For adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

**Doptelet.**  
(avatrombopag) tablets

# LIFT PLATELETS. NO SWEAT.

**No food-type restrictions:** Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.<sup>1</sup>

**No liver monitoring:** Doptelet does not require additional liver-function monitoring; no significant hepatotoxicity seen in Doptelet clinical trials.<sup>1,2</sup>

**No injections:** Doptelet can be taken anytime, anywhere, without adding trips to the doctor (platelet monitoring required).<sup>1\*</sup>



\*After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of  $\geq 50 \times 10^9/L$  has been achieved, and then obtain platelet counts monthly thereafter.

## INDICATION

DOPELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS

**Thrombotic/Thromboembolic Complications.** DOPELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

### Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

## Adverse Reactions

The most common adverse reactions ( $\geq 10\%$ ) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

## Postmarketing Experience

Following the approval of DOPELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

**These are not all the possible risks associated with DOPELET. Please see Full Prescribing Information for DOPELET at [www.doptelethcp.com](http://www.doptelethcp.com)**

**To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.**

**Please see Brief Summary of Full Prescribing Information on the adjacent page.**

Visit us at

[LiftPlatelets.com](http://LiftPlatelets.com),

or scan the QR code:



**Reference: 1.** DOPELET [package insert]. Durham, NC: AkaRx, Inc. **2.** Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. *Br J Haematol.* 2018;183(3):479-490.

**sobi**  
rare strength

Doptelet is a registered trademark of AkaRx, Inc. Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) ©2022 Sobi, Inc. - All rights reserved. PP-13394 01/2022

**BRIEF SUMMARY OF PRESCRIBING INFORMATION**

**DOPTELET® (avatrombopag) tablets, for oral use**

**1 INDICATIONS AND USAGE**

**1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD)**

DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

**1.2 Treatment of Thrombocytopenia in Patients with Chronic Immune Thrombocytopenia (ITP)**

DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

**4 CONTRAINDICATIONS**

None.

**5 WARNINGS AND PRECAUTIONS**

**5.1 Thrombotic/Thromboembolic Complications**

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving DOPTELET. In patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving DOPTELET.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and follow the dosing guidelines to achieve target platelet counts [see *Dosage and Administration (2.2)*]. Monitor patients receiving DOPTELET for signs and symptoms of thromboembolic events and institute treatment promptly.

**6 ADVERSE REACTIONS**

The following clinically significant adverse reactions are discussed in detail in other sections of the labeling:

- Thrombotic/Thromboembolic Complications [see *Warnings and Precautions (5.1)*]

**6.1 Clinical Trial Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

**Patients with Chronic Liver Disease**

The safety of DOPTELET was evaluated in two international, identically designed, randomized, double-blind, placebo-controlled trials, ADAPT-1 and ADAPT-2, in which 430 patients with chronic liver disease and thrombocytopenia received either DOPTELET (n=274) or placebo (n=156) daily for 5 days prior to a scheduled procedure, and had 1 post-dose safety assessment. Patients were divided into two groups based on their mean platelet count at baseline:

- Low Baseline Platelet Count Cohort (less than 40x10<sup>9</sup>/L) who received DOPTELET 60 mg once daily for 5 days
- High Baseline Platelet Count Cohort (40 to less than 50x10<sup>9</sup>/L) who received DOPTELET 40 mg once daily for 5 days

The majority of patients were males (65%) and median subject age was 58 years (ranging from 19-86 years of age). The racial and ethnic distribution was White (60%), Asian (33%), Black (3%) and Other (3%).

The most common adverse reactions (those occurring in ≥3% of patients) in the DOPTELET-treated groups (60 mg or 40 mg) across the pooled data from the two trials are summarized in Table 5.

**Table 5: Adverse Reactions with a Frequency ≥3% in Patients with Chronic Liver Disease Treated with DOPTELET – Pooled Data ADAPT-1 and ADAPT-2**

Adverse Reactions	Low Baseline Platelet Count Cohort (<40x10 <sup>9</sup> /L)		High Baseline Platelet Count Cohort (≥40 to <50x10 <sup>9</sup> /L)		Combined Baseline Platelet Count Cohorts (<50x10 <sup>9</sup> /L)	
	DOPTELET		DOPTELET		Total	
	60 mg (N=159) %	Placebo (N=91) %	40 mg (N=115) %	Placebo (N=85) %	DOPTELET (N=274) %	Placebo (N=156) %
Pyrexia	11	9	8	9	10	9
Abdominal Pain	6	7	7	6	7	6
Nausea	6	8	7	6	7	7
Headache	4	8	7	5	6	6
Fatigue	4	4	3	2	4	3
Edema Peripheral	3	2	4	2	3	2

For the Low Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 7% (11/159) in the 60 mg DOPTELET treatment group. For the High Baseline Platelet Count Cohort, the incidence of serious adverse reactions was 8% (9/115) in the 40 mg DOPTELET treatment group. The most common serious adverse reaction reported with DOPTELET was hyponatremia. Two DOPTELET-treated patients (0.7%) developed hyponatremia.

Adverse reactions resulting in discontinuation of DOPTELET were anemia, pyrexia, and myalgia; each was reported in a single (0.4%) patient in the DOPTELET (60 mg) treatment group.

**Patients with Chronic Immune Thrombocytopenia**

The safety of DOPTELET was evaluated in four clinical trials in patients with chronic immune thrombocytopenia: two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial, and one open-label extension trial) in 161 patients with chronic immune thrombocytopenia in both the double-blind and open-label extension phases.

The pooled safety data from these four clinical trials includes 128 patients who received 2.5 to 40 mg of DOPTELET once daily for a median duration of exposure of 29.1 weeks and had 1 post-dose safety assessment. The majority of patients were female (63%) and median subject age was 50.5 years (ranging from 18-88 years of age). The racial and ethnic distribution was White (84%), Black (6%), Asian (6%) and Other (6%).

The most common adverse reactions (those occurring in ≥10% of patients) in the DOPTELET-treated patients across the pooled safety data from the four trials are summarized in Table 6.

**Table 6: Adverse Reactions with a Frequency ≥10% in Patients with Chronic Immune Thrombocytopenia Treated with DOPTELET – Pooled Data from Clinical Trials**

Adverse Reactions	DOPTELET (N=128) %	Placebo (N=22) %
Headache	31	14
Fatigue	28	9
Contusion	26	18
Epistaxis	19	18
Upper Respiratory Tract Infection	15	5
Arthralgia	13	0
Gingival Bleeding	13	0
Petechiae	11	9
Nasopharyngitis	10	0

The incidence of serious adverse reactions was 9% (12/128) in the DOPTELET treatment group. Serious adverse reactions reported in more than 1 individual DOPTELET-treated patient included headache, occurring in 1.6% (2/128).

Adverse reactions resulting in discontinuation of DOPTELET that were reported in more than 1 patient included headache, occurring in 1.6% (2/128).

**6.2 Postmarketing Experience**

The following adverse reactions have been identified during post approval use of DOPTELET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Immune System Disorders:** Hypersensitivity reactions including pruritus, rash, choking sensation, erythema, pharyngeal edema, pruritus generalized, rash macular, swelling face, and swollen tongue.

**7 DRUG INTERACTIONS**

**7.1 Effect of Other Drugs on DOPTELET in Patients with Chronic Immune Thrombocytopenia**

**Moderate or Strong Dual Inhibitors of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 increases avatrombopag AUC [see *Clinical Pharmacology (12.3)*], which may increase the risk of DOPTELET toxicities. Reduce the starting dosage of DOPTELET when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4) [see *Dosage and Administration (2.3)*].

In patients starting moderate or strong dual inhibitors of CYP2C9 and CYP3A4 while receiving DOPTELET, monitor platelet counts and adjust DOPTELET dose as necessary (see Table 3) [see *Dosage and Administration (2.2)*].

**Moderate or Strong Dual Inducers of CYP2C9 and CYP3A4**

Concomitant use with a moderate or strong dual inducer of CYP2C9 and CYP3A4 decreases avatrombopag AUC [see *Clinical Pharmacology (12.3)*], which may reduce DOPTELET efficacy. Increase the recommended starting dosage of DOPTELET when used concomitantly with a moderate or strong dual inducer of CYP2C9 and CYP3A4 (see Table 4) [see *Dosage and Administration (2.3)*].

In patients starting moderate or strong dual inducers of CYP2C9 and CYP3A4 while receiving DOPELET, monitor platelet counts and adjust DOPELET dose as necessary (see Table 3) [see *Dosage and Administration* (2.2)].

#### **Patients with Chronic Liver Disease**

No dosage adjustments are required for patients with chronic liver disease.

### **8 USE IN SPECIFIC POPULATIONS**

#### **8.1 Pregnancy**

##### Risk Summary

Based on findings from animal reproduction studies, DOPELET may cause fetal harm when administered to a pregnant woman (see *Data*). The available data on DOPELET in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, oral administration of avatrombopag resulted in adverse developmental outcomes when administered during organogenesis in rabbits and during organogenesis and the lactation period in rats. However, these findings were observed at exposures based on an AUC substantially higher than the AUC observed in patients at the maximum recommended dose of 60 mg once daily. Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

##### Data

##### Animal Data

In embryo-fetal development studies, avatrombopag was administered during organogenesis at doses of 100, 300, and 1000 mg/kg/day in rats and doses of 100, 300, and 600 mg/kg/day in rabbits. Minimal decreases in fetal weights were observed in rats at the maternally toxic dose of 1000 mg/kg/day with exposures 190 times the human exposure based on AUC. Spontaneous abortions were observed at all doses tested in rabbits and were associated with decreased body weights and food consumption at 300 and 600 mg/kg/day; exposures at the lowest dose of 100 mg/kg/day were 10 times the AUC in patients at the maximum recommended dose of 60 mg once daily. There were no embryo-fetal effects in rats administered avatrombopag at doses up to 100 mg/kg/day (53 times the human exposure based on AUC) or rabbits administered avatrombopag at doses up to 600 mg/kg (35 times the human exposure based on AUC).

In pre- and postnatal development studies in rats, avatrombopag was administered during both the organogenesis and lactation periods at doses ranging from 5 to 600 mg/kg/day. Doses of 100, 300, and 600 mg/kg/day caused maternal toxicity leading to total litter losses, decreased body weight in pups, and increased pup mortality, with the majority of the pup mortality occurring from postnatal days 14 to 21. At a dose of 50 mg/kg/day that did not produce clear maternal toxicity, avatrombopag caused increased pup mortality from postnatal days 4 to 21, and mortality continued through postnatal day 25. The 50 mg/kg/day dose also decreased body weight gain in the pups, resulting in a delay in sexual maturation. There were no effects on behavioral or reproductive functions in the offspring. The 50 mg/kg/day dose resulted in maternal exposures 43 times and pup exposures approximately 3 times the AUC observed in patients at the maximum recommended dose of 60 mg once daily.

#### **8.2 Lactation**

##### Risk Summary

There is no information regarding the presence of avatrombopag in human milk, the effects on the breastfed child, or the effects on milk production. Avatrombopag was present in the milk of lactating rats. When a drug is present in animal milk, it is likely the drug will be present in human milk. Due to the potential for serious adverse reactions in a breastfed child from DOPELET, breastfeeding is not recommended during treatment with DOPELET and for at least 2 weeks after the last dose (see *Clinical Considerations*).

##### Clinical Considerations

##### Minimizing Exposure

A lactating woman receiving DOPELET for brief periods, such as prior to an invasive procedure, should interrupt breastfeeding and pump and discard breastmilk during treatment and for two weeks after the last dose of DOPELET in order to minimize exposure to a breastfed child. Advise lactating women receiving chronic DOPELET therapy not to breastfeed during treatment with DOPELET and for at least 2 weeks after the last dose.

#### **8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

In a 10-week juvenile toxicology study in rats, avatrombopag was administered at doses ranging from 20 to 300 mg/kg/day. There was no test article-related mortality and there were no clinical signs at doses up to 300 mg/kg/day. In the stomach, dose-dependent degeneration, regenerative hyperplasia, and atrophy of the glandular epithelium occurred at 100 and 300 mg/kg/day; exposures at 100 mg/kg/day in male rats were 14 times the AUC in patients at the highest recommended dose of 60 mg once daily. An increased incidence of background focal mineralization was also observed in the kidneys of females at 300 mg/kg/day (female rat exposure was 50 times the human exposure based on AUC at the 60 mg daily dose).

#### **8.5 Geriatric Use**

Clinical studies of DOPELET did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

### **10 OVERDOSAGE**

In the event of overdose, platelet count may increase excessively and result in thrombotic or thromboembolic complications. Closely monitor the patient and platelet count. Treat thrombotic complications in accordance with standard of care.

No antidote for DOPELET overdose is known.

Hemodialysis is not expected to enhance the elimination of DOPELET because DOPELET is only approximately 6% renally excreted and is highly bound to plasma proteins.

### **17 PATIENT COUNSELING INFORMATION**

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).

Prior to treatment, patients should fully understand and be informed of the following risks and considerations for DOPELET:

##### Risks

##### Thrombotic/Thromboembolic Complications

DOPELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Various thromboembolic complications (arterial and venous) have been reported in patients treated with DOPELET [see *Warnings and Precautions* (5.1)].

##### Drug Interactions

DOPELET may be affected by other drugs and may require a dose adjustment when co-administered with other drugs; therefore, advise patients to report their use of any other prescription or nonprescription medications or dietary supplements [see *Dosage and Administration* (2.3), *Drug Interactions* (7)].

##### Pregnancy

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see *Use in Specific Populations* (8.1)].

##### Lactation

Advise women not to breastfeed during treatment with DOPELET and for at least 2 weeks after the final dose [see *Use in Specific Populations* (8.2)].

#### **Rx Only**

**Please see package insert for Full Prescribing Information at [www.DopeleteHCP.com](http://www.DopeleteHCP.com).**

This Brief Summary is based on Dopelet (avatrombopag) Prescribing Information P10002 R6 July 2021

DOPELET is a registered trademark of AkaRx, Inc.  
Manufactured for AkaRx, Inc., Durham, North Carolina 27707

Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)  
© 2021 Sobi, Inc.

For more information, go to [www.DOPELET.com](http://www.DOPELET.com) or call 1-855-454-3887.

PP-13400 11/21



# Call for Papers

NEW FROM ASH®



*Blood Neoplasia* joins *Blood* and *Blood Advances* in the *Blood* Journals portfolio, expanding our journal footprint. This new specialty journal will publish open access original research and will focus on hematologic malignancies, including leukemia, lymphoma, multiple myeloma, Waldenström macroglobulinemia, myeloproliferative neoplasms, minimal residual disease, and precursor conditions to neoplasia. The journal is open for submissions.

With a long publishing history that exemplifies superior quality and reach, the *Blood* Journals portfolio, anchored by our high-impact flagship, *Blood*, is a natural home for research in specialty areas of hematology.

## WHY SUBMIT?

*Blood Neoplasia* helps place your research within the reputable and highly visible *Blood* Journals portfolio. By publishing within these journals, you align your research with the long-trusted ASH and *Blood* brands.

## BENEFITS TO AUTHORS:

- ASH & *Blood* Portfolio Brand Visibility
- Fast Peer Review
- Seamless Transfers
- Speed to Publication
- Open Science

ASH is the home for hematology. Long embraced by the hematology community, the *Blood* Journals are a sought-after platform for researchers to advance their work. Expansion gives more authors an opportunity to be published in a *Blood* journal.

► **Submit your paper now**



**Jonathan Licht, MD**  
Editor-in-Chief  
*University of Florida Health  
Cancer Center*

*Blood Neoplasia*  
Joins the *Blood*  
Journals Portfolio

# SCIENTIFIC SESSIONS

The Scientific Program features sessions developed by the Society's 18 Scientific Committees. The sessions highlight emerging areas of science in the field of hematology and address topics referenced in ASH's Agenda for Hematology Research.

Sessions will be held Saturday, December 9, through Monday, December 11. Following the didactic lectures, there will be a panel

discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

## Scientific Program Co-Chairs:

KOJO S.J. ELENITOBA-JOHNSON, MD, Memorial Sloan Kettering Cancer Center, New York, NY

ELIZABETA NEMETH, PhD, University of California, Los Angeles, Los Angeles, CA

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes

**Saturday 9:30 a.m. – 10:45 a.m.**  
Room 7  
San Diego Convention Center

### Scientific Committee on Bone Marrow Failure

#### Chair:

MARCIN W. WŁODARSKI, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

#### Speakers:

JEAN SOULIER, MD, Hôpital Saint-Louis, Paris, France  
*Revertant Mosaicism in Fanconi Anemia*

ALYSSA KENNEDY, MD, PhD, Boston Children's Hospital, Boston, MA  
*Clonal Hematopoiesis in Shwachman Diamond Syndrome*

SUSHREE S. SAHOO, PhD, St. Jude Children's Research Hospital, Memphis, TN  
*Somatic Genetic Rescue in SAMD9 and SAMD9L Syndromes*

## Next Generation of Gene-Based Therapies for Bleeding Disorders

**Saturday 9:30 a.m. – 10:45 a.m.**  
Room 31  
San Diego Convention Center

### Scientific Committee on Hemostasis

#### Chair:

DENISE E. SABATINO, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

#### Speakers:

LEAH SABIN, PhD, Regeneron Pharmaceuticals, Goldens Bridge, NY  
*Novel Approaches for Gene-Based Therapies*

LINDSEY A. GEORGE, MD, University Medical Centre Hamburg-Eppendorf, Haddonfield, NJ  
*Novel Variants of Coagulation Factors for Improved Gene Therapy*

JEROEN EIKENBOOM, MD, PhD, Leiden University Medical Center, Leiden, Netherlands  
*siRNA-Mediated/Novel Strategies to Treat Bleeding*

## The Evolution of Multiple Myeloma: From Inside-Out

**Saturday 9:30 a.m. – 10:45 a.m.**  
Grand Hall C  
Manchester Grand Hyatt San Diego

### Scientific Committee on Plasma Cell Neoplasia

#### Chair:

NINA SHAH, MD, AstraZeneca, San Francisco, CA

#### Speakers:

MARTA CHESI, PhD, Mayo Clinic Arizona, Scottsdale, AZ  
*The Big Myc – What We Know About Myc Signaling in Myelomagenesis*

EUGENIO MORELLI, MD, Dana Farber Cancer Institute, Boston, MA  
*Alternate Code: The Role of Non-Coding RNAs in Multiple Myeloma*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

TOM CUPEDO, PhD, Erasmus University Medical Center, Rotterdam, Netherlands  
*Fertile Soil: The Contribution of the Non-Immune Microenvironment in the Development of Multiple Myeloma*

### Co-Operativity in the Pathogenesis of Myeloid Malignancies

**Saturday 2:00 p.m. – 3:15 p.m.**  
Marriott Grand Ballroom 11-13  
Marriott Marquis San Diego Marina

*Scientific Committee on Myeloid Neoplasia*

#### Chair:

SAAR GILL, MD, PhD, University of Pennsylvania, Philadelphia, PA

#### Speakers:

SEISHI OGAWA, MD, PhD, Kyoto University, Kyoto, Japan  
*Interplay Between Chromosomal Alterations and Gene Mutations*

LINDE A. MILES, PhD, Cincinnati Children's Hospital, Cincinnati, OH  
*Single Cell Mutation Analysis of Clonal Evolution and Its Clinical Implications*

MARK A. DAWSON, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia  
*Beyond Somatic Mutations in the Pathogenesis of Myeloid Neoplasia*

### Emerging Methodologies to Investigate Platelet Biology

**Saturday 2:00 p.m. – 3:15 p.m.**  
Room 25  
San Diego Convention Center

*Scientific Committee on Megakaryocytes and Platelets*

#### Chair:

HERVE FALET, PhD, Versiti Blood Research Institute, Milwaukee, WI

#### Speakers:

ANITA ECKLY, PhD, Inserm-Université De Strasbourg, Strasbourg, France  
*High-Resolution 3D Imaging of Megakaryocytes*

FLORIAN GAERTNER, MD, PhD, Institute of Science and Technology Austria, Klosterneuburg, Austria  
*Dynamic Live Imaging of Platelets*

ANDREW D. JOHNSON, PhD, National Heart, Lung, and Blood Institute, Bethesda, MD  
*Next Generation Sequencing in Platelet Biology*

### Spatial Genomic & Epigenomic Profiling in Hematology

**Saturday 2:00 p.m. – 3:15 p.m.**  
Marriott Grand Ballroom 8-9  
Marriott Marquis San Diego Marina

*Scientific Committee on Epigenetics and Genomics*

#### Chair:

DINESH S. RAO, MD, PhD, University of California, Los Angeles, CA

#### Speakers:

FEI CHEN, PhD, Broad Institute of MIT, Boston, MA  
*Spatial Mapping of Immune Cells & Clonal Heterogeneity in Tissues*

ELHAM AZIZI, PhD, Columbia University, New York, NY  
*Understanding the Spatial-contextual Regulatory Mechanisms That Shape Cellular Identity and Heterogeneity*

RONG FAN, PhD, Yale School of Engineering and Applied Science, New Haven, CT  
*Spatial Mapping of Chromatin and Proteomes*

### Iron and Heme in Stem Cell Maintenance and Erythropoiesis

**Saturday 4:00 p.m. – 5:15 p.m.**  
Room 24  
San Diego Convention Center

*Scientific Committee on Iron and Heme*

#### Chair:

LAURA SILVESTRI, PhD, San Raffaele Scientific Institute, Università Vita-Salute, Milan, Italy

#### Speakers:

DACHUAN ZHANG, PhD, Shanghai Jiao Tong University School of Medicine, Shanghai, China  
*Iron and Heme Shape the Hematopoietic Stem Cell Fate and the Erythron Function*

ANNAMARIA APRILE, PhD, Ospedale San Raffaele, Milan, Italy  
*Iron and Hematopoietic Stem Cell in Ineffective Erythropoiesis*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

LEON KAUTZ, PhD, Inserm, Toulouse, France  
*Mechanisms Controlling the Iron Supply to the Erythron and Their Pathophysiological Contributions*

DANIEL LUCAS-ALCARAZ, PhD, Cincinnati Children's Medical Center, Cincinnati, OH  
*High Resolution Imaging to Visualize Changes in the Bone Marrow Niche*

### Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis

**Saturday** 4:00 p.m. – 5:15 p.m.  
Room 31  
San Diego Convention Center

### The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.

**Saturday** 4:00 p.m. – 5:15 p.m.  
Room 25  
San Diego Convention Center

#### Scientific Committee on Thrombosis & Vascular Biology

##### Chair:

RAFAL PAWLINSKI, PhD, University of North Carolina, Chapel Hill, NC

##### Speakers:

KIMBERLY MARTINOD, PhD, KU Leuven, Leuven, Belgium  
*Neutrophil Extracellular Traps and Thrombosis in Different Disease States*

EVI X. STAVROU, MD, University Hospitals Cleveland Medical Center, Cleveland, OH  
*Role of Neutrophils in In Vivo Models of Thrombosis*

IOANNIS MITROULIS, MD, PhD, Democritus University of Thrace, Alexandroupolis, Greece  
*Role of Immune Cells in the Pathophysiology of Thrombosis*

### Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis

**Saturday** 4:00 p.m. – 5:15 p.m.  
Marriott Grand Ballroom 8-9  
Marriott Marquis San Diego Marina

#### Scientific Committee on Hematopoiesis

##### Chair:

MARIEKE ESSERS, PhD, HI-STEM Gmbh, Heidelberg, Germany

##### Speakers:

TIAGO C. LUIS, PhD, University of Oxford, Oxford, United Kingdom  
*Niche Regulation of HSCs in Homeostasis and Emergency Hematopoiesis*

MARIA C. FLORIAN, PhD, The Bellvitge Institute for Biomedical Research, Barcelona, Spain  
*Ageing in the Hematopoietic Stem Cells Niche*

#### Scientific Committee on Red Cell Biology

##### Chair:

JANE A. LITTLE, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC

##### Speakers:

MITCHELL J. WEISS, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN  
*Understanding Fetal Hgb Regulation: HIF1alpha and LNC RNA*

ANN DEAN, PhD, National Institutes of Health, Bethesda, MD  
*Understanding Fetal Hgb Regulation: LNC RNA*

GERD A. BLOBEL, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA  
*Mechanisms of Developmental Globin Gene Expression Control Revealed via Functional CRISPR Screens*

### JOINT SESSION: Lymphomagenesis - What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies

**Saturday** 4:00 p.m. – 5:35 p.m.  
Ballroom 20AB  
San Diego Convention Center

#### Scientific Committee on Hematopathology & Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia

##### Co-Chairs:

PARUL BHARGAVA, MD, University of California San Francisco, Redwood City, CA

CARON A. JACOBSON, MD, MMSc, Dana-Faber Cancer Institute, Boston, MA

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

ASWIN SEKAR, MD, PhD, Dana-Farber Cancer Institute, Boston, MA  
*Mutations in Healthy Humans Associated with Lymphoid Malignancies*

LAURA PASQUALUCCI, MD, Columbia University, New York, NY  
*Aberrant Germinal Center Expansion and Lymphomagenesis*

CHRISTIAN MUNZ, PhD, University of Zurich, Zurich, Switzerland  
*Infections and Lymphomagenesis*

MANDEEP SINGH, PhD, University of New South Wales, Sydney, Australia  
*Immune Dysregulation and Lymphomagenesis*

**JOINT SESSION: Ontogeny and Myeloid Disorders of Childhood**

**Saturday 4:00 p.m. – 5:35 p.m.**  
**Marriott Grand Ballroom 5-6**  
**Marriott Marquis San Diego Marina**

*Scientific Committee on Myeloid Biology & Scientific Committee on Stem Cells and Regenerative Medicine*

**Co-Chairs:**

EIRINI PAPANETROU, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY

JEFFREY MAGEE, MD, PhD, Washington University School of Medicine, Saint Louis, MO

**Speakers:**

SHANNON MCKINNEY-FREEMAN, PhD, St. Jude Children's Research Hospital, Memphis, TN  
*Normal Hematopoietic Ontogeny*

JAN-HENNING KLUSMANN, MD, Goethe University Frankfurt, Frankfurt, Germany  
*Ontogeny and Malignant Disorders of Childhood*

ALAN B. CANTOR, MD, PhD, Boston Children's Hospital, Boston, MA  
*Ontogeny and Inherited Myeloid Disorders*

ANNA E. BEAUDIN, PhD, University of Utah, Salt Lake City, UT  
*Microenvironmental Contributions to Fetal/ Neonatal Blood Development and Diseases*

**JOINT SESSION: Genome Engineering for Enhanced Blood Cancer Immunotherapy** (non-CME)

**Sunday 9:30 a.m. – 11:05 a.m.**  
**Room 6CF**  
**San Diego Convention Center**

*Scientific Committee on Immunology and Host Defense & Scientific Committee on Transplantation Biology & Cellular Therapies*

**Co-Chairs:**

TODD A. FEHNIGER, MD, PhD, Washington University School of Medicine, Saint Louis, MO

CARL JUNE, MD, University of Pennsylvania, Philadelphia, PA

**Speakers:**

ALEXANDER MARSON, MD, PhD, University of California, San Francisco, San Francisco, CA  
*Decoding and Rewriting Immune Cells to Advance Immune Responses to Cancer*

DAN S KAUFMAN, MD, PhD, University of California San Diego, La Jolla, CA  
*Engineering Alternative Immune Cells as Blood Cancer Immunotherapy*

CHIARA BONINI, MD, Ospedale San Raffaele, Milano, Italy  
*TCR Engineering of Immune Cells to Enhance Responses to Blood Cancers*

CARL JUNE, MD, University of Pennsylvania, Philadelphia, PA  
*Applying Genome Engineering to Enhance CAR T Cell Responses to Blood Cancers*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Pre- and Post-Thrombus: Risk Factors of Clotting and Post-Thrombosis Syndrome

**Monday** 10:30 a.m. – 11:45 a.m.  
Room 31  
San Diego Convention Center

#### *Scientific Committee on Blood Disorders in Childhood*

##### **Chair:**

NATASHA ARCHER, MD, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, MA

##### **Speakers:**

JORDAN SHAVIT, MD, PhD, University of Michigan, Ann Arbor, MI  
*Genetics of Thrombosis*

PAVEL DAVIZON-CASTILLO, MD, University of Colorado, Denver, Denver, CO  
*The Role of Inflammation in Thrombosis*

SUZAN WILLIAMS, MD, Hospital for Sick Children, Toronto, ON, Canada  
*Post-Thrombotic Syndrome*

### Interplay of Coagulation and Complement in Transfusion Medicine

**Monday** 2:45 p.m. – 4:00 p.m.  
Room 29  
San Diego Convention Center

#### *Scientific Committee on Transfusion Medicine*

##### **Chair:**

SEAN STOWELL, MD, Harvard University, Boston, MA

##### **Speakers:**

SATHEESH CHONAT, MD, Children's Healthcare of Atlanta, Atlanta, GA  
*The Role of Complement in Bystander Hemolysis*

RICK KAPUR, MD, PhD, Sanquin Research, Utrecht, Netherlands  
*Complement and TRALI*

DEMIN WANG, PhD, The Blood Research Institute, Milwaukee, WI  
*Role of Complement in HIT*



# American Society of Hematology

Helping hematologists conquer blood diseases worldwide

## ASH® Clinical Practice Guidelines

**Evidence-based guidelines covering the prevention, diagnosis, and treatment of blood disorders.**

The American Society of Hematology (ASH) Clinical Practice Guidelines support clinicians and their patients with hematologic conditions to make decisions about diagnostic and treatment options based on a systematic review of the best available evidence. The guidelines are published in ASH's open access scientific journal *Blood Advances*.

The guidelines are monitored annually for currency by experts. ASH will revise its guidelines when there is new evidence that could substantially change published recommendations.

### Mobile Access to Guidelines and Pocket Guides



**ASH Guidelines App:** Easily access all ASH guideline recommendations from the convenience of your smartphone or tablet.



**ASH Pocket Guides App:** Get interactive versions of all the Society's clinical pocket guides right on your smartphone or tablet, as well as various tools and calculators to aid in clinical decision making.

[hematology.org/guidelines](https://hematology.org/guidelines)

### Sickle Cell Disease (SCD)

- Stem Cell Transplantation
- Cardiopulmonary and Kidney Disease
- Transfusion Support
- Cerebrovascular Disease
- Management of Acute and Chronic Pain

### Venous Thromboembolism (VTE)

- Treatment
- Prophylaxis in Medical Patients
- Prevention in Surgical Patients
- Diagnosis
- Anticoagulation Therapy
- Heparin-Induced Thrombocytopenia (HIT)
- Pregnancy
- Pediatrics
- Cancer Thrombophilia Testing
- VTE Guidelines Adapted for Latin America
- Anticoagulation in Patients with COVID-19

### Immune Thrombocytopenia (ITP)

### Von Willebrand Disease (VWD)

- Diagnosis
- Management

### Acute Myeloid Leukemia (AML)

- Treatment of Newly Diagnosed Acute Myeloid Leukemia in Older Adults

### Coming Soon:

- Aplastic Anemia
- Acute Lymphoblastic Leukemia in Adolescents and Young Adults
- Amyloidosis

# SCIENTIFIC SYMPOSIA

The Scientific Symposia features transformative basic, translational, and clinical research poised to advance the field of hematology. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

## SATURDAY

### Alternative Immune Effector Cells

**Saturday 2:00 p.m. – 3:15 p.m.**  
**Room 6DE**  
**San Diego Convention Center**

#### Chair:

FABIANA PERNA, MD, PhD, Moffitt Cancer Center, Indianapolis, IN

#### Speakers:

EVAN WEBER, PhD, Children's Hospital of Philadelphia, Philadelphia, PA  
*Optimizing Use of Immune Effector Cells*

MARIE BLEAKLEY, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA  
*Advances in TCR Based Therapeutics for Hematologic Malignancies*

## SUNDAY

### The Impact of the Microbiota on Immunotherapy of Hematological Malignancies

**Sunday 9:30 a.m. – 10:45 a.m.**  
**Room 25**  
**San Diego Convention Center**

#### Chair:

MARCO RUELLE, MD, University of Pennsylvania, Philadelphia, PA

#### Speakers:

AMI S. BHATT, MD, PhD, Stanford University, Stanford, CA  
*Microbiota and the Development of Hematological Malignancies*

MARCEL R.M. VAN DEN BRINK, MD, PhD, Memorial Sloan Kettering Cancer Center, New York  
*Microbiota's Impact on Stem Cell Transplant Outcomes and GVHD*

KATE A. MARKEY, MBBS, PhD, FRACP, MPH, Fred Hutchinson Cancer Center, Seattle, WA  
*The Role of the Microbiota on Hemopoiesis and Immune Reconstitution after Therapy*

### Understanding Sickle Cell Pathophysiology

**Sunday 9:30 a.m. – 10:45 a.m.**  
**Room 3**  
**San Diego Convention Center**

#### Chair:

PAYAL DESAI, MD, Wake Forest University, Charlotte, NC

#### Speakers:

ENRICO M NOVELLI, MD, University of Pittsburgh Medical Center, Pittsburgh, PA  
*The Role of Heme in Acute and Chronic Sickle Cell Complications*

LUCIA DE FRANCESCHI, MD, University of Verona & AOUI Verona, Policlinico GB Rossi, Verona, Italy  
*The Role of Complement Activation in Complications of Sickle Cell Disease*

JEFFREY CHALMERS, PhD, The Ohio State University, Columbus, OH  
*Novel Testing Techniques in SCD*

## MONDAY

## Multi-Omics Driven Precision Hematology

**Monday** 2:45 p.m. – 4:00 p.m.  
 Room 30  
 San Diego Convention Center

**Chair:**

PAMELA S. BECKER, MD, PhD, City of Hope, Duarte, CA

**Speakers:**

JUN J. YANG, PhD, St. Jude Children's Research Hospital, Memphis, TN  
*Innovations in Precision Medicine Approaches to Hematologic Malignancies: Beyond NextGen Sequencing*

MIKA KONTRO, MD, PhD, Helsinki University Hospital and University of Helsinki, Helsinki, Finland  
*Functional Screening for Precision Medicine Approaches in Acute Myeloid Leukemia*

PAMELA S. BECKER, MD, PhD, City of Hope, Duarte, CA  
*Precision Medicine Approaches to Rare Blood Disorders*

## Special Symposium on the Basic Science in Hemostasis and Thrombosis

**Monday** 4:30 p.m. – 6:00 p.m.  
 Room 30  
 San Diego Convention Center

**Co-Chairs:**

DENISE E. SABATINO, PhD, Children's Hospital of Philadelphia, Philadelphia, PA  
 HERVE FALET, PhD, Versiti Blood Research Institute, Milwaukee, WI  
 Rafal Pawlinski, PhD, University of North Carolina, Chapel Hill, NC

**Speakers:**

CATERINA CASARI, PhD, University Paris-Saclay, Le Kremlin-Bicetre, France  
*Antibody-Based Strategies As Potential New Treatments for Von Willebrand Disease*

MATTHEW J. FLICK, PhD, University of North Carolina, Chapel Hill, NC  
*Novel Mechanisms for Targeting Fibrin(ogen) to Suppress Thrombosis*

MARIE LORDKIPANIDZÉ, Research Center, Montreal Heart Institute, Montreal, Quebec, Canada  
*Platelets As Biomarkers and Vectors of Neuroactive Agents*

# SCIENTIFIC SPOTLIGHT SESSIONS

The Scientific Spotlight sessions are crowd-sourced from the hematology community and cover niche topic areas that are of interest to specific communities.

Sessions will be held Sunday, December 10, through Monday, December 11. Following the

didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SUNDAY

### Immunometabolism as a Tool to Advance Cell Therapy

**Sunday** 4:30 p.m. – 5:45 p.m.  
Room 11  
San Diego Convention Center

#### Co-Chairs:

GREG DELGOFFE, PHD, University of Pittsburgh Medical Center, Pittsburgh, PA

MAY DAHER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

#### Speakers:

MAY DAHER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX  
*Metabolic Reprogramming to Enhance the Anti-tumor Activity of Adoptive Cell Therapy*

GREG DELGOFFE, PHD, University of Pittsburgh Medical Center, Pittsburgh, PA  
*Intersection of Metabolism and Immunity in Cancer*

### Tackling Greater Burden of Multiple Myeloma in African American Patients

**Sunday** 4:30 p.m. – 5:45 p.m.  
Room 6B  
San Diego Convention Center

#### Co-Chairs:

YVONNE EFEBERA, MD, OhioHealth, Columbus, OH

SRINIVAS DEVARAKONDA, MD, Louisiana State University Health, Columbus, OH

#### Speakers:

YVONNE EFEBERA, MD, OhioHealth, Columbus, OH  
*Interplay of Healthcare Access and Outcomes in Multiple Myeloma*

SRINIVAS DEVARAKONDA, MD, Louisiana State University Health, Columbus, OH  
*Redesigning Clinical Trials in Multiple Myeloma - Need of the Hour*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## MONDAY

### Advances in Genomics: Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma

**Monday 10:30 a.m. – 11:45 a.m.**  
**Grand Hall D**  
**Manchester Grand Hyatt, San Diego**

#### Co-Chairs:

RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada

LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD

#### Speakers:

RYAN MORIN, PhD, Simon Fraser University, Burnaby, British Columbia, Canada

*Divide and Conquer: The Emerging Molecular Subdivisions of BL*

LUDMILA PROKUNINA-OLSSON, PhD, National Cancer Institute, Bethesda, MD

*Genome-wide Association Study of Burkitt Lymphoma: Insights About Host Genetic Architecture and Risk*

### The Mysteries of Factor XI

**Monday 2:45 p.m. – 4:00 p.m.**  
**Room 31**  
**San Diego Convention Center**

#### Co-Chairs:

DAVID GAILANI, MD, Vanderbilt University, Nashville, TN

OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel

#### Speakers:

DAVID GAILANI, MD, Vanderbilt University, Nashville, TN

*Mechanistic Understanding of Factor XI inhibitors*

OPHIRA SALOMON, MD, Tel Aviv University, Tel Hashomer, Israel

*Conundrums of Factor XI Deficiency*





AT THE FOREFRONT  
**UChicago**  
**Medicine**

David and Etta Jonas  
Center for Cellular  
Therapy

# Leaders in Cellular Therapy Care & Research

The physician scientists at the University of Chicago Medicine are world renowned for cellular therapy research and clinical care. As leaders in stem cell transplantation, cellular therapies, and clinical trials, they continue to discover breakthrough treatments and therapeutic approaches for patients.

## OUTCOMES & QUALITY

- The 2020, 2021 and 2022 CIBMTR® Annual report results showed that UChicago Medicine had the best one-year outcomes in Chicago and the highest relative to their predicted outcomes.
- Our pediatric program at Comer Children's Hospital also ranked highly, with actual survival numbers surpassing predicted outcomes.

## TRANSPLANT OPTIMIZATION PROGRAM FOR OLDER ADULTS

- The Transplant Optimization Program (TOP) at UChicago Medicine plays a vital role in addressing hematopoietic cell transplantation treatment options for older adults.
- For patients that are at least 60 years old, our TOP clinic provides a personalized supportive care plan including a multidisciplinary team approach that fosters more successful outcomes.

## AYA EXPERTS

- Adolescents and young adults (AYA) often confront different personal, psychosocial and medical challenges.
- Our nationally known AYA team includes pediatric and adult hematologists/ oncologists, dedicated nurse practitioners, social workers, psychologists and physical therapists who work collaboratively to provide a comprehensive, one-stop model of care for young adults (ages 15-39) in significant life transition.

## SOLID TUMOR & BLOOD CANCER TRIALS

- Our portfolio of clinical trials for patients with hematologic malignancies is one of the largest in the country.
- We have some of the latest Phase I and II trials and our portfolio also has extensive solid tumor cell therapy trials, which are showing promising results. These targeted therapies have wide applicability across various tumor types.

## JONAS CENTER FOR CELLULAR THERAPY

- Physicians and scientists at the David and Etta Jonas Center for Cellular Therapy are working to develop novel cellular therapy products for hematologic malignancies and solid tumors. This team is aided by the state-of-the-art Advanced Cellular Therapeutics Facility (ACTF).
- The ACTF is a 10,000 square foot facility dedicated to both manufacturing cells for existing therapies, but also for developing and scaling up new cellular therapies from investigator-initiated and pharmaceutical company sponsored clinical trials for blood cancers, solid tumors, and benign conditions such as sickle cell disease.

## SPECIALIZED HIGH-RISK CLINICS

- Our newly launched High-Risk Lymphoma and Complex Leukemias Clinics provide the full spectrum of treatments for the most complex cases, including options not widely available at most hospitals.
- These aggressive cancers require prompt, focused care from a team of highly skilled interdisciplinary specialists, which is why we created these clinics to meet the unique needs of patients.



Learn more at  
**UChicagoMedicine.org/  
cellular-therapy**



A Cancer Center Designated by the  
National Cancer Institute



# SCIENTIFIC WORKSHOPS

The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops at no additional fee.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## Scientific Workshop on Defining Goals and Utilizing Tools for Enhancing Diversity, Equity and Inclusion (DEI) in Clinical Trials in Hematology

**2:00 p.m. – 5:00 p.m.**  
**Room 33**  
**San Diego Convention Center**

### Co-Chair:

ARUSHI KHURANA, MBBS, Virginia Commonwealth University, Rochester, MN

ALAN E. MAST, MD, PhD, Blood Center of Wisconsin, Milwaukee, WI

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 3:00 p.m.	Current State and Anticipated Barriers in Increasing DEI in Hematology Clinical Trials
3:00 p.m. – 3:55 p.m.	Setting Realistic Goals for DEI in Hematology Trials
3:55 p.m. – 4:45 p.m.	Tools for Enhancing DEI in Hematology Trials
4:45 p.m. – 4:55 p.m.	Keynote Address: Road Map to Increase DEI in Clinical Trials
4:55 p.m. – 5:00 p.m.	Closing Remarks

## Scientific Workshop on Diagnostic Techniques in Classical and Malignant Hematology

**2:00 p.m. – 5:00 p.m.**  
**Room 28 A-D**  
**San Diego Convention Center**

### Co-Chairs:

PIERS BLOMBERG, PhD, MBBS, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

BRUNO FATTIZZO, MD, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico Milano, Italy

TORSTEN HAFERLACH, MD, PhD, MLL Munich Leukemia Laboratory, Munich, Germany

IRINA MURAKHOVSKAYA, MD, Montefiore Medical Center, Brooklyn, NY

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 3:20 p.m.	Diagnostic Testing in Classical Hematologic Disorders
3:20 p.m. – 4:25 p.m.	Translational Molecular Diagnostics
4:25 p.m. – 4:55 p.m.	Molecular Hematology Case-Based Discussion
4:55 p.m. – 5:00 p.m.	Closing Remarks

## Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

**2:00 p.m. – 5:00 p.m.**  
**Room 29**  
**San Diego Convention Center**

### Co-Chairs:

LUCY GODLEY, MD, PhD, University of Chicago Medical Center, Chicago, IL

MARCIN W. WLODARSKI, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

2:00 p.m. – 2:01 p.m.	Opening Remarks
2:01 p.m. – 2:42 p.m.	Preclinical Development of Model Systems and Organisms
2:42 p.m. – 2:58 p.m.	Special Focus on Telomeropathies and Somatic Rescue - Part 1
2:58 p.m. – 3:14 p.m.	Special Focus on Telomeropathies and Somatic Rescue - Part 2
3:14 p.m. – 3:30 p.m.	Special Focus on Telomeropathies and Somatic Rescue - Part 3
3:37 p.m. – 4:18 p.m.	Germline Predisposition That Intersects With Lymphoid Malignancies, Solid Tumors, and DNA Repair Pathways

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

4:18 p.m. – 4:59 p.m.	How Scientific Advances Impact Clinical Predictive Models and Recommendations
4:59 p.m. – 5:00 p.m.	Closing Remarks

### Scientific Workshop on Mitochondria and Metabolism in Blood Cancer- From Worms to Patients

**2:00 p.m. – 5:00 p.m.**  
**Room 24**  
**San Diego Convention Center**

#### Co-Chairs:

MARINA Y. KONOPLEVA, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

AARON D. SCHIMMER, MD, PhD, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

### Scientific Workshop on Hematology and Aging

**2:00 p.m. – 5:00 p.m.**  
**Room 11**  
**San Diego Convention Center**

#### Co-Chairs:

ASHLEY E ROSKO, MD, The Ohio State University, Columbus, OH

MEGAN WEIVODA, PhD, Mayo Clinic, Rochester, MN

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:45 p.m.	Biomarkers of Biological Aging in Hematologic Malignancies
2:45 p.m. – 3:20 p.m.	Gauging Response of BiTees and CAR-T in Aging Adults
3:30 p.m. – 4:20 p.m.	Mechanisms of Microbiome-Immune Cross talk in Hematologic Disorders
4:20 p.m. – 4:58 p.m.	Mechanisms By Which Cell Stress Drives Aging vs Malignant Adaptation
4:58 p.m. – 5:00 p.m.	Closing Remarks

### Scientific Workshop on the Interplay between Coagulation and Malignancy

**2:00 p.m. – 5:00 p.m.**  
**Room 25**  
**San Diego Convention Center**

#### Co-Chairs:

LISA BAUMANN KREUZIGER, MD, MS, Versiti, Menomonee Falls, WI

JEFFREY I. ZWICKER, MD, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:50 p.m.	Coagulation Alterations in Hematologic Malignancies
2:50 p.m. – 3:45 p.m.	Mechanisms of Thrombosis in Brain Tumors
4:00 p.m. – 4:55 p.m.	Role of Neuroendocrine Tumors in Cancer Associated Thrombosis
4:55 p.m. – 5:00 p.m.	Closing Remarks

2:00 p.m. – 2:10 p.m.	Opening Remarks
2:10 p.m. – 2:55 p.m.	Mitochondrial and Metabolism - Fundamental Discovery and Model Organisms
3:05 p.m. – 3:50 p.m.	Translational Research - Targeting Mitochondria and Metabolism in Cancer
4:10 p.m. – 4:55 p.m.	Mitochondria and Metabolism - Blood Cancer Clinical Trials
4:55 p.m. – 5:00 p.m.	Closing Remarks

### Scientific Workshop on Myeloid Development

**2:00 p.m. – 5:00 p.m.**  
**Room 6CF**  
**San Diego Convention Center**

#### Co-Chairs:

PATRICIA ERNST, PhD, University of Colorado Denver, Aurora, CO

ULRICH STEIDL, MD, PhD, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 2:45 p.m.	Stem Cell Biology
2:45 p.m. – 3:33 p.m.	Signaling and Development
3:33 p.m. – 4:15 p.m.	Myeloid Malignancies
4:15 p.m. – 4:57 p.m.	Gene Regulation in Myeloid Differentiation
4:57 p.m. – 5:00 p.m.	Closing Remarks

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

2:00 p.m. – 5:00 p.m.  
Room 7  
San Diego Convention Center

#### Co-Chairs:

CHRISTINA GLYTSOU, PhD, Rutgers University, Newark, NJ

PANAGIOTIS NTZIACHRISTOS, PhD, Ghent University, Ghent, Belgium

DANIEL T. STARCZYNSKI, PhD, University of Cincinnati College of Medicine, Cincinnati, OH

2:00 p.m. – 2:01 p.m.	Opening Remarks
2:01 p.m. – 2:45 p.m.	Epigenetic and Chromatin Mechanisms Implicated in Therapy Resistance
2:45 p.m. – 3:29 p.m.	Post-Transcriptional Mechanisms Controlling Therapy Response
3:29 p.m. – 4:14 p.m.	Post-Translational Underpinnings of Therapy Response and Resistance to Therapy
4:14 p.m. – 4:59 p.m.	Metabolic Mechanisms and Mitochondria Biology Behind Therapy Resistance
4:59 p.m. – 5:00 p.m.	Closing Remarks

### Scientific Workshop on Viruses in Hematology: Emerging Challenges and Therapeutic Vulnerabilities

2:00 p.m. – 5:00 p.m.  
Room 8  
San Diego Convention Center

#### Co-Chairs:

MAHER K. GANDHI, PhD, University of Queensland Diamantina Institute, Brisbane, QLD, Australia

HELEN ELISABETH HESLOP, MD, DSc (HON), Baylor College of Medicine, Houston, TX

RAYNE ROUCE, MD, BS, Texas Children's Hospital, Houston, TX

KERI TONER, MD, Children's National Hospital, Washington, DC

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 2:43 p.m.	Background to Virally Driven Lymphoproliferative Disorders
2:43 p.m. – 3:33 p.m.	Emerging Vulnerabilities in Special Populations
3:33 p.m. – 4:13 p.m.	The Landscape of Viral Reactivation After Transplantation
4:13 p.m. – 4:53 p.m.	Anti-Viral Cellular Immunotherapies
4:53 p.m. – 5:00 p.m.	Closing Remarks



# American Society of Hematology

Helping hematologists conquer blood diseases worldwide

**SPECIAL  
PRICES &  
3 YEARS OF  
ACCESS**

## 2023 ASH Annual Meeting Webcasts

Get access to more than 400 hours of recorded content from the 2023 ASH Annual Meeting, including oral abstract sessions.

### WEBCAST PACKAGES AVAILABLE FOR PURCHASE

Included Sessions	WEBCAST PACKAGES				Poster Presentations
	Invited Program Plus Oral Abstracts	Invited Program	Education Program Only	Scientific Program Only	
Education Program*	✓	✓	✓		
Scientific Program	✓	✓		✓	
General Sessions	✓	✓	✓	✓	
Special-Interest Sessions	✓	✓	✓	✓	
Trainee Didactic Sessions	✓	✓	✓	✓	
Oral Abstract Sessions* Please note that webcast packages do not include the poster sessions.	✓				
Poster Presentations					✓

\* Please note that the oral abstract sessions are only included as part of the Invited Program Plus Oral Abstracts webcast package.

### WEBCAST PURCHASE PRICING

Registration Category	BEST VALUE	Invited Program	Education Program Only	Scientific Program Only	Poster Presentations
	Invited Program Plus Oral Abstracts				
Active or International Member	\$450	\$350	\$250	\$250	\$99
Non-Member	\$650	\$550	\$350	\$350	\$125
Associate, International Associate, Medical Student, Graduate Student, or Resident Member	\$225	\$175	\$120	\$120	\$25
Non-Member in Training	\$225	\$175	\$120	\$120	\$25
Allied Health Professional	\$650	\$550	\$350	\$350	\$25
Honorary/Emeritus Member	\$225	\$175	\$120	\$120	\$25

## SPECIAL CONFERENCE PRICES

ASH STORE — SAILS PAVILION, UPPER LEVEL

# ASH POSTER WALKS

*ASH Poster Walks as of October 24, 2023.*

The ASH Poster Walks highlight posters selected for the Annual Meeting that showcase emerging science in hematology.

Two of the Poster Walks will take place as in-person sessions in the Blood Journals

Studio during the Annual Meeting, while four will take place virtually following the Annual Meeting.

ASH Poster Walks are not offered for CME credit.

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

## SATURDAY

**ASH Poster Walk on Hemostasis and Thrombosis hosted by *Blood VTH* (for in-person participants)**

**4:00 p.m. – 5:00 p.m.**  
Halls G-H - Blood Journals Studio  
San Diego Convention Center

LISA BAUMANN KREUZIGER, MD,MS, Versiti,  
Menomonee Falls, WI

HARVEY ROWETH, PhD,BSc, Brigham and Women's  
Hospital, Boston, MA

### Co-Chairs:

MARIE HOLLENHORST, MD, PhD, Brigham and  
Women's Hospital, Boston, MA  
Harvard Medical School, Boston, MA

## SUNDAY

**ASH Poster Walk on the Progression of Clonal Hematopoiesis to Hematologic Neoplasms: Biology, Risk Stratification and Therapeutic Interventions hosted by Blood Neoplasia (for in-person participants)**

**4:30 p.m. – 5:30 p.m.**  
Halls G-H - Blood Journals Studio  
San Diego Convention Center

**ASH Poster Walk on Genetic Mutations in Myeloma and Leukemia**

**10:00 a.m. – 11:00 a.m.**  
Virtual Program

### Chair:

KARUN NEUPANE, MD, MBBS, Jacobi Medical Center/  
Albert Einstein College of Medicine, Bronx, NY

**ASH Poster Walk on What's Hot in Sickle Cell Disease Clinical Research in 2023**

**5:00 p.m. – 6:00 p.m.**  
Virtual Program

### Chair:

ELIZABETH KLINGS, MD, Boston University, Boston,  
MA

## THURSDAY

**ASH Poster Walk on Diversity, Equity and Inclusion (DEI) in Hematology**

**10:00 a.m. – 11:00 a.m.**  
Virtual Program

**ASH Poster Walk on Time to Examine Time Toxicity in Hematology**

**5:00 p.m. – 6:00 p.m.**  
Virtual Program

### Co-Chairs:

ELNA SAAH, MD, Emory School of Medicine, Atlanta,  
GA

### Chair:

RAHUL BANERJEE, MD, Fred Hutchinson Cancer  
Center, Seattle, WA



# Share Your Expertise Treating R/R AML With a FLT3 Mutation

What should your  
patient's next step be?

Compare your approach at  
**BOOTH 2311**

AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; R/R=relapsed or refractory.



© 2023 Astellas Pharma US, Inc. All rights reserved.  
Printed in the USA. 074-1071-PM 10/23  
Astellas and the flying star logo are registered  
trademarks of Astellas Pharma Inc.

**Not a real patient.**

# MEET THE SCIENTIST

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 7, at the Ticketed Sessions Counter in Building A, Level 1, Hall A1.

## Ticket Prices (per session)

Active or International Member	\$75
Non-Member	\$75
Associate, International Associate, Resident, or Graduate/Medical Student, or honorary/Emeritus Member	\$50
Non-Member in Training	\$50
Allied Health Professional	\$50

## Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SATURDAY

### Genome Engineering for Enhanced Blood Cancer Immunotherapy (for in-person participants)

**Saturday 8:00 a.m. – 9:00 a.m.**  
Aqua 314  
Hilton San Diego Bayfront

#### Speaker:

CARL JUNE, MD, University of Pennsylvania, Philadelphia, PA  
*Genome Engineering for Enhanced Blood Cancer Immunotherapy*

### Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle (for in-person participants)

**Saturday 8:00 a.m. – 9:00 a.m.**  
Aqua 313  
Hilton San Diego Bayfront

#### Speaker:

ADETOLA A. KASSIM, MBBS, MS, Vanderbilt University Medical Center, Nashville, TN  
*Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle*

### Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies (for in-person participants)

**Saturday 8:00 a.m. – 9:00 a.m.**  
Aqua 300  
Hilton San Diego Bayfront

#### Speaker:

LAURA PASQUALUCCI, MD, Columbia University, New York, NY  
*Lymphomagenesis - What Normal Immunology, Abnormal Immunology and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies*

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SUNDAY

### Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes (for in-person participants)

**Sunday** 8:00 a.m. – 9:00 a.m.  
Aqua 314  
Hilton San Diego Bayfront

**Speaker:**

JEAN SOULIER, MD, University of Paris, Saint-Louis Hospital, Paris, France  
*Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes*

### Natural Killer Cells: A New Frontier for Cancer Immunotherapy (for in-person participants)

**Sunday** 8:00 a.m. – 9:00 a.m.  
Aqua 300  
Hilton San Diego Bayfront

**Speaker:**

KATAYOUN REZVANI, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX  
*Natural Killer Cells: A New Frontier for Cancer Immunotherapy*

### Research in Complications Sickle Cell Disease (for in-person participants)

**Sunday** 8:00 a.m. – 9:00 a.m.  
Aqua 313  
Hilton San Diego Bayfront

**Speaker:**

OYEBIMPE ADESINA, MD, MS, University of California, Mountain View, CA  
*Research in Complications Sickle Cell Disease*

### The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression (for in-person participants)

**Sunday** 8:00 a.m. – 9:00 a.m.  
Aqua 311  
Hilton San Diego Bayfront

**Speaker:**

MITCHELL WEISS, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN  
*The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression*

# 2023 SCIENTIFIC CATEGORIES

For the 65th ASH Annual Meeting, abstracts were submitted in 66 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number.

Oral Abstract Sessions' titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.

## 100s—Red Cell Physiology and Disorders

- 101 Red Cells and Erythropoiesis, Excluding Iron
- 102 Iron Homeostasis and Biology
- 112 Thalassemia and Globin Gene Regulation
- 113 Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
- 114 Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

## 200s—Leukocytes, Inflammation, and Immunology

- 201 Granulocytes, Monocytes, and Macrophages
- 203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

## 300s—Hemostasis, Thrombosis, and Vascular Wall Biology

- 301 Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
- 311 Disorders of Platelet Number or Function: Clinical and Epidemiological
- 321 Coagulation and Fibrinolysis: Basic and Translational
- 322 Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological
- 331 Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological
- 332 Thrombosis and Anticoagulation: Clinical and Epidemiological

## 400s—Transfusion Medicine

- 401 Blood Transfusion

## 500s—Hematopoiesis

- 501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
- 503 Clonal Hematopoiesis, Aging and Inflammation
- 506 Bone Marrow Microenvironment
- 508 Bone Marrow Failure: Acquired
- 509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

## 600s—Hematologic Malignancy

- 602 Myeloid Oncogenesis: Basic
- 603 Lymphoid Oncogenesis: Basic
- 604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
- 605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
- 612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
- 613 Acute Myeloid Leukemias: Clinical and Epidemiological
- 614 Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
- 615 Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
- 616 Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
- 617 Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

- 618 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
- 621 Lymphomas: Translational—Molecular and Genetic
- 622 Lymphomas: Translational—Non-Genetic
- 623 Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
- 624 Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
- 626 Aggressive Lymphomas: Prospective Therapeutic Trials
- 627 Aggressive Lymphomas: Clinical and Epidemiological
- 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
- 632 Chronic Myeloid Leukemia: Clinical and Epidemiological
- 634 Myeloproliferative Syndromes: Clinical and Epidemiological
- 636 Myelodysplastic Syndromes—Basic and Translational
- 637 Myelodysplastic Syndromes—Clinical and Epidemiological
- 641 Chronic Lymphocytic Leukemias: Basic and Translational
- 642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological
- 651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
- 652 Multiple Myeloma: Clinical and Epidemiological
- 653 Multiple Myeloma Prospective Therapeutic Trials
- 654 MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
- 700s—Transplantation and Adoptive Cell Therapies**
- 701 Experimental Transplantation: Basic and Translational
- 703 Cellular Immunotherapies: Basic and Translational
- 704 Cellular Immunotherapies: Early Phase and Investigational Therapies
- 705 Cellular Immunotherapies: Late Phase and Commercially Available Therapies
- 711 Cell Collection and Processing
- 721 Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
- 722 Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
- 723 Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence
- 731 Autologous Transplantation: Clinical and Epidemiological
- 732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
- 800s—Gene Therapies, Chemical Biology, and Emerging Diagnostics**
- 801 Gene Therapies
- 802 Chemical Biology and Experimental Therapeutics
- 803 Emerging Tools, Techniques and Artificial Intelligence in Hematology
- 900s—Health Services, Quality Improvement, and Outcomes Research**
- 901 Health Services and Quality Improvement—Non-Malignant Conditions
- 902 Health Services and Quality Improvement—Lymphoid Malignancies
- 903 Health Services and Quality Improvement—Myeloid Malignancies
- 904 Outcomes Research—Non-Malignant Conditions
- 905 Outcomes Research—Lymphoid Malignancies
- 906 Outcomes Research—Myeloid Malignancies



# Breakthrough Discoveries. Life-Changing Results.

City of Hope<sup>®</sup> is renowned for rapidly translating hematologic breakthroughs into lifesaving treatment. A leader in treating blood cancers and improving outcomes for patients, we deliver world-class, personalized care to patients from all over the United States and the world.



Visit us at **Booth 2204** during  
the **2023 ASH Annual Meeting**.



LEUKEMIA, LYMPHOMA & MYELOMA SURGERY

*Our NCI-designated comprehensive cancer center near Los Angeles has repeatedly been ranked by U.S. News & World Report among the nation's best hospitals for cancer.*

# ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 9, through Monday, December 11. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter.

The Plenary Scientific Session will be held Sunday, September 10, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited. All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt. All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina.

## SATURDAY

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions 

- |  |   |
|--|---|
| <p>101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Emerging Gene Regulatory Mechanisms in Erythroid Differentiation (7–12)<br/><b>Room 25</b></p> <p>113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Emerging Therapies for Sickle Cell Disease (13–18)<br/><b>Room 29</b></p> <p>321. Coagulation and Fibrinolysis: Basic and Translational: Coagulation Protein: Molecular Insights and Molecular Therapies (19–24)<br/><b>Room 33</b></p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Out of the Box: Acquired, Vascular and Other Neglected Bleeding Disorders (25–30)<br/><b>Room 30</b></p> <p>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation, Metabolism, and Stress (31–36)<br/><b>Room 24</b></p> <p>603. Lymphoid Oncogenesis: Basic: Mechanisms of Acute Lymphoblastic Leukemia Development and Progression (37–42)<br/><b>Marriott Grand Ballroom 11-13</b></p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies (43–48)<br/><b>Ballroom 20CD</b></p> <p>605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma (49–54)<br/><b>Grand Hall D</b></p> <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML (55–60)<br/><b>Pacific Ballroom Salons 21-22</b></p> | <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response (61–66)<br/><b>Pacific Ballroom Salons 24-26</b></p> <p>627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL (67–72)<br/><b>Seaport Ballroom EFGH</b></p> <p>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies (73–78)<br/><b>Ballroom 20AB</b></p> <p>641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation (79–84)<br/><b>Grand Hall B</b></p> <p>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment (85–90)<br/><b>Harbor Ballroom</b></p> <p>652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications (91–96)<br/><b>Seaport Ballroom ABCD</b></p> <p>703. Cellular Immunotherapies: Basic and Translational: Overcoming Challenges in CAR-T Therapies Through Biological Insights (97–102)<br/><b>Room 6DE</b></p> <p>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data (103–108)<br/><b>Room 6A</b></p> <p>721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Improving Outcomes by Reducing Transplant-Related Complications (109–114)<br/><b>Room 11</b></p> <p>802. Chemical Biology and Experimental Therapeutics: Novel Targets in Blood Disorders (115–120)<br/><b>Marriott Grand Ballroom 8-9</b></p> |
|--|---|


All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Reading the Blood: Generative and Discriminative AI in Hematology (121–126)  
**San Diego Ballroom AB**
902. Health Services and Quality Improvement – Lymphoid Malignancies: Making a Splash In Outcomes Data (127–132)  
**Marriott Grand Ballroom 2-4**

904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients (133–138)  
**Pacific Ballroom Salons 18-19**


**2:00 p.m. – 3:30 p.m. Oral Abstract Sessions** 

101. Red Cells and Erythropoiesis, Excluding Iron: Red Cells: Erythropoiesis in Stress and Disease (139–144)  
**Room 33**
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Hot Topics in Clinical Care and Genomic Factors (145–150)  
**Room 31**
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Decoding the Complex Landscape of Human Immunity: Insights From Genetic Mutations to Cellular Heterogeneity (151–156)  
**San Diego Ballroom AB**
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents (157–162)  
**Room 6A**
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics (163–168)  
**Pacific Ballroom Salons 24-26**
621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc. (169–174)  
**Ballroom 20AB**
622. Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma (175–180)  
**Seaport Ballroom ABCD**
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas (181–186)  
**Grand Hall B**
627. Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas (187–192)  
**Grand Hall C**
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS (193–198)  
**Pacific Ballroom Salons 18-19**
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation (199–204)  
**Grand Hall D**
653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma (205–210)  
**Harbor Ballroom**
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders (211–216)  
**Seaport Ballroom EFGH**
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies (217–222)  
**Room 6B**
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors (223–228)  
**Room 6CF**
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia (229–234)  
**Marriott Grand Ballroom 5-6**
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Long-Term Survival and Survivorship From Clinical Trials And Observations (235–240)  
**Room 7**
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology (241–246)  
**Room 30**
901. Health Services and Quality Improvement – Non-Malignant Conditions: Sickle Cell Disease Across the Spectrum (247–252)  
**Pacific Ballroom Salons 15-17**
902. Health Services and Quality Improvement – Lymphoid Malignancies: Innovative Care in CAR-T Therapy (253–258)  
**Marriott Grand Ballroom 2-4**
903. Health Services and Quality Improvement – Myeloid Malignancies: From Blood to Bombs: Identifying and Addressing Barriers to Care for Myeloid Malignancies (259–264)  
**Hall A**
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data (265–270)  
**Pacific Ballroom Salons 21-22**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.  
All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt  
All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

**4:00 p.m. – 5:30 p.m. Oral Abstract Sessions** 

- |  |  |
|--|--|
| <p>114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease (271–276)<br/><b>Room 28 A-D</b></p> <p>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias (277–282)<br/><b>Room 33</b></p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Beyond the Numbers: Non-Factor Factors in Bleeding Disorder Care (283–288)<br/><b>Room 30</b></p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control (289–294)<br/><b>Room 6CF</b></p> <p>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL (295–300)<br/><b>Seaport Ballroom ABCD</b></p> <p>624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas (301–306)<br/><b>Grand Hall B</b></p> <p>627. Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents (307–312)<br/><b>Grand Hall C</b></p> <p>636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications (313–318)<br/><b>Pacific Ballroom Salons 21-22</b></p> <p>637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS (319–324)<br/><b>Pacific Ballroom Salons 18-19</b></p> <p>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL (325–330)<br/><b>Grand Hall D</b></p> | <p>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment (331–336)<br/><b>Seaport Ballroom EFGH</b></p> <p>652. Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics (337–342)<br/><b>Harbor Ballroom</b></p> <p>701. Experimental Transplantation: Basic and Translational: GVHD, Intestinal Immunity, and the Gut Microbiome (343–348)<br/><b>Room 7</b></p> <p>703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights (349–354)<br/><b>Room 6A</b></p> <p>705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity (355–360)<br/><b>Room 6B</b></p> <p>723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes (361–366)<br/><b>Room 11</b></p> <p>901. Health Services and Quality Improvement – Non-Malignant Conditions: Access to Quality Care in Classical Hematology (367–372)<br/><b>Marriott Grand Ballroom 2-4</b></p> <p>903. Health Services and Quality Improvement – Myeloid Malignancies: Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies (373–378)<br/><b>Pacific Ballroom Salons 15-17</b></p> <p>905. Outcomes Research – Lymphoid Malignancies: Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma (379–384)<br/><b>Hall A</b></p> <p>906. Outcomes Research – Myeloid Malignancies: Risk Factors and Health Disparities (385–390)<br/><b>Marriott Grand Ballroom 11-13</b></p> |
|--|--|

**SUNDAY**
**9:30 a.m. – 11:00 a.m. Oral Abstract Sessions** 


- |   |   |
|---|---|
| <p>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Practice, Natural History, and Patient Reported Outcomes (391–396)<br/><b>Room 30</b></p> <p>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Cell Fate Decisions and Fitness (397–402)<br/><b>Room 24</b></p> | <p>602. Myeloid Oncogenesis: Basic: Therapeutic Strategies and Cellular Mechanisms (403–408)<br/><b>Marriott Grand Ballroom 11-13</b></p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Strategies to Overcome Therapy Resistance in Myeloid Malignancies (409–414)<br/><b>Pacific Ballroom Salons 24-26</b></p> |
|---|---|

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Therapy in Lymphoid Leukemias (415–420)  
**Grand Hall B**
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response (421–426)  
**Marriott Grand Ballroom 8-9**
622. Lymphomas: Translational – Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma (427–432)  
**Grand Hall C**
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma (433–438)  
**Seaport Ballroom ABCD**
627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient (439–444)  
**Grand Hall D**
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Treatment-Free Remission and Prognostication (445–450)  
**Pacific Ballroom Salons 21-22**
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs (451–456)  
**Harbor Ballroom**
701. Experimental Transplantation: Basic and Translational: T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution (457–462)  
**Room 6B**
703. Cellular Immunotherapies: Basic and Translational: Novel Approaches for Next Generation Cellular Immunotherapies (463–468)  
**Room 6A**
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies (469–474)  
**Pacific Ballroom Salons 18-19**
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Emerging Insights in GVHD Immunobiology (475–480)  
**Marriott Grand Ballroom 2-4**
801. Gene Therapies: New Approaches From Bench to Bedside (481–486)  
**Ballroom 20CD**
904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders (487–492)  
**Pacific Ballroom Salons 15-17**
905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology (493–498)  
**San Diego Ballroom AB**

**12:00 p.m. – 1:30 p.m. Oral Abstract Sessions** 

301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis (499–504)  
**Room 28 A-D**
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Bleeding Disorder Management Throughout the Lifespan (505–510)  
**Room 29**
506. Bone Marrow Microenvironment: Bone Marrow Microenvironment in Health and Disease (511–516)  
**Room 11**
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL (517–522)  
**Grand Hall B**
621. Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma (523–528)  
**Harbor Ballroom**
652. Multiple Myeloma: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance - Novel Insights on the Relevance of Gammopathies and Misc. (529–534)  
**Grand Hall C**
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis (535–540)  
**Seaport Ballroom EFGH**
905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Myeloma: What's New? (541–546)  
**Marriott Grand Ballroom 2-4**
906. Outcomes Research – Myeloid Malignancies: Real-World Treatment Patterns and Outcomes (547–552)  
**Marriott Grand Ballroom 11-13**

**4:30 p.m. – 6:00 p.m. Oral Abstract Sessions** 

112. Thalassemia and Globin Gene Regulation: Finding New Pathways to Treat Thalassemia (553–558)  
**Room 31**
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Pathophysiology of Sickle Hemoglobinopathies: From Mice to Humans (559–564)  
**Room 33**
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT): Understanding Risk as a Potential Means to Improve Patient Care (565–570)  
**Room 28 A-D**
508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials (571–576)  
**Room 7**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.  
All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt  
All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

602. Myeloid Oncogenesis: Basic: Chemical and Genetic Approaches for Targeting Leukemic Stem Cells (577–582)  
**Marriott Grand Ballroom 11-13**
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies (583–588)  
**Pacific Ballroom Salons 18-19**
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Real World Outcomes and Treatment Approaches (589–594)  
**Pacific Ballroom Salons 24-26**
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Targeted Therapies and The Immune Microenvironment (595–600)  
**Grand Hall D**
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy (601–606)  
**Grand Hall C**
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma (607–612)  
**Grand Hall B**
627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas (613–618)  
**Ballroom 20AB**
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies (619–624)  
**Ballroom 20CD**
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers (625–630)  
**Pacific Ballroom Salons 21-22**
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia (631–636)  
**Seaport Ballroom ABCD**
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States (637–642)  
**Harbor Ballroom**
652. Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma (643–648)  
**Seaport Ballroom EFGH**
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment (649–654)  
**Marriott Grand Ballroom 8-9**
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Use of Molecular Techniques for Risk Stratification (655–660)  
**Marriott Grand Ballroom 5-6**
901. Health Services and Quality Improvement – Non-Malignant Conditions: Raising the bar in Anemia, Bleeding, and Thrombotic Disorders (661–666)  
**Pacific Ballroom Salons 15-17**
905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies (667–672)  
**Marriott Grand Ballroom 2-4**

## MONDAY

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions (non-CME)

201. Granulocytes, Monocytes, and Macrophages: Granulocytes, Monocytes and Disorders of Histocytes (673–678)  
**Room 24**
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Targeting platelet reactivity in thrombosis (679–684)  
**Room 30**
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Innovative Treatments for Immune Thrombocytopenia (685–690)  
**Hall A**
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: New Frontiers in TTP: Diagnostic and Therapeutic Innovations (691–696)  
**Room 29**
401. Blood Transfusion: Advances in Transfusion Medicine (697–702)  
**Room 33**
508. Bone Marrow Failure: Acquired: Immune AA and VEXAS – Biology, Diagnosis and Treatment (703–708)  
**Room 6DE**
602. Myeloid Oncogenesis: Basic: RNA Splicing, Transcription, and Chromatin Dynamics (709–714)  
**Marriott Grand Ballroom 11-13**
603. Lymphoid Oncogenesis: Basic: Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis (715–720)  
**Pacific Ballroom Salons 15-17**
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication (721–726)  
**Room 6B**
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL (727–732)  
**Room 6A**
623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents (733–738)  
**Grand Hall B**
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stromal-Immune and Signaling Context (739–744)  
**Ballroom 20AB**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Treatment and Outcomes in MPNs (745–750)  
**Ballroom 20CD**
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia (751–756)  
**Harbor Ballroom**
652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma (757–762)  
**Seaport Ballroom EFGH**
703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies (763–768)  
**Marriott Grand Ballroom 5-6**
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas (769–774)  
**Room 6CF**
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Advancements in GVHD Management (775–780)  
**Marriott Grand Ballroom 8-9**
731. Autologous Transplantation: Clinical and Epidemiological: Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas: A Therapeutic Approach (781–786)  
**Pacific Ballroom Salons 18-19**
901. Health Services and Quality Improvement – Non-Malignant Conditions: Improving Care in Sickle Cell Disease Via Technologies and Medical Education (787–792)  
**Marriott Grand Ballroom 2-4**

**2:45 p.m. – 4:15 p.m. Oral Abstract Sessions** 

114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advances in Clinical Care and Implementation (793–798)  
**Room 28 A-D**
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombocytopenia in Special Populations (799–804)  
**Room 25**
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Genetics, Pregnancy, and Pediatrics: Advances in Venous Thromboembolism (805–810)  
**Room 33**
503. Clonal Hematopoiesis, Aging and Inflammation: From Omics to Discoveries (811–816)  
**Room 24**
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML – De Novo and Myelodysplasia-Related (817–822)  
**Pacific Ballroom Salons 24-26**
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL (823–828)  
**Grand Hall C**
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML (829–834)  
**San Diego Ballroom AB**
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features (835–840)  
**Pacific Ballroom Salons 15-17**
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Novel Disease Subclassifications and Clinical Prognosis (841–846)  
**Grand Hall D**
621. Lymphomas: Translational – Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics (847–852)  
**Room 6DE**
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas (853–858)  
**Seaport Ballroom ABCD**
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery (859–864)  
**Pacific Ballroom Salons 21-22**
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches (865–870)  
**Pacific Ballroom Salons 18-19**
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions (871–876)  
**Harbor Ballroom**
652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes (877–882)  
**Seaport Ballroom EFGH**
703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers (883–888)  
**Room 6B**
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies (889–894)  
**Room 6A**
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Modern Challenges in Transplantation (895–900)  
**Ballroom 20CD**
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Image-Based Machine Learning in Hematology (901–906)  
**Room 6CF**
902. Health Services and Quality Improvement – Lymphoid Malignancies: Improving Processes and Outcomes in Plasma Cell Dyscrasias (907–912)  
**Marriott Grand Ballroom 2-4**
906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies (913–918)  
**Marriott Grand Ballroom 8-9**

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.  
 All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt  
 All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

**4:30 p.m. – 6:00 p.m. Oral Abstract Sessions** 

102. Iron Homeostasis and Biology: Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis (919–924)  
**Room 25**
114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Sickle Cell Treatment: Present and Future (925–930)  
**Room 31**
201. Granulocytes, Monocytes, and Macrophages: New Insights into Inherited and Acquired Neutropenias (931–936)  
**Room 33**
503. Clonal Hematopoiesis, Aging and Inflammation: Translational Innovations (937–942)  
**Room 24**
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital and Misc. (943–948)  
**Room 7**
602. Myeloid Oncogenesis: Basic: Mechanisms and Models of Myeloid Malignancy (949–954)  
**Marriott Grand Ballroom 11-13**
613. Acute Myeloid Leukemias: Clinical and Epidemiological: AML– Molecular Targets, Ethnicity, and AI (955–960)  
**Pacific Ballroom Salons 24-26**
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL (961–966)  
**Grand Hall D**
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML (967–972)  
**San Diego Ballroom AB**
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant (973–978)  
**Pacific Ballroom Salons 15-17**
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy (979–984)  
**Grand Hall C**
627. Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL (985–990)  
**Harbor Ballroom**
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Oncogenic Drivers and Genetic Models (991–996)  
**Pacific Ballroom Salons 21-22**
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Genomic Classification and Prognostication of MDS (997–1002)  
**Pacific Ballroom Salons 18-19**
652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma (1003–1008)  
**Seaport Ballroom EFGH**
653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma (1009–1014)  
**Seaport Ballroom ABCD**
703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies (1015–1020)  
**Room 6B**
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas (1021–1026)  
**Room 6A**
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence (1027–1032)  
**Room 6CF**
711. Cell Collection and Processing: Hematopoietic Stem/Progenitor Cells Graft and Immune Effector Cells (1033–1038)  
**Room 6DE**
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Expanding the Donor Pool (1039–1044)  
**Ballroom 20AB**
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Donor and Conditioning Regimen Selection (1045–1050)  
**Ballroom 20CD**
801. Gene Therapies: The Long and the Short of Clinical Trials in Blood Disorders (1051–1056)  
**Hall A**
904. Outcomes Research – Non-Malignant Conditions: Blending the Old With the New: Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease (1057–1062)  
**Marriott Grand Ballroom 8-9**
905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma (1063–1068)  
**Marriott Grand Ballroom 2-4**

Test your knowledge and earn CME credit at [academy.hematology.org](http://academy.hematology.org)



# Hematology 2023

AMERICAN SOCIETY of HEMATOLOGY  
Education Program™  
65<sup>th</sup> ASH® Annual Meeting and Exposition  
December 9-12, 2023

**FREE  
SHIPPING\***

## NEW HEMATOLOGY 2023

### NEW PRINT EDITION — FREE SHIPPING

Member - Active and International	\$120
Member - U.S. & International Associate	\$100
Member - Graduate/Medical Student/Resident	\$100
Non-member	\$160

ORDER TODAY AT

- ▶ **ASH STORE onsite**
- ▶ **[Hematology.org/store](http://Hematology.org/store)**



\*Free shipping ends on 12/31/2023.



The *Hematology* ASH Education Program 2023 provides review articles from the Education Program at the 2023 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.

# POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the San Diego Convention Center, Halls G-H. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Pacific time) each day, as

well as access posters from previous days on the virtual platform.

The Poster Hall hours are as follows:

Saturday, December 09 9:00 a.m. – 7:30 p.m.

Sunday, December 10 9:00 a.m. – 8:00 p.m.

Monday, December 11 9:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SATURDAY, DECEMBER 9, 2023

9:00 a.m. – 7:30 p.m. **Poster Session I – Viewing** (non-CME)

5:30 p.m. – 7:30 p.m. **Poster Session I – Presentations** (non-CME)


### Halls G-H, San Diego Convention Center

- |   |   |
|---|---|
| <p>101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1069–1087)</p> <p>102. Iron Homeostasis and Biology: Poster I (1088–1098)</p> <p>112. Thalassemia and Globin Gene Regulation: Poster I (1099–1107)</p> <p>113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1108–1123)</p> <p>114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1124–1159)</p> <p>201. Granulocytes, Monocytes, and Macrophages: Poster I (1160–1172)</p> <p>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1173–1185)</p> <p>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I (1186–1205)</p> <p>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1206–1226)</p> <p>321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1227–1235)</p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I (1236–1256)</p> <p>331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-Related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I (1257–1265)</p> <p>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1266–1285)</p> <p>401. Blood Transfusion: Poster I (1286–1295)</p> | <p>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1296–1314)</p> <p>503. Clonal Hematopoiesis, Aging and Inflammation: Poster I (1315–1327)</p> <p>506. Bone Marrow Microenvironment: Poster I (1328–1337)</p> <p>508. Bone Marrow Failure: Acquired: Poster I (1338–1354)</p> <p>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1355–1366)</p> <p>602. Myeloid Oncogenesis: Basic: Poster I (1367–1394)</p> <p>603. Lymphoid Oncogenesis: Basic: Poster I (1395–1409)</p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1410–1435)</p> <p>605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1436–1455)</p> <p>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1456–1468)</p> <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1469–1496)</p> <p>614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1497–1512)</p> <p>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1513–1535)</p> <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I (1536–1555)</p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1556–1599)</p> |
|---|---|

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1600–1616)
621. Lymphomas: Translational – Molecular and Genetic: Poster I (1617–1638)
622. Lymphomas: Translational – Non-Genetic: Poster I (1639–1654)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1655–1688)
624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster I (1689–1717)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I (1718–1737)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I (1738–1776)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1777–1794)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1795–1811)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1812–1843)
636. Myelodysplastic Syndromes – Basic and Translational: Poster I (1844–1854)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I (1855–1884)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I (1885–1896)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (1897–1919)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1920–1952)
652. Multiple Myeloma: Clinical and Epidemiological: Poster I (1953–2004)
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I (2005–2024)
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (2025–2040)
701. Experimental Transplantation: Basic and Translational: Poster I (2041–2054)
703. Cellular Immunotherapies: Basic and Translational: Poster I (2055–2089)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I (2090–2117)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I (2118–2143)
711. Cell Collection and Processing: Poster I (2144–2148)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I (2149–2175)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I (2176–2201)
723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Poster I (2202–2213)
731. Autologous Transplantation: Clinical and Epidemiological: Poster I (2214–2227)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2228–2247)
801. Gene Therapies: Poster I (2248–2258)
802. Chemical Biology and Experimental Therapeutics: Poster I (2259–2267)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I (2268–2294)
901. Health Services and Quality Improvement – Non-Malignant Conditions: Poster I (2295–2325)
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I (2326–2345)
903. Health Services and Quality Improvement – Myeloid Malignancies: Poster I (2346–2358)
904. Outcomes Research – Non-Malignant Conditions: Poster I (2359–2384)
905. Outcomes Research – Lymphoid Malignancies: Poster I (2385–2422)
906. Outcomes Research – Myeloid Malignancies: Poster I (2423–2442)
- TIP1. TIP – Classical Hematology: Poster I
- TIP2. TIP – Transplant/Immunotherapies: Poster I
- TIP3. TIP – Myeloid Malignancies: Poster I
- TIP4. TIP – Lymphoid Malignancies (Including Myeloma): Poster I

## SUNDAY, DECEMBER 10, 2023

9:00 a.m. – 8:00 p.m. **Poster Session II – Viewing** 

5:30 p.m. – 8:00 p.m. **Poster Session II – Presentations** 

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2443–2461)
102. Iron Homeostasis and Biology: Poster II (2462–2471)
112. Thalassemia and Globin Gene Regulation: Poster II (2472–2480)
113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2481–2497)
114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2498–2532)
201. Granulocytes, Monocytes, and Macrophages: Poster II (2533–2546)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2547–2558)
301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II (2559–2576)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2577–2597)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (2598–2607)
322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II (2608–2628)
331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II (2629–2636)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2637–2658)
401. Blood Transfusion: Poster II (2659–2668)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2669–2687)
503. Clonal Hematopoiesis, Aging and Inflammation: Poster II (2688–2699)
506. Bone Marrow Microenvironment: Poster II (2700–2710)
508. Bone Marrow Failure: Acquired: Poster II (2711–2727)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2728–2738)
602. Myeloid Oncogenesis: Basic: Poster II (2739–2766)
603. Lymphoid Oncogenesis: Basic: Poster II (2767–2781)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2782–2807)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2808–2826)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2827–2839)
613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2840–2867)
614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2868–2883)
615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2884–2905)
616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II (2906–2925)
617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2926–2968)
618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2969–2984)
621. Lymphomas: Translational—Molecular and Genetic: Poster II (2985–3006)
622. Lymphomas: Translational—Non-Genetic: Poster II (3007–3021)
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3022–3055)
624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II (3056–3084)
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II (3085–3104)
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (3105–3144)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3145–3163)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3164–3180)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3181–3211)
636. Myelodysplastic Syndromes—Basic and Translational: Poster II (3212–3225)
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II (3226–3253)
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II (3254–3265)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3266–3288)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3289–3323)
652. Multiple Myeloma: Clinical and Epidemiological: Poster II (3324–3376)
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II (3377–3396)
654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3397–3416)
701. Experimental Transplantation: Basic and Translational: Poster II (3417–3430)
703. Cellular Immunotherapies: Basic and Translational: Poster II (3431–3464)
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II (3465–3493)
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II (3494–3519)
711. Cell Collection and Processing: Poster II (3520–3524)
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II (3525–3550)
722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II (3551–3576)
723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II (3577–3591)
731. Autologous Transplantation: Clinical and Epidemiological: Poster II (3592–3603)
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3604–3622)
801. Gene Therapies: Poster II (3623–3633)
802. Chemical Biology and Experimental Therapeutics: Poster II (3634–3642)
803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II (3643–3670)
901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster II (3671–3701)
902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster II (3702–3719)
903. Health Services and Quality Improvement – Myeloid Malignancies: Poster II (3720–3733)
904. Outcomes Research—Non-Malignant Conditions: Poster II (3734–3759)
905. Outcomes Research—Lymphoid Malignancies: Poster II (3760–3798)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

906. Outcomes Research—Myeloid Malignancies:  
Poster II (3799–3816)

MONDAY,  
DECEMBER 11, 2023

9:00 a.m. – 8:00 p.m. **Poster Session III – Viewing** 

5:30 p.m. – 8:00 p.m. **Poster Session III – Presentations** 

- |  |  |
|--|--|
| <p>101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3817–3835)</p> <p>102. Iron Homeostasis and Biology: Poster III (3836–3845)</p> <p>112. Thalassemia and Globin Gene Regulation: Poster III (3846–3852)</p> <p>113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (3853–3870)</p> <p>114. Sickle cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (3871–3905)</p> <p>201. Granulocytes, Monocytes, and Macrophages: Poster III (3906–3918)</p> <p>203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3919–3931)</p> <p>301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III (3932–3950)</p> <p>311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3951–3970)</p> <p>321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3971–3979)</p> <p>322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III (3980–4000)</p> <p>331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III (4001–4009)</p> <p>332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4010–4031)</p> <p>401. Blood Transfusion: Poster III (4032–4040)</p> <p>501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4041–4058)</p> <p>503. Clonal Hematopoiesis, Aging and Inflammation: Poster III (4059–4070)</p> <p>506. Bone Marrow Microenvironment: Poster III (4071–4081)</p> <p>508. Bone Marrow Failure: Acquired: Poster III (4082–4098)</p> <p>509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4099–4110)</p> <p>602. Myeloid Oncogenesis: Basic: Poster III (4111–4137)</p> <p>603. Lymphoid Oncogenesis: Basic: Poster III (4138–4151)</p> <p>604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (4152–4178)</p> <p>605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (4179–4197)</p> <p>612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4198–4209)</p> <p>613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4210–4237)</p> | <p>614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4238–4253)</p> <p>615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4254–4276)</p> <p>616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III (4277–4295)</p> <p>617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4296–4339)</p> <p>618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4340–4356)</p> <p>621. Lymphomas: Translational—Molecular and Genetic: Poster III (4357–4378)</p> <p>622. Lymphomas: Translational–Non-Genetic: Poster III (4379–4393)</p> <p>623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4394–4427)</p> <p>624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III (4428–4456)</p> <p>626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III (4457–4475)</p> <p>627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4476–4513)</p> <p>631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4514–4533)</p> <p>632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4534–4550)</p> <p>634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4551–4581)</p> <p>636. Myelodysplastic Syndromes—Basic and Translational: Poster III (4582–4593)</p> <p>637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III (4594–4621)</p> <p>641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III (4622–4633)</p> <p>642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4634–4657)</p> <p>651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4658–4692)</p> <p>652. Multiple Myeloma: Clinical and Epidemiological: Poster III (4693–4745)</p> <p>653. Multiple Myeloma: Prospective Therapeutic Trials: Poster III (4746–4765)</p> <p>654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4766–4785)</p> |
|--|--|

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

- 701. Experimental Transplantation: Basic and Translational: Poster III (4786–4799)
- 703. Cellular Immunotherapies: Basic and Translational: Poster III (4800–4834)
- 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III (4835–4863)
- 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III (4864–4889)
- 711. Cell Collection and Processing: Poster III (4890–4894)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III (4895–4921)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (4922–4947)
- 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III (4948–4961)
- 731. Autologous Transplantation: Clinical and Epidemiological: Poster III (4962–4974)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4975–4993)
- 801. Gene Therapies: Poster III (4994–5004)
- 802. Chemical Biology and Experimental Therapeutics: Poster III (5005–5013)
- 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III (5014–5040)
- 901. Health Services and Quality Improvement - Non-Malignant Conditions: Poster III (5041–5071)
- 902. Health Services and Quality Improvement - Lymphoid Malignancies: Poster III (5072–5090)
- 903. Health Services and Quality Improvement –Myeloid Malignancies: Poster III (5091–5105)
- 904. Outcomes Research—Non-Malignant Conditions: Poster III (5106–5131)
- 905. Outcomes Research—Lymphoid Malignancies: Poster III (5132–5170)
- 906. Outcomes Research—Myeloid Malignancies: Poster III (5171–5191)

# ASC<sup>2</sup>ESCALATE

Now Enrolling<sup>1</sup>

NCT05384587<sup>1</sup>

Asciminib monotherapy for 2L and 1L CML with dose escalation

For more information on the ASC<sup>2</sup>ESCALATE study



Visit [novartis.com/clinicaltrials](https://novartis.com/clinicaltrials)  
(NCT05384587)



Call 1-888-NOW-NOVA  
(1-888-669-6682)



Email  
[mic.inquiry@novartis.com](mailto:mic.inquiry@novartis.com)

## Select Inclusion Criteria<sup>1,2\*</sup>

### For both cohorts:

- Patients ≥18 years of age with a diagnosis of CML-CP
- No previous accelerated phase or blast crisis
- No T315I mutation at any time prior to study entry

### For 2L patient cohort:


- Warning or failure with 1L TKI therapy at the time of screening
  - Warning is defined as:
    - $BCR::ABL1^{IS} >1\%$  to 10% 6 months after treatment initiation
    - $BCR::ABL1^{IS} >0.1\%$  to 1% 12 months after treatment initiation
  - Treatment failure with/resistance to 1L TKI is defined as:
    - $BCR::ABL1^{IS} >10\%$  if 1L treatment duration between 6 and 12 months
    - $BCR::ABL1^{IS} >1\%$  if 1L treatment duration is longer than 12 months
    - Loss of MMR beyond 12 months after treatment initiation<sup>2</sup>
- Treatment intolerance of 1L TKI and  $BCR::ABL1^{IS} >0.1\%$  at screening<sup>2</sup>

### For 1L patient cohort:

- Patients with newly diagnosed CML-CP (treatment with 1 prior TKI [imatinib, dasatinib, nilotinib, or bosutinib] for ≤4 weeks is allowed)

This Phase II trial will evaluate the efficacy and safety of asciminib monotherapy as 2L and 1L therapy for patients with CML-CP, starting at 80 mg QD with dose escalation from 80 mg QD to 200 mg QD or 200 mg QD to 200 mg BID in patients who do not achieve response milestones at 6 and 12 months<sup>1,2</sup>

## Study Design<sup>2</sup>



**Abbreviations:** 1L, first line; 2L, second line; ABL1, Abelson tyrosine kinase 1; BCR, breakpoint cluster region; BID, twice daily; CML-CP, chronic myeloid leukemia in chronic phase; IS, International Scale; MMR, major molecular response ( $BCR::ABL1^{IS} \leq 0.1\%$ ); NGS, next-generation sequencing; QD, once daily; TKI, tyrosine kinase inhibitor.

\* For complete eligibility criteria, please see [ClinicalTrials.gov](https://clinicaltrials.gov).

<sup>a</sup> For those patients who experience any grade 3 or 4 toxicity, or persistent grade 2 toxicity unresponsive to optimal management, the dose escalation mentioned above will not apply, and those patients will be continued on asciminib at the most current dosage.

<sup>b</sup> Based on investigator's clinical judgment of prospect treatment benefit. Patients switching to investigator's choice will be taken off study.

**References:** 1. [ClinicalTrials.gov](https://clinicaltrials.gov). Accessed September 5, 2023. <https://clinicaltrials.gov/ct2/show/NCT05384587> 2. Data on file. Clinical Trial Protocol CABL001AUS08. Novartis Pharmaceuticals Corp; 2023.

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.



Please visit us at booth 2429



# SATELLITE SYMPOSIA

Friday Satellite Symposia (FSS) will take place on Friday, December 8, 2023, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of the community play in an effort to provide hematologists with quality educational programs. Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## FRIDAY MORNING SYMPOSIA

7:00 A.M. – 10:00 A.M.

### Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice (for in-person participants)

7:00 a.m. – 10:00 a.m.  
Room 6CF  
San Diego Convention Center

*This program is provided by the Cleveland Clinic, The Aplastic Anemia and MDS International Foundation.*

#### Chair:

SUDIPTO MUKHERJEE, MD, PhD, MPH, Cleveland Clinic, Cleveland, OH

#### Speakers:

UMA M. BORATE, MBBS, MS, The Ohio State University Comprehensive Cancer Center, Columbus, OH

MARCO DAVILA, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

AUSTIN KULASEKARARAJ, MD, PhD, MPH, King's College Hospital, London, United Kingdom

ESTHER NATALIE OLIVA, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

KRISTEN MARIE PETTIT, MD, C.S. Mott Children's Hospital, Ann Arbor, MI

ABHAY SINGH, MD, MPH, Cleveland Clinic, Cleveland, OH

Contact: Kristin Bower  
Email: [bowerk@ccf.org](mailto:bowerk@ccf.org)

### Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

7:00 a.m. – 10:00 a.m.  
Pacific Ballroom Salons 21-22  
Marriott Marquis San Diego Marina

*This program is provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC and supported by educational grants from AstraZeneca, BeiGene, and Lilly.*

#### Chair:

BRIAN T. HILL, MD, PhD, Cleveland Clinic, Cleveland, OH

#### Speakers:

DANIELLE M. BRANDER, MD, Duke Cancer Center, Durham, NC

DEBORAH M. STEPHENS, DO, University of Utah, Salt Lake City, UT

Contact: Ishana Fleurant  
Email: [ifleurant@clinicaloptions.com](mailto:ifleurant@clinicaloptions.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)**

7:00 a.m. – 10:00 a.m.  
Grand Ballroom  
Omni San Diego

*This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck, and Seagen Inc.*

**Chair:**

NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

**Speakers:**

JEREMY S. ABRAMSON, MD, Massachusetts General Hospital Cancer Center, Boston, MA  
STEPHEN M. ANSELL, MD, PhD, Mayo Clinic, Rochester, MN  
NANCY L. BARTLETT, MD, Washington University School of Medicine, Saint Louis, MO  
JONATHON B. COHEN, MD, MS, Winship Cancer Institute, Emory University, Atlanta, GA  
JONATHAN W. FRIEDBERG, MD, MMSc, University of Rochester, Rochester, NY  
BRAD S. KAHL, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO

Contact: Sylvia Eriksen  
Email: [meetings@researchtopractice.com](mailto:meetings@researchtopractice.com)

**Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease**

7:00 a.m. – 10:00 a.m.  
Ballroom 20CD  
San Diego Convention Center

*This program is provided by PVI, PeerView Institute for Medical Education and supported by Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics, and Novartis Pharmaceuticals.*

**Speakers:**

RORY M. SHALLIS, MD, Yale School of Medicine and Yale Cancer Center, Killingworth, CT

ADITI SHASTRI, MD, Albert Einstein College of Medicine, Bronx, NY

Contact: Leigh Anne Bongiovanni  
Email: [leighanne.bongiovanni@peerview.com](mailto:leighanne.bongiovanni@peerview.com)

**Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies**

7:00 a.m. – 10:00 a.m.  
Room 6B  
San Diego Convention Center

*This program is provided by Physicians Education Resources, LLC and supported by Lilly, Merck & Co., Inc., and Pharmacyclics.*

**Chair:**

IAN W. FLINN, MD, PhD, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

**Speakers:**

CATHERINE C. COOMBS, MD, University of California Irvine, Irvine, CA  
PAOLO STRATI, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
STEVEN P. TREON, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA  
MICHAEL WANG, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

**Myelodysplastic Syndromes 2023: What's New?**

7:00 a.m. – 10:00 a.m.  
San Diego Ballroom AB  
Marriott Marquis San Diego Marina

*This program is provided and supported by MDS Foundation, Inc.*

**Co-Chairs:**

RENA BUCKSTEIN, MD, FRCPC, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

MOSHE MITTELMAN, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

**Speakers:**

MARIO CAZZOLA, MD, University of Pavia, Pavia, Italy  
MATTEO GIOVANNI DELLA PORTA, MD, Cancer Center IRCCS Humanitas Research Hospital, Milan, Italy

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

GUILLERMO GARCIA-MANERO, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
 ARISTOTELES GIAGOUNIDIS, MD, Marienhospital Düsseldorf, Düsseldorf, Germany  
 CHRISTOPHER JAMES GIBSON, MD, Dana-Farber Cancer Institute, Boston, MA  
 AZIZ NAZHA, MD, Thomas Jefferson University, Philadelphia, PA  
 UWE PLATZBECKER, MD, Leipzig University Hospital, Leipzig, Germany  
 MICHAEL R. SAVONA, MD, Vanderbilt University Medical Center, Nashville, TN

Contact: Lea Harrison  
 Email: [lharrison@mds-foundation.org](mailto:lharrison@mds-foundation.org)

### Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

7:00 a.m. – 10:00 a.m.  
 Room 6A  
 San Diego Convention Center

*This program is provided by Physicians' Education Resource, LLC and supported by Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.*

#### Chair:

IRENE M. GHOBRIAL, MD, Dana-Farber Cancer Institute, Boston, MA

#### Speaker:

CRAIG EMMITT COLE, MD, Michigan State University, East Lansing, MI

OMAR NADEEM, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Kelly Donald  
 Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

### Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

7:00 a.m. – 10:00 a.m.  
 Pacific Ballroom Salons 15-17  
 Marriott Marquis San Diego Marina

*This program is sponsored by PVI, PeerView Institute for Medical Education and supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.*

#### Chair:

NIKHIL C. MUNSHI, MD, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA

#### Speakers:

MOHAMAD MOHTY, MD, PhD, Saint-Antoine Hospital, Sorbonne University, Paris, France  
 KRINA K. PATEL, MD, MSc, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Leigh Anne Bongiovanni  
 Email: [leighanne.bongiovanni@peerview.com](mailto:leighanne.bongiovanni@peerview.com)

### FRIDAY EARLY AFTERNOON SYMPOSIA: 11:00 A.M. – 2:00 P.M.

### A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

11:00 a.m. – 2:00 p.m.  
 San Diego Ballroom AB  
 Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by educational grants from CTI Biopharma, Geron Corporation, GSK, and Karyopharm Therapeutics.*

#### Speakers:

JEAN-JACQUES KILADJIAN, MD, PhD, Hospital Saint-Louis, Paris, France  
 ABDULRAHEEM YACOB, MD, The University of Kansas, Leawood, KS

Contact: Ishana Fleurant  
 Email: [ifleurant@clinicaloptions.com](mailto:ifleurant@clinicaloptions.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

11:00 a.m. – 2:00 p.m.

Pacific Ballroom Salons 21-22  
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by an educational grant from AstraZeneca.*

#### Chair:

JOHN P. LEONARD, MD, Weill Cornell Medicine, New York, NY

#### Speakers:

ANN LACASCE, MD, Dana-Farber Cancer Institute, Boston, MA

MATTHEW A. LUNNING, DO, FACP, University of Nebraska, Omaha, NE

Contact: Ishana Fleurant

Email: [ifleurant@clinicaloptions.com](mailto:ifleurant@clinicaloptions.com)

### BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)

11:00 a.m. – 2:00 p.m.

Grand Ballroom  
Omni San Diego

*This program is provided by Research To Practice and supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.*

#### Chair:

NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

#### Speakers:

MICHAEL DICKINSON, MBBS, D. MED SCI, FRACP, FRCPA, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

GRZEGORZ S. NOWAKOWSKI, MD, Mayo Clinic, Rochester, MN

GILLES SALLES, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

LAURIE H. SEHN, MD, MPH, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada

JASON WESTIN, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Sylvia Eriksen

Email: [meetings@researchtopractice.com](mailto:meetings@researchtopractice.com)

### CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

11:00 a.m. – 2:00 p.m.

Room 30 A-E  
San Diego Convention Center

*This program is provided by Answers in CME and supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.*

#### Speakers:

SIKANDER AILAWADHI, MD, Mayo Clinic, Jacksonville, FL

AJAI CHARI, MD, University of California, San Francisco, San Francisco, CA

Contact: Caitlan Bose

Email: [caitlan.bose@answersincme.com](mailto:caitlan.bose@answersincme.com)

### Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

11:00 a.m. – 2:00 p.m.

Ballroom 20CD  
San Diego Convention Center

*This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, AstraZeneca, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.*

#### Chair:

PROF. JOHN G. GRIBBEN, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, United Kingdom

#### Speakers:

JOHN N. ALLAN, MD, Weill Cornell Medicine, New York, NY

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

NICOLE LAMANNA, MD, Herbert Irving  
Comprehensive Cancer Center, New York-  
Presbyterian/Columbia University Medical Center,  
New York, NY  
MEGHAN C. THOMPSON, MD, Memorial Sloan Kettering  
Cancer Center, New York, NY

Contact: Leigh Anne Bongiovanni  
Email: [leighanne.bongiovanni@peerview.com](mailto:leighanne.bongiovanni@peerview.com)

### Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

11:00 a.m. – 2:00 p.m.  
Room 6A  
San Diego Convention Center

*This program is provided by Physicians' Education Resource, LLC., and supported by Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc., and Curis, Inc.*

#### Chair:

NAVAL DAVER, MD, University of Texas MD Anderson  
Cancer Center, Houston, TX

#### Speakers:

COURTNEY D. DiNARDO, MD, MSc, University of Texas  
MD Anderson Cancer Center, Houston, TX  
AMIR T. FATHI, MD, Massachusetts General Hospital,  
Boston, MA  
GAIL J. ROBOZ, MD, Weill Cornell Medicine and The  
New York-Presbyterian Hospital, New York, NY  
EYTAN M. STEIN, MD, Memorial Sloan Kettering  
Cancer Center, New York, NY

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

### Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma

11:00 a.m. – 2:00 p.m.  
Room 6DE  
San Diego Convention Center

*This program is provided by PRIME Education, LLC and supported by Genmab, US Inc. and ADC Therapeutics.*

#### Chair:

KRISH PATEL, MD, Swedish Cancer Institute, Seattle,  
WA

#### Speakers:

DOUGLAS BURGOYNE, PHARM.D, FAMCP, University of  
Utah, Salt Lake City, UT  
KRISH PATEL, MD, Swedish Cancer Institute, Seattle,  
WA  
PETER A. RIEDELL, MD, University of Chicago,  
Chicago, IL

Contact: Jill Friedman  
Email: [j.friedman@primeinc.org](mailto:j.friedman@primeinc.org)

### Medical Crossfire®: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

11:00 a.m. – 2:00 p.m.  
Pacific Ballroom Salons 24-26  
Marriott Marquis San Diego Marina

*This program is provided by Physicians' Education Resource and supported by American Regent, Inc.*

#### Chair:

GEORGE M. RODGERS, MD, PhD, University of Utah  
Medical Center, Salt Lake City, UT

#### Speaker:

SIDARTH ANAND, MD, UCLA HEALTH, LOS ANGELES, CA  
PATRICIA A. LOCANTORE-FORD, MD, Pennsylvania  
Hospital, Philadelphia, PA

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

### Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

11:00 a.m. – 2:00 p.m.  
Marriott Grand Ballroom 11-13  
Marriott Marquis San Diego Marina

*This program is provided by Physicians' Education Resource, LLC and supported by Amgen, Inc., Servier Pharmaceuticals, and Takeda Oncology.*

#### Chair:

ELIAS JABBOUR, MD, University of Texas MD Ander-  
son Cancer Center, Houston, TX

#### Speakers:

LIA GORE, MD, University of Colorado Cancer  
Center, Aurora, CO

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

HAGOP M. KANTARJIAN, MD, University of Texas MD Anderson Cancer Center, Houston, TX  
AARON C. LOGAN, MD, PhD, University of California San Francisco, San Francisco, CA  
CLAIRE RODDIE, MD, PhD, University College London, London, England

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

### More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia

**11:00 a.m. – 2:00 p.m.**  
**Marriott Grand Ballroom 2-4**  
**Marriott Marquis San Diego Marina**

*This program is provided by Medscape Oncology and supported by an independent educational grant from Argenx US, Inc., Sanofi, and Novartis Oncology.*

#### Chair:

SPERO CATALAND, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH

#### Speakers:

SRIKANTH NAGALLA, MBBS, Miami Cancer Institute, Miami, FL  
MARIE SCULLY, MD, University College London, London, England

Contact: Harmony Washington  
Email: [hWashington@medscapealive.com](mailto:hWashington@medscapealive.com)

### Multiple Myeloma: Clinical Challenges for the Community Clinician

**11:00 a.m. – 2:00 p.m.**  
**Marriott Grand Ballroom 5-6**  
**Marriott Marquis San Diego Marina**

*This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, Janssen, Sanofi, Karyopharm, and Legend.*

#### Chair:

C. OLA LANDGREN, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

#### Speakers:

LUCIANO COSTA, MD, PhD, University of Alabama at Birmingham, Birmingham, AL  
NISHA S. JOSEPH, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Contact: Harmony Washington  
Email: [hWashington@medscapealive.com](mailto:hWashington@medscapealive.com)

### Optimizing Myelofibrosis Management With Current and Emerging Therapies

**11:00 a.m. – 2:00 p.m.**  
**Marriott Grand Ballroom 8-9**  
**Marriott Marquis San Diego Marina**

*This program is provided by Medscape Oncology and supported by AbbVie, Bristol Myers Squibb, GSK, and Karyopharm Therapeutics.*

#### Chair:

PRITHVIRAJ BOSE, MD, University of Texas MD Anderson Cancer Center, Houston, TX

#### Speakers:

STEPHEN T. OH, MD, PhD, Washington University School of Medicine, Saint Louis, MO  
NIKOLAI A. PODOLTSEV, MD, PhD, Yale University School of Medicine, New Haven, CT

Contact: Harmony Washington  
Email: [hWashington@medscapealive.com](mailto:hWashington@medscapealive.com)

### Reimaging Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies

**11:00 a.m. – 2:00 p.m.**  
**Pacific Ballroom Salons 18-19**  
**Marriott Marquis San Diego Marina**

*This program is provided by Catalyst Medical Education and supported by Sanofi.*

#### Chair:

GUY YOUNG, MD, Children's Hospital Los Angeles, Los Angeles, CA

#### Speakers:

GLAIVY BATSULI, MD, Stanford University, Stanford, CA  
CINDY A. LEISSINGER, MD, Tulane University School of Medicine, New Orleans, LA

Contact: Cathy Zehr  
Email: [cathy.zehr@catalystmeded.com](mailto:cathy.zehr@catalystmeded.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

11:00 a.m. – 2:00 p.m.  
Room 6B  
San Diego Convention Center

*This program is provided by Physicians' Education Resource, LLC and supported by Geron Corporation, Incyte Corporation, Protagonist Therapeutics, and PharmaEssentia USA.*

#### Chair:

ANDREW T. KUYKENDALL, MD, Moffitt Cancer Center, Tampa, FL

#### Speakers:

GABRIELA S. HOBBS, MD, Massachusetts General Hospital, Boston, MA  
BARBARA MORA, MD, Ospedale ASST Sette Laghi, University of Insubria, Varese, Italy  
NAVEEN PEMMARAJU, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

### Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

11:00 a.m. – 2:00 p.m.  
Ballroom 20AB  
San Diego Convention Center

*This program is provided by Karmanos Cancer Institute and supported by Prothena, Amyloidosis Foundation Amyloidosis Support Group.*

#### Chair:

JEFFREY A. ZONDER, MD, Karmanos Cancer Institute, Detroit, MI

#### Speakers:

RAFAT ABONOUR, MD, Indiana University School of Medicine, Indianapolis, IN  
GIADA BIANCHI, MD, Brigham and Women's Hospital, Boston, MA  
ELI MUCHTAR, MD, Mayo Clinic, Rochester, MN  
LAURA OBICI, MD, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Contact: Christiane Houde  
Email: [houdec@karmanos.org](mailto:houdec@karmanos.org)

### FRIDAY LATE AFTERNOON SYMPOSIA: 3:00 P.M. – 6:00 P.M.

#### A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

3:00 p.m. – 6:00 p.m.  
Marriott Grand Ballroom 11-13  
Marriott Marquis San Diego Marina

*This program is provided by Medscape Oncology and supported by Agios and Novartis Oncology.*

#### Chair:

MORAG GRIFFIN, FRCPATH, MRCP, St James's University Hospital, Leeds, United Kingdom

#### Speaker:

MICHAEL R. DEBAUN, MD, MPH, Vanderbilt University Medical Center, Nashville, TN

Contact: Harmony Washington  
Email: [hWashington@medscapelive.com](mailto:hWashington@medscapelive.com)

#### Achieving "Next-Level" Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

3:00 p.m. – 6:00 p.m.  
Pacific Ballroom Salons 15-17  
Marriott Marquis San Diego Marina

*This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.*

#### Chair:

SERGIO A. GIRALT, MD, FACP, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Speakers:**

PINKAL DESAI, MD, MPH, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY

GHAYAS C. ISSA, MD, University of Texas MD Anderson Cancer Center, Houston, TX

TAPAN M. KADIA, MD, University of Texas MD Anderson Cancer Center, Houston, TX

SELINA M LUGER, MD, FRCPC, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Contact: Leigh Anne Bongiovanni

Email: [leighanne.bongiovanni@peerview.com](mailto:leighanne.bongiovanni@peerview.com)

### Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

3:00 p.m. – 6:00 p.m.

San Diego Ballroom AB  
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC. and supported by Sanofi.*

**Chair:**

CATHERINE BROOME, MD, Georgetown University, Washington, DC

**Speakers:**

DAVID DINGLI, MD, Mayo Clinic, Rochester, MN

DEVA SHARMA, MD, Vanderbilt University School of Medicine, Nashville, TN

Contact: Ishana Fleurant

Email: [Ifleurant@clinicaloptions.com](mailto:Ifleurant@clinicaloptions.com)

### Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

3:00 p.m. – 6:00 p.m.

Room 30 A-E  
San Diego Convention Center

*This program is provided by RMEI Medical Education, LLC and supported by an educational grant from Genmab US, Inc. and AbbVie.*

**Chair:**

JOSHUA BRODY, MD, Icahn School of Medicine at Mount Sinai, New York, NY

**Speakers:**

LORENZO FALCHI, MD, Memorial Sloan Kettering Cancer Center, New York, NY

LORI A. LESLIE, MD, Hackensack Meridian School of Medicine, Hackensack, NJ

Contact: Erika Sinofsky

Email: [esinofsky@rmei.com](mailto:esinofsky@rmei.com)

### Advancing cTTP Care Through Integration of the Latest Clinical Evidence

3:00 p.m. – 6:00 p.m.

Ballroom 20AB  
San Diego Convention Center

*This program is provided by PRIME Education, LLC and supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.*

**Speakers:**

AZRA BOROGOVAC, MD, City of Hope National Medical Center, Irvine, CA

CHRISTINA HAAF, PHARM.D, University of Illinois at Chicago College of Pharmacy, Chicago, IL

LONG ZHENG, MD, PH.D, University of Kansas Medical Center, Kansas City, KS

Contact: Eryn Litvinas

Email: [e.litvinas@primeinc.org](mailto:e.litvinas@primeinc.org)

### AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

3:00 p.m. – 6:00 p.m.

Pacific Ballroom Salons 21-22  
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by educational grants from Alexion Pharmaceuticals, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, and Prothena.*

**Chair:**

ANGELA DISPENZIERI, MD, Mayo Clinic, Rochester, MN

**Speaker:**

ASHUTOSH D. WECHALEKAR, MBBS, DM, FRCP, FRCPATH, University College London Hospitals, London, United Kingdom

Contact: Ishana Fleurant

Email: [Ifleurant@clinicaloptions.com](mailto:Ifleurant@clinicaloptions.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

3:00 p.m. – 6:00 p.m.  
Room 6DE  
San Diego Convention Center

*This program is provided by PRIME Education, LLC and supported by Gilead Sciences, Inc.*

#### Chair:

AMER M. ZEIDAN, MBBS, MHS, Yale University, New Haven, CT

#### Speakers:

DOUGLAS BURGOYNE, PHARM.D, FAMCP, University of Utah, Salt Lake City, UT  
RAMI S. KOMROKJI, MD, Moffitt Cancer Center, Tampa, FL

Contact: Eryn Litvinas  
Email: [e.litvinas@primeinc.org](mailto:e.litvinas@primeinc.org)

### An Expert Guide to What's New and What's Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

3:00 p.m. – 6:00 p.m.  
Pacific Ballroom Salons 18-19  
Marriott Marquis San Diego Marina

*This program is provided by Clinical Care Options, LLC and supported by educational grants from Genentech, a member of the Roche Group, Genmab, Ipsen Biopharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.*

#### Chair:

JULIE M. VOSE, MD, MBA, University of Nebraska Medical Center, Omaha, NE

#### Speakers:

PETER MARTIN, MD, Weill Cornell Medical College, New York, NY  
SONALI M. SMITH, University of Chicago, Chicago, IL

Contact: Ishana Fleurant  
Email: [ifleurant@clinicaloptions.com](mailto:ifleurant@clinicaloptions.com)

### BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

3:00 p.m. – 6:00 p.m.  
Grand Ballroom  
Omni San Diego

*This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.*

#### Chair:

NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

#### Speakers:

FARRUKH T. AWAN, MD, The University of Texas, Dallas, TX  
MATTHEW S. DAVIDS, MD, MMSc, Dana-Farber Cancer Institute, Inc., Boston, MA  
STEPHEN J. SCHUSTER, MD, University of Pennsylvania, Philadelphia, PA  
WILLIAM G. WIERDA, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX  
JENNIFER A. WOYACH, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Contact: Sylvia Eriksen  
Email: [meetings@researchtopractice.com](mailto:meetings@researchtopractice.com)

### Case Challenges in Myelofibrosis for the Community Clinician

3:00 p.m. – 6:00 p.m.  
Marriott Grand Ballroom 5-6  
Marriott Marquis San Diego Marina

*This program is provided by Medscape Oncology and supported by CTI Biopharma Corp.*

#### Chair:

RUBEN A. MESA, MD, Atrium Health Levine Cancer Institute, Charlotte, NC

#### Speakers:

ANGELA G. FLEISCHMAN, MD, PhD, University of California, Irvine, Irvine, CA  
RAAJIT K. RAMPAL, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Harmony Washington  
Email: [hWashington@medscapelive.com](mailto:hWashington@medscapelive.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Changing the Path of Myelofibrosis: Exploring How We Can Do More for Our Patients

3:00 p.m. – 6:00 p.m.

Marriott Grand Ballroom 8-9  
Marriott Marquis San Diego Marina

*This program is provided by Medscape Oncology and supported by Morphosys.*

#### Chair:

JOHN MASCARENHAS, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

#### Speakers:

CLAIRE N HARRISON, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom  
RONALD HOFFMAN, MD, Tisch Cancer Institute, New York, NY  
ANN MULLALLY, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Harmony Washington  
Email: [hWashington@medscapelive.com](mailto:hWashington@medscapelive.com)

### Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH

3:00 p.m. – 6:00 p.m.

Marriott Grand Ballroom 2-4  
Marriott Marquis San Diego Marina

*This program is provided by Medscape Oncology and supported by Alexion Pharmaceuticals, Inc.*

#### Chair:

ILENE C. WEITZ, MD, Keck School of Medicine of USC, Los Angeles, CA

#### Speakers:

VINCENT T. HO, MD, Harvard Medical School, Boston, MA  
DAVID J KUTER, MD, DPHIL, Massachusetts General Hospital, Boston, MA

Contact: Harmony Washington  
Email: [hWashington@medscapelive.com](mailto:hWashington@medscapelive.com)

### Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients' Lifespans

3:00 p.m. – 6:00 p.m.

Room 6B  
San Diego Convention Center

*This program is provided by Physicians' Education Resource, LLC and supported by Vertex Pharmaceuticals.*

#### Chair:

BIREE ANDEMARIAM, MD, University of Connecticut Health, Farmington, CT

#### Speakers:

LYDIA H. PECKER, MD, Johns Hopkins University School of Medicine, Baltimore, MD  
NIRMISH SHAH, MD, Duke University Medical Center, Durham, NC

Contact: Kelly Donald  
Email: [kdonald@mjevents.com](mailto:kdonald@mjevents.com)

### Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings

3:00 p.m. – 6:00 p.m.

Pacific Ballroom Salons 24-26  
Marriott Marquis San Diego Marina

*This program is provided by Physicians' Education Resource, LLC and supported by Novartis Pharmaceuticals Corporation.*

#### Chair:

JORGE CORTES, MD, Augusta University, Augusta, GA

#### Speakers:

ANDREAS HOCHHAUS, MD, Universitätsklinikum Jena, Jena, Germany  
AMANDA RODRIGUEZ, PA-C, Moffitt Cancer Center, Tampa, FL

Contact: Kelly Donald  
Email: [kdonald@mjevents.com](mailto:kdonald@mjevents.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

**Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care**

**3:00 p.m. – 6:00 p.m.**  
**Room 6A**  
**San Diego Convention Center**

*This program is provided by Physicians' Education Resource, LLC and supported by Jazz Pharmaceuticals, Inc and Servier Pharmaceuticals.*

**Chair:**

RACHEL E. RAU, MD, Texas Children's Hospital/Baylor College of Medicine, Houston, TX

**Speakers:**

LAUREN HUANG, DNP, ARNP, PNP-PC, Seattle Children's Hospital, Seattle, WA  
 LUKE MAESE, DO, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT  
 ETAN ORGEL, MD, Keck School of Medicine of USC, Los Angeles, CA

Contact: Kelly Donald  
 Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

**Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents**

**3:00 p.m. – 6:00 p.m.**  
**Ballroom 20CD**  
**San Diego Convention Center**

*This program is provided by PVI, PeerView Institute for Medical Education and supported by AstraZeneca LP.*

**Chair:**

SHMUEL SHOHAM, MD, Johns Hopkins University School of Medicine, Baltimore, MD

**Speakers:**

GHADY HAIDAR, MD, University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA  
 CAROL ANN HUFF, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD

Contact: Leigh Anne Bongiovanni  
 Email: [leighanne.bongiovanni@peerview.com](mailto:leighanne.bongiovanni@peerview.com)

**FRIDAY EVENING SYMPOSIA:  
 7:00 P.M. – 10:00 P.M.**

**BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)**

**7:00 p.m. – 10:00 p.m.**  
**Grand Ballroom**  
**Omni San Diego**

*This program is provided by Research To Practice and supported by educational grants from Abbvie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi.*

**Chair:**

NEIL LOVE, MD, Research To Practice, Key Biscayne, FL

**Speakers:**

AMRITA KRISHNAN, MD, City of Hope, Irvine, CA  
 SAGAR LONIAL, MD, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA  
 ROBERT Z. ORLOWSKI, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX  
 NOOPUR RAJE, MD, Massachusetts General Hospital Cancer Center, Boston, MA  
 PAUL G. RICHARDSON, MD, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Contact: Sylvia Eriksen  
 Email: [meetings@researchtopractice.com](mailto:meetings@researchtopractice.com)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

### Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

7:00 p.m. – 10:00 p.m.

Marriott Grand Ballroom 11-13  
Marriott Marquis San Diego Marina

*This program is provided by Medscape Oncology and supported by Bristol Myers Squibb, and Seagen.*

#### Chair:

ALEX F. HERRERA, MD, City of Hope, Duarte, CA

#### Speakers:

PHILIPPE ARMAND, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

CARLA CASULO, MD, University of Rochester, Rochester, NY

Contact: Harmony Washington  
Email: [h washington@medscapelive.com](mailto:h washington@medscapelive.com)

### How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

7:00 p.m. – 10:00 p.m.

Pacific Ballroom Salons 24-26  
Marriott Marquis San Diego Marina

*This program is provided by Physicians' Education Resource, LLC and supported by Incyte Corporation, ST Shared Services LLC, a Mallinckrodt company, and Equillium Bio.*

#### Chair:

COREY CUTLER, Dana-Farber Cancer Institute, Boston, MA

#### Speakers:

HANNAH CHOE, MD, The Ohio State University Wexner Medical Center, Columbus, OH

CARRIE L. KITKO, MD, Vanderbilt University, Nashville, TN

MIGUEL-ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kelly Donald  
Email: [kdonald@mjhevents.com](mailto:kdonald@mjhevents.com)

# PRODUCT THEATERS

Product Theaters as of October 19, 2023.

Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SATURDAY

*Sponsored by Johnson & Johnson*

**Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types** (non-CME)

**11:30 a.m. – 12:30 p.m.**  
**Room 3**  
**San Diego Convention Center**

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

VIPIN KHARE, MD, Johnson & Johnson

*Sponsored by Bristol Myers Squibb*

**Learn More About a CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)**

(non-CME)

**11:30 a.m. – 12:30 p.m.**  
**Room 2**  
**San Diego Convention Center**

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speakers:**

AMANI KITALI, MBA, MPH, PMP, Bristol Myers Squibb

JOSEPHINE MACHADO, MSN, APN-C, AOCNP, Bristol Myers Squibb

*Sponsored by Blueprint Medicines*

**The FIRST and ONLY Therapy Approved for Adults with Indolent Systemic Mastocytosis (ISM)** (non-CME)

**11:30 a.m. – 12:30 p.m.**  
**Room 4**  
**San Diego Convention Center**

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

DANIEL SHAHEEN, PHARM.D, Blueprint Medicines

## SUNDAY

*Sponsored by Pfizer***A Treatment Option for Relapsed or Refractory Multiple Myeloma from Pfizer** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 2  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

CAROLINE HOANG, PhD, Pfizer

*Sponsored by BioLineRx, Inc.***APHEXDA (motixafortide): Learn about this new FDA approved treatment option** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 3  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

ELLA SORANI, PhD, BioLineRx, Inc.

*Sponsored by Pharming Healthcare Inc.***Could there be a Link Between Autoimmune Cytopenias, Lymphadenopathy, and Splenomegaly? A Physician's Perspective and a Patient's Experience** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 4  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

This session will include a patient perspective provided by a Pharming Healthcare, Inc. Patient Ambassador.

**Speaker:**

ANURAG RELAN, MD, Pharming Healthcare Inc.

*Sponsored by AbbVie Oncology***Exploring Time Off Treatment with a BCL-2 Inhibitor** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speakers:**

JALAJA POTLUIR, MD, AbbVie  
AHMED KOTB, MD, AbbVie

*Sponsored by Genmab and AbbVie***Unveiling a Subcutaneous Therapy for 3L+ DLBCL** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 5A  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

SAMANTHA BRODKIN, DO, MS, Genmab

*Sponsored by Apellis Pharmaceuticals***A Complement Inhibitor for PNH** (non-CME)

11:30 a.m. – 12:30 p.m.  
Room 5B  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

This session will include a patient perspective provided by Louis Hernandez.

**Speakers:**

PETER HILLMEN, MD, Apellis Pharmaceuticals  
MARY ROWAN, RN, BSN, Apellis Pharmaceuticals

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

*Sponsored by Pfizer*

### A Discussion on a Treatment Option for Sickle Cell Disease (non-CME)

11:30 a.m. – 12:30 p.m.  
Room 5A  
San Diego Convention Center

**For in-person participants only.**

**Speaker:**

KIM SMITH-WHITLEY, MD, Pfizer

*Sponsored by Johnson & Johnson*

**Janssen invites you to learn about a treatment for adult patients with RRMM who have received at least four prior lines of therapy, including a PI, IMiD, and anti-CD38 monoclonal antibody**

(non-CME)

11:30 a.m. – 12:30 p.m.  
Room 1B  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

AGNE PANER-STRASEVICIUTE, MD, Johnson & Johnson

*Sponsored by Eli Lilly and Company*

**Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC. (non-CME)**

11:30 a.m. – 12:30 p.m.  
Room 2  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speakers:**

JOHN PAGEL, MD, PhD, LOXO@Lilly  
DONALD E. TSAI, MD, PhD, LOXO@Lilly

*Sponsored by GSK*

**Learn more about a new FDA-approved treatment, OJJAARA (mometinib) (non-CME)**

11:30 a.m. – 12:30 p.m.  
Room 4  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

ANTHONY VAGANOS, MBIOTECH, GSK

*Sponsored by AstraZeneca*

**Long-term Clinical Trial Results for CALQUENCE in the Treatment of All Patients with CLL/SLL**

(non-CME)

11:30 a.m. – 12:30 p.m.  
Room 3  
San Diego Convention Center

**For in-person participants only.**

**Speaker:**

VIKRAM SHETTY, MD, AstraZeneca

*Sponsored by Bristol Myers Squibb*

**Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases (non-CME)**

11:30 a.m. – 12:30 p.m.  
Room 1A  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

PAVIT SINGH, PHARM D, RPH, MBA, Bristol Myers Squibb

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## MONDAY

*Sponsored by Johnson & Johnson*

**A new, first-in-class treatment for RRMM patients** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 5B  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

SAURABH N. PATEL, MD, Johnson & Johnson

*Sponsored by Sanofi*

**Achieving Higher Factor VIII Levels in Hemophilia A** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 3  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**This session will include a patient perspective provided by David, living with Hemophilia A and Sanofi Peer Ambassador.**

**Speakers:**

PETER CHEN, PhD, Sanofi

EKTA SETH CHHABRA, PhD, Sanofi

*Sponsored by Genentech*

**An Advancement in Frontline DLBCL and A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 1B  
San Diego Convention Center

**For in-person participants only.**

**Speaker:**

JAMIE H. HIRATA, PHARM.D, Genentech

*Sponsored by Gamida Cell*

**Latest Advancement in Allogeneic Hematopoietic Cell Transplantation** (non-CME)

8:00 a.m. – 9:00 a.m.  
Room 5A  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

RONIT SIMANTOV, MD, Gamida Cell

*Sponsored by Bristol Myers Squibb*

**An FDA approved treatment option for anemia in LR-MDS** (non-CME)

12:15 p.m. – 1:15 p.m.  
Room 3  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

CHRISTINA HUGHES, PhD, Bristol Myers Squibb

*Sponsored by Johnson & Johnson and Legend Biotech*

**CARVYKTI® Product Summary for Healthcare Providers** (non-CME)

12:15 p.m. – 1:15 p.m.  
Room 1B  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

LISA KALLENBACH, MD, MPA, Johnson & Johnson

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Sponsored by Sanofi

**Outcomes and Economic Impact of Treatment  
with CABLIVI® (caplacizumab-yhdp) non-CME**

**12:15 p.m. – 1:15 p.m.**  
**Room 4**  
**San Diego Convention Center**

**For in-person participants only.**

**Speakers:**

RAHUL BOHRA, MSc, PhD, Sanofi  
ALIX ARNAUD, MSc, Sanofi



# INDUSTRY THEATERS

Industry Theaters as of October 19, 2023.  
Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SATURDAY

Sponsored by *AbbVie (Pharmacyclics)*

### BTK Mutations and the Emergence of Treatment Resistance: Changing the CLL Landscape

(non-CME)

11:30 a.m. – 12:30 p.m.  
Room 5A  
San Diego Convention Center

For in-person participants only.

Speaker:

JAMES P. DEAN, MD, PhD, AbbVie

Sponsored by *AstraZeneca*

### COVID-19: Protecting Vulnerable Populations

(non-CME)

11:30 a.m. – 12:30 p.m.  
Room 5B  
San Diego Convention Center

For in-person participants only.

Speaker:

KETUL PATEL, PhD, AstraZeneca

Sponsored by *GSK*

### GSK Oncology: Breaking Barriers for Patients with Multiple Myeloma (non-CME)

11:30 a.m. – 12:30 p.m.  
Room 1B  
San Diego Convention Center

For in-person participants only.

Speakers:

TANIA SMALL, MD, GSK Collegeville PA  
JULIAN PEREZ RONCO, MD, MBH, MPH, GSK

Sponsored by *Genentech, A Member of the Roche Group*

### Quality of Life, Burden of Illness, and Treatment Burden in Paroxysmal Nocturnal Hemoglobinuria: A Current Perspective on C5 Inhibitors (non-CME)

11:30 a.m. – 12:30 p.m.  
Room 1A  
San Diego Convention Center

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

JOHN PASI, MD, PhD, Genentech

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

## SUNDAY

*Sponsored by X4 Pharmaceutical*

### Classical Hematology: Looking into the Future

(non-CME)

**8:00 a.m. – 9:00 a.m.**  
**Room 1B**  
**San Diego Convention Center**

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speaker:**

CHRISTOPHE ARBET-ENGELS, MD, PhD, X4 Pharmaceutical

*Sponsored by Vertex Pharmaceuticals Inc.*

### The disease burden of transfusion dependent beta-thalassemia and approaches to cell and genetic therapy

(non-CME)

**8:00 a.m. – 9:00 a.m.**  
**Room 1A**  
**San Diego Convention Center**

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speakers:**

ARIC PARNES, MD, Vertex Pharmaceuticals Inc.  
 TONY BOITANO, PhD, Vertex Pharmaceuticals Inc.  
 NNENNA UKACHI, MD, MPH, Vertex Pharmaceuticals Inc.

## MONDAY

*Sponsored by AstraZeneca*

### Emerging AstraZeneca Hematology Pipeline

(non-CME)

**12:15 p.m. – 1:15 p.m.**  
**Room 5B**  
**San Diego Convention Center**

For in-person participants only.

**Speakers:**

ALAN YONG, MD, AstraZeneca  
 RICHARD HERMANN, MD, AstraZeneca  
 VIKRAM SHETTY, MD, AstraZeneca

*Sponsored by Gilead and Kite Oncology*

### Gilead and Kite Oncology Pipeline

(non-CME)

**12:15 p.m. – 1:15 p.m.**  
**Room 1A**  
**San Diego Convention Center**

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

**Speakers:**

CAROL O'HEAR, MD, PhD, Gilead and Kite Oncology  
 ROLONDO ENOCH, MS, Gilead and Kite Oncology  
 FRANK NEUMANN, MD, PhD, Gilead and Kite Oncology  
 CHRIS McDONALD, MBA, Gilead and Kite Oncology

*Sponsored by Agios Pharmaceuticals, Inc.*

### In Pursuit of Healthier Red Blood Cells: The RISE UP Phase 2/3 Clinical Trial of Mitapivat in Sickle Cell Disease

(non-CME)

**12:15 p.m. – 1:15 p.m.**  
**Room 5A**  
**San Diego Convention Center**

For in-person participants only.

This session will include a patient perspective provided by Golie Lorenzo Green.

**Speakers:**

AHMAR U ZAIDI, MD, Agios Pharmaceuticals  
 SARAH GHEUENS, MD, PhD, Agios Pharmaceuticals

# COMPANY SHOWCASES

Company Showcases as of October 19, 2023.

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies' services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

*All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.*

## SATURDAY

*Sponsored by Galapagos*

### Galapagos' 7 Day Vein-to-Vein Point-of-Care CAR-T Manufacturing Model (non-CME)

1:30 p.m. – 1:45 p.m.  
Room 5A  
San Diego Convention Center

**For in-person participants only.**

**Speakers:**

RUIZ ASTIGARRAGA, MSc, Galapagos  
JACQUELINE VINK-KORNDORFFER, MSc, Galapagos

*Sponsored by GRAIL LLC*

### Showcase on Galleri<sup>®</sup>, a Multi-Cancer Early Detection Test (non-CME)

1:30 p.m. – 1:45 p.m.  
Room 5B  
San Diego Convention Center

**This presentation is intended for U.S. based registered meeting attendees.**

**For in-person participants only.**

**Speaker:**

RITA SHAKNOVICH, MD, PhD, GRAIL, LLC

*Sponsored by Precision NanoSystems*

### Genetic Engineering of T Cells and CD34+ HSPCs using RNA-Lipid Nanoparticle for Cell and Gene Therapies (non-CME)

3:30 p.m. – 3:45 p.m.  
Room 5B  
San Diego Convention Center

**For in-person participants only.**

**Speaker:**

ANGELA ZHANG, PhD, Precision NanoSystems

*Sponsored by Syndax Pharmaceuticals*

### Reimaging Cancer Care at Syndax: Clinical Development of Targeted Therapies (non-CME)

3:30 p.m. – 3:45 p.m.  
Room 5A  
San Diego Convention Center

**For in-person participants only.**

**Speakers:**


NEIL GALLAGHER, MD, PhD, Syndax Pharmaceuticals  
KATE MADIGAN, MD, Syndax Pharmaceuticals

---

**SUNDAY**

*Sponsored by Halia Therapeutics*

**Halia Therapeutics- Targeting the Chronic  
Inflammatory Bone Marrow Microenvironment**

 non-CME

**4:00 p.m. – 4:15 p.m.  
Room 5B  
San Diego Convention Center**

**This presentation is intended for U.S. based registered  
meeting attendees.**

**For in-person participants only.**

**Speakers:**

DAVID BEARSS, PHD, Halia Therapeutics  
ALAN LIST, MD, Halia Therapeutics

# EXHIBITORS

Participating Exhibitors as of October 13, 2023

Exhibitors	Booth Number
AbbVie	309
Acrotech Biopharma	2100
Actinium Pharmaceuticals	2033
Adaptive Biotechnologies Corporation	2129
ADC Therapeutics	1325
Agios Pharmaceuticals	133
Aixial	2450
Allogene Therapeutics	3205
Alpine Immune Sciences	3443
American Association for Cancer Research	200
American Society for Transplantation and Cellular Therapy (ASTCT)	2120
American Society of Gene and Cell Therapy (ASGCT)	11
American Society of Hematology	1215, Virtual
American Society of Pediatric Hematology Oncology (ASPHO)	23
Amgen	833
Amyloidosis Foundation	2056
Amyloidosis Support Groups	37
Apellis Pharmaceuticals	615, 714
Aplastic Anemia and MDS International Foundation, Inc.	2130
AplusA	1849
Applied Cells	3447
Aptitude Health	2257
Aptose Biosciences Inc.	505
Arcellx	748
argenx	3318
ARUP Laboratories	2453
Ascentage Pharma	3355
Association for Value-Based Cancer Care	16
Association of PAs in Oncology	Virtual
Association of Public Health Laboratories	29
Astellas Pharma US, Inc.	2311
Astex Pharmaceuticals, Inc.	1549
AstraZeneca	1433
Atara Biotherapeutics, Inc.	1456

## EXHIBITORS

<b>AVM Biotechnology LLC</b>	<b>112</b>
<b>Bayer</b>	<b>1454</b>
<b>Beam Therapeutics</b>	<b>3255</b>
<b>Beckman Coulter Life Sciences</b>	<b>2351</b>
<b>BeiGene USA</b>	<b>3013</b>
<b>Binaytara Foundation</b>	<b>26</b>
<b>Binding Site, Inc.</b>	<b>132</b>
<b>Bio Products Laboratory USA, Inc.</b>	<b>2022, 2026</b>
<b>Biognosys</b>	<b>3451</b>
<b>BioIVT</b>	<b>3409</b>
<b>BioLineRx, Inc.</b>	<b>3155</b>
<b>BioMarin Pharmaceutical Inc.</b>	<b>1948</b>
<b>Biomea Fusion, Inc</b>	<b>3223</b>
<b>BioSkryb Genomics</b>	<b>2102</b>
<b>BioSpyder</b>	<b>3044</b>
<b>Blood Cancers Today / Mashup Media</b>	<b>3154</b>
<b>Blue Spark Technologies, Inc.</b>	<b>1256</b>
<b>bluebird bio</b>	<b>743, 756</b>
<b>Blueprint Medicines</b>	<b>1749</b>
<b>BostonGene</b>	<b>2350</b>
<b>Brazilian Association of Hematology, Hemotherapy And Cell Therapy (AHHH)</b>	<b>40</b>
<b>Bristol Myers Squibb</b>	<b>2609, Virtual</b>
<b>Cardinal Health</b>	<b>3201</b>
<b>Caribou Biosciences, Inc.</b>	<b>2551</b>
<b>Cellular Highways Ltd</b>	<b>3444</b>
<b>Centessa Pharmaceuticals</b>	<b>3401</b>
<b>Certara</b>	<b>3425</b>
<b>Children's Hospital of Philadelphia</b>	<b>3348</b>
<b>CIBMTR (Center for International Blood &amp; Marrow Transplant Research)</b>	<b>2118</b>
<b>Citius Pharmaceuticals</b>	<b>3354</b>
<b>City of Hope Comprehensive Cancer Center</b>	<b>2204</b>
<b>Cleveland Clinic Taussig Cancer Institute</b>	<b>2134</b>
<b>Clinical Advances in Hematology and Oncology</b>	<b>2801</b>
<b>CLL Society</b>	<b>7, Virtual</b>
<b>Cogent Biosciences</b>	<b>2704</b>
<b>College of American Pathologists</b>	<b>14</b>
<b>Cooley's Anemia Foundation</b>	<b>Virtual</b>
<b>CRISPR Therapeutics</b>	<b>3043</b>
<b>Cryoport Systems</b>	<b>455</b>
<b>CSL Behring</b>	<b>643</b>
<b>Curis, Inc.</b>	<b>2107</b>
<b>Cytiva</b>	<b>2251</b>

## EXHIBITORS

D2V Clinical, Inc.	3446
Daiichi Sankyo	2819
Dana-Farber Cancer Institute	2900
DAVA Oncology	1156, 1157
Diagenode, Inc.	2132
Diamond Blackfan Anemia Canada	19
Diamond Blackfan Anemia Foundation Inc.	20
Doximity	2355
Edenbridge Pharmaceuticals, LLC	2016
Editas Medicine	2152
Elsevier	2605
Emmaus Medical, Inc.	3305
Emmes Company LLC	2356
Enable Injections	405
EpiCypher	3442
Eurasian Hematology Oncology Group	39
Eurofins Viracor	3405
European Hematology Association	2449
Flagship Biosciences	3349
Flatiron Health	3156
Florida Cancer Specialists & Research Institute	3145
Food And Drug Administration - Center for Biologics Evaluation And Research	34
Foresight Diagnostics	2014
Fortrea	3242
Foundation for Sickle Cell Disease Research	5
Foundation for the Accreditation of Cellular Therapy (FACT)	12
Foundation for Women & Girls with Blood Disorders	21
Foundation Medicine	3203
Fred Hutchinson Cancer Center	3337
Fulcrum Therapeutics	752
Fulgent Oncology	3345
Galapagos	3419
Gamida Cell	2653, 2752
Genentech	333
Genmab	3029
Genmab - Patient Support Services	2945
Genomic Testing Cooperative	3315
GenPath	142
GenScript ProBio USA Inc	2155
Geron Inc.	1251
Gilead and Kite Oncology	1415
Global Pediatric MDS Initiative	31

## EXHIBITORS

GRAIL	1326
GSK	1814
Gundersen Health System	4
Halia Therapeutics	2254
Harborside	3253
Haymarket Oncology	2614
HCU Network America	Virtual
Healgen Scientific LLC	754
HealthTree Foundation	24
HealthWell Foundation	32
HEMA Biologics	1853
Hemophilia Federation of America (HFA)	17
Horizon Therapeutics	3416
Hospital Information Services for Jehovah's Witnesses (USA)	33
Ichnos Sciences	305
ICON plc	3249
Imaging Endpoints II, LLC	104
Incyte Corporation	1233
Intermountain Health	3303
International Myeloma Foundation	3351
International Myeloma Society	2
International Society on Thrombosis and Haemostasis (ISTH)	8
Intrinsic LifeSciences	2020
Invivoscribe, Inc.	349
iProcess Global Research Inc	3438
Ipsen Biopharmaceuticals	1453
IQVIA Biotech	2151
Italian Society of Hematology	1449
JAMA Network	301
Johnson & Johnson Innovative Medicine	1033, 1225, 1324
Jazz Pharmaceuticals, Inc.	2419
John Theurer Cancer Center	401
Kaiser Permanente/ The Southeast Permanente Medical Group	3445
Karyopharm Therapeutics Inc.	733
Kindstar Globalgene (HK) Limited	3448
Kura Oncology	2701
Kyan Technologies PTE LTD	3457
Kyowa Kirin, Inc.	1949
Labcorp Oncology	2753
Larvol	3347
Legend Biotech	3005
Leukemia Research Foundation	1

## EXHIBITORS

Loxo@Lilly	2729, Virtual
Lunaphore Technologies	3453
Machaon Diagnostics, Inc.	3055
Mallinckrodt Pharmaceuticals	3412
Mayo Clinic Laboratories	3415
Mayo Clinic Referring Provider Office	2041
MD Anderson Cancer Center	122
MDoutlook	3219
Mechatronics Instruments B.V.	1057
Med Learning Group	755, 2545
Medexus Pharma	2502
Medidata, a Dassault Systèmes company	2142
Medpace Inc.	136
Medscape Oncology & Hematology	2340
Melinta Therapeutics	3257
Menarini Silicon Biosystems	555
Menarini Stemline	1047
Merck & Co., Inc.	2111
Miltenyi Biotec	3329
Mission Bio	2015
MJH Life Sciences	2019
MLM Medical Labs	604
Moffitt Cancer Center	655
MorphoSys	2405
Multiple Myeloma Research Foundation	22
National Comprehensive Cancer Network (NCCN)	13
National Heart, Lung, and Blood Institute	2401
NeoGenomics Laboratories	851
NMDP	2112
Northside Hospital	2105
Northwell Health	2029
Notable Labs	2454
Novartis	2429
Novo Nordisk	619
NURIX	821
Omeros Corporation	2305
ONO PHARMA	243
OPTOLANE Technologies, Inc.	2027
Ossium Health, Inc.	300
OxyDial Inc	2501
Parexel	449
Pfizer	1832

## EXHIBITORS

PharmaEssentia Corporation	2915
Pharming Healthcare, Inc.	2250
Platelet Disorder Support Association	10
PlatformQ Health	116
Precision for Medicine	649
Precision NanoSystems	2255
Premier Research	2148
ProPharma Group	3343
Protagonist Therapeutics, Inc	2122
PROTEINA Co., LTD.	3455
Proteintech	2852
Prothena	400
PSI CRO	3352
Q2 Solutions	2548
Rapid Novor Inc.	1548
Rare Disease Therapeutics, Inc.	1355
Recordati Rare Diseases	2500
Recordati Rare Diseases – Medical	3001
Regeneron Pharmaceuticals	633
Rigel Pharmaceuticals	2805
Roswell Park Comprehensive Cancer Center	3411
Rutgers Cancer Institute of New Jersey/RWJBarnabas Health	3150
Sanofi	915
Sanofi	3429
Sarah Cannon Research Institute	2104
Seagen	117, 355
Sebia	2455
Secura Bio Inc.	3321
SeQure Dx	3449
Servier Pharmaceuticals	1347
Shanghai Model Organisms Center	2550
Shield Therapeutics	2745
Shwachman-Diamond Syndrome Foundation	27
Sight Diagnostics	1357
Silence Therapeutics	3057
Sobi, Inc.	105, 2028
Society for Immunotherapy of Cancer (SITC)	18
Society of Hematologic Oncology	2552
Spark Therapeutics, Inc.	549
Stanford Cancer Institute	3436
Star Therapeutics	2157
STEMCELL Technologies	118

## EXHIBITORS

Sumitomo Pharma Oncology	143
Sutro Biopharma	302
Sutter Health – Bay Area	3244
Syndax Pharmaceuticals, Inc.	2400
Syneos Health	1555
Syros	2804
Taiho	827, 2141
Takeda Hematology	2321
Takeda Oncology	2229
Team Telomere	30
Telo Genomics	404
Tempus Labs, Inc.	3051
The Japanese Society of Hematology	9
The Leukemia & Lymphoma Society	2705
The MDS Foundation, Inc.	3
Theradex Oncology	815
ThermoFisher	727
ThinkCyte, Inc.	140
Trinity Biotech	3000
Turkish Society of Hematology	6
TwinStrand Biosciences	3143
U.S. Department of State Bureau of Medical Services	38
UC San Diego Hemophilia and Thrombosis Treatment Center	25
UCI Health	28
University of Chicago – Data for the Common Good	41
Vaniam Group	3149
Vertex Pharmaceuticals Inc.	715, 841
Viracta Therapeutics	504
wAIHA Warriors	36
Waldenstrom’s Macroglobulinemia Foundation	15
Wolters Kluwer	2301
Worldwide Clinical Trials	3313
X4 Pharmaceuticals	501, 1957
Xcene Research	2515



# 66th ASH® Annual Meeting and Exposition




**SAVE THE DATE**  
December 7-10, 2024 • San Diego, CA

# CD47-Blocking Agents:

## Emerging Checkpoint Inhibitor Approach in Hematologic Malignancies

CD47 signaling has been shown to inhibit phagocytosis and promotes tumor cell immune evasion

1




- CD47, or integrin-associated protein, is a **cell-surface ligand expressed at low levels** by nearly all cells of the body<sup>1</sup>
- CD47 is **overexpressed in various hematologic malignancies** and expressed by cells within the tumor microenvironment<sup>1</sup>
- Its interaction with **signal regulatory protein (SIRP) $\alpha$  on phagocytic cells** sends an inhibitory “Don’t eat me” signal that is known to prevent phagocytosis of the tumor cell<sup>1</sup>
- Overexpression of CD47 is thus often associated with **poor clinical outcomes**<sup>1</sup>

▶ VISIT US AT **BOOTH #1832**  
TO LEARN MORE

CD47 blockade may enhance phagocytosis and may promote antitumor activity


2



- **CD47-blocking agents** can bind to CD47 on tumor cells and **prevent** it from delivering **its inhibitory signal to phagocytic cells**<sup>1</sup>
- Some CD47-blocking agents in development include an Fc region from human IgG, which may potentially generate a **prophagocytic signal**<sup>1</sup>

CD47 blockade may promote both innate and adaptive immunity

3



- Upon engulfment, the antigen-presenting cell (APC) presents antigens from the engulfed tumor cells, potentially leading to **T-cell activation and tumor cell lysis**<sup>2</sup>

CD, cluster of differentiation; Fc, fragment crystallizable; Fc $\gamma$ R, Fc gamma receptor; IgG, immunoglobulin G.

1. Eladl E, et al. *J Hematol Oncol*. 2020; 2020;13(1):96. 2. Tseng D, et al. *Proc Natl Acad Sci*. 2013;110(27):11103-11108.

This document contains medical information concerning a mechanism still under investigation.

PP-TT2-USA-0012 © 2023 Pfizer Inc. All rights reserved. October 2023.



# DISCOVER THE CURRENT OF CALQUENCE

Follow the current to the latest long-term efficacy and safety data,  
now with up to ~6 years of median follow-up\*<sup>1</sup>

Visit Booth #1433  
at the 2023 ASH Annual Meeting



SEE MORE INFORMATION AT  
[calquencehcp.com](http://calquencehcp.com) OR SCAN QR CODE

\*At median 74.5-month follow-up (range: 0.0-89.0 months).<sup>1</sup>

Reference: 1. Sharman JP, et al. Abstract 636. Presented at: 2023 ASH Annual Meeting, December 9-12.



**CALQUENCE**<sup>®</sup>

acalabrutinib 100 mg tablets



CALQUENCE is a registered trademark of the AstraZeneca group of companies. ©2023 AstraZeneca. All rights reserved. US-80102 10/23